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 Pharmaceutical cocrystals have generated enormous interest due to their potential 
for improving the physicochemical shortcomings of a drug, such as poor aqueous 
solubility.  Poor aqueous solubility can compromise drug performance and 
cocrystallization is an emerging strategy to design materials with desirable properties.  
This approach is currently limited because cocrystal solution chemistry remains largely 
unexplored.  This dissertation explores the influence of two critically important solution 
phase interactions, ionization and micellar solubilization, on cocrystal solubility and 
stability. 
 The objectives of this work are to (1) understand the effect of ionization on 
cocrystal solubility, (2) investigate the role of micellar solubilization on cocrystal 
solubility and stability, (3) develop mathematical models to describe cocrystal solubility 
and stability via ionization and micellar solubilization equilibria, and (4) understand how 
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ionization and micellar solubilization affect cocrystal eutectic points and regions of 
thermodynamic stability. 
 Cocrystal solubility, stability, and eutectic points were investigated as a function 
of pH and sodium lauryl sulfate concentration for a series of carbamazepine cocrystals in 
water.  The cocrystals represented two stoichiometries (1:1 and 2:1) and four coformers 
(salicylic acid, saccharin, 4-aminobenzoic acid, and succinic acid) with various ionization 
properties.  Mathematical models for cocrystal solubility were developed in terms of 
experimentally accessible thermodynamic parameters based on cocrystal dissociation, 
component ionization, and micellar solubilization.  These models demonstrated that 
cocrystal solubility relative to drug could be strongly dependent on surfactant 
concentration and pH, and that the thermodynamic stability of cocrystals could be 
controlled via predictable parameters called the critical stabilization concentration (CSC) 
and pHmax.  This enabled for the first time the thermodynamic stabilization of cocrystals 
that would otherwise be unstable in water under stoichiometric solution conditions.  
Several methods were developed to evaluate CSC and were challenged by the 
carbamazepine cocrystals.  The important factors that affect CSC and pHmax were 
identified as (1) cocrystal aqueous solubility relative to drug, (2) micellar solubilization 
constants and acid dissociation constants for the cocrystal components, (3) cocrystal 
stoichiometry, and (4) surfactant CMC.  The mathematical models demonstrated 
excellent predictive capacity in describing the influence of pH and surfactant 
concentration on cocrystal solubility, CSC, and eutectic points for the carbamazepine 





CHAPTER 1  
Introduction 
 
 Cocrystals have generated tremendous interest in pharmaceutical research and 
development because of the potentital to customize physicochemical properties of the 
solid while maintaining the chemical integrity of the drug.  Cocrystals are part of a 
broader class of multicomponent crystals, where two or more molecules (commonly 
referred to as drug and coformer) populate a homogeneous crystalline lattice in a well-
defined stoichiometry.  What distinguishes cocrystals from other types of 
multicomponent crystals such as salts and solvates is that drug and coformer are solids at 
ambient temperature and that the intermolecular interactions are nonionic in nature.  The 
diversity of solid forms that can be generated from a drug greatly increases through 
cocrystallization; the physicochemical properties of the cocrystals can vary depending on 
the characteristics of its constituent molecules. 
 Pharmaceutically relevant properties that can change via cocrystallization include 
but are not limited to solubility, dissolution, moisture uptake, chemical stability, 
mechanical properties, and bioavailability.1-6  Of these properties, solubility is the most 
widely appreciated in the literature.  Cocrystals have the potential to address the 
solubility limitations of poorly soluble pharmaceutical compounds, a problem which can 
pose a serious challenge to successful formulation.  Lipinski reported that between 1987 
 
2 
and 1994, nearly one-third of newly synthesized compounds in academic laboratories had 
solubilities less than 20 μg/mL.7, 8  Serajuddin estimates that one-third of newly 
synthesized compounds have aqueous solubilities less than 10 μg/mL, and another one-
third have aqueous solubilities between 10 and 100 μg/mL.9  Poor aqueous solubility can 
result in poor dissolution, which can then affect bioavailability and pharmacokinetics. 
 Other solid forms that have been investigated for solubility enhancement include 
salts, polymorphs, solvates, and amorphous, among others.  High energy polymorphs and 
amorphous formulations can achieve improved solubilities but the system is at serious 
risk of crystallizing the thermodynamically stable form, even in the solid state.10-15  Such 
transformations can compromise the performance of the formulation.  Salt formation is a 
common approach to address poor aqueous solubility, but is limited to ionizable 
compounds.  Adding ionizable moieties to a nonionizable drug can improve solubility but 
may affect the desired pharmacological effect of the molecule.  Cocrystals offer the solid 
state stability of a crystalline compound and the solubility enhancement of a high-energy 
solid. 
 This chapter introduces cocrystals in the context of design, synthesis, 
physicochemical properties, the current understanding of cocrystal solution chemistry, 
and what role additives currently play in cocrystal research.  This chapter will conclude 
with a statement of research objectives. 
 
Cocrystal design 
 Cocrystals are designed based on the principles of crystal engineering and 
supramolecular chemistry, where cocrystal components are selected based on favorable 
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molecular recognition interactions.  Table 1.1 gives several examples of reported 
cocrystals of pharmaceutically active compounds.  Typically, though not exclusively, the 
drug component is hydrophobic and poorly soluble in water.  In general the coformers are 
small organic acids, though coformers with other ionization properties have been 
successfully cocrystallized.16-19 
 
Table 1.1.  Examples of pharmaceutical cocrystals. 
Drug Coformers References 
Carbamazepine succinic, benzoic, ketoglutaric, maleic, glutaric, 
malonic, oxalic, adipic, (+)-camphoric, 4-
hydroxybenzoic, salicylic, 1-hydroxy-2-naphthoic, 
DL-tartaric, L-tartaric, glycolic, fumaric, DL-malic, 





Piroxicam L-tartaric, citric, fumaric, adipic acid succinic, L-
malic, glutaric, DL-malic, oxalic, (+)-camphoric, 
ketoglutaric, benzoic, 4-hydroxybenzoic, malonic, 
salicylic, glycolic, 1-hydroxy-2-naphthoic, gentisic, 
DL-tartaric, maleic, caprylic, hippuric, L-
pyroglutamic acid 
16 





Cocrystals depend on noncovalent, nonionic interactions, which include hydrogen 
bonding, π-π, and van der Waals interactions.  Analysis of cocrystal structures in the 
Cambridge Structural Database (CSD) indicates that hydrogen bonding is the most 
prevalent mode of interaction among cocrystals.21-24  These studies show that there exist 
certain hydrogen bond motifs called synthons that occur frequently among reported 
cocrystals.  Examples of such synthons are shown in Figure 1.1.  Synthons are generally 
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classified into two categories, homosynthons and heterosynthons.  Homosynthons are 
interactions between two of the same functional group (I-II), and heterosynthons are 
interactions between two different functional groups (III-X).24-28 
 
 
Figure 1.1.  Hydrogen bond synthons common in cocrystal structures.29 
 
 Based on these principles and a statistical analysis of the CSD, a set of guidelines 
were developed for selecting favorable hydrogen bonding assemblies in the crystal 
structure.  (1) all acidic hydrogens available in a molecule will be used in hydrogen 
bonding in the crystal structure of that compound (2) all good acceptors will be used in 
hydrogen bonding when there are available hydrogen-bond donors, and (3) the best 
hydrogen-bond donor and the best hydrogen-bond acceptor will preferentially form 
hydrogen bonds to one another.23, 30  These rules do have several notable limitations, e.g. 
steric hindrance, competing dipole/hydrogen bonding/ionic interactions, and 
conformational freedom. 
 The hydrogen bonding rules offer a good starting point for cocrystal synthesis and 
coformer selection, but are not able to ab initio determine crystal structure or the 
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existence of cocrystal.  Crystal structure prediction is a complex discipline that requires 
consideration of a number of factors in addition to synthon formation, including van der 
Waals interactions, crystal packing, symmetry elements, and electrostatic interactions 
between within molecules.31 
 
Cocrystal synthesis 
 Currently the most established methods for cocrystal formation are solvothermal 
and mechanical techniques.  In solvothermal cocrystal synthesis, stoichiometric ratios of 
reactants are dissolved in a solvent of choice and supersaturation is achieved either 
through a temperature difference or through evaporation of the solvent.  In mechanical 
cocrystal synthesis, stoichiometric ratios of reactants are mechanically agitated (e.g. by 
grinding in a mill) to induce phase transformations from a physical mixture into 
cocrystal.32-35  Drops of solvent, which are considered plasticizers, have been shown to 
impact the crystallization outcome.36-39  Mechanical methods are often favored due to 
their speed, procedural simplicity, and potential for green chemistry. 
 While these two methods have been largely successful in the discovery of 
cocrystals, they have some particular limitations.  Solvothermal techniques often rely on 
empirical choices of solvent, temperature conditions, and molar ratio of reactants.  There 
is a risk of crystallizing one or more undesirable phases if conditions are chosen such that 
cocrystal is not the thermodynamically stable phase.  Mechanical techniques are also 
subject to empirically selected conditions (such as selection of solvent drop and grinding 
time), but the main challenges include process scalability, reactant stability during 
mechanically/thermally energetic processes, and extent of transformation. 
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 Reaction crystallization is an emerging solution-mediated cocrystal synthesis 
method that complements the other more established methods.40  The reaction 
crystallization method (RCM) relies on creating supersaturation through cocrystal 
solution phase chemistry.  Cocrystal solubility is described by solubility product 
behavior, which indicates that cocrystal solubility decreases as coformer concentration 
increases.1, 41  Cocrystal solubility is decreased below that of the drug by adding coformer 
at or near the coformer solubility.  Therefore, conditions are chosen to maximize the 
likelihood of obtaining cocrystal by operating in a region of the phase diagram where 
cocrystal is least soluble.  The theoretical framework developed for cocrystal solubility 
allows for rational selection of the solvent and solute concentrations to control and 
optimize cocrystallization processes.  RCM is a scalable technique, amenable to both 
large and small scales.  RCM has been successfully used in addition to other methods to 
screen for carbamazepine and piroxicam cocrystals,16, 18 and can be applied with equal 
success in green solvents such as water. 
 
Cocrystal properties 
 The main advantage of cocrystals is the ability to generate a variety of solid forms 
of a drug that have physicochemical properties distinct from the solid cocrystal 
components.  Such properties include but are not limited to solubility, dissolution, 
bioavailability, hygroscopicity, hydrate/solvate formation, crystal morphology, fusion 
properties, chemical and thermal stability, and mechanical properties.  These properties 
can directly or indirectly affect the suitability of a particular API as a pharmaceutical 
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product.  Consideration of how these physicochemical properties change as a result of 
cocrystallization is an ongoing area of cocrystal research. 
 
Bioavailability and dissolution 
 Several studies have demonstrated improved bioavailability with a cocrystal than 
with the crystalline API.  McNamara et al. showed that a 1:1 cocrystal of 2-[4-(4-chloro-
2-fluorophenoxy)phenyl]pyrimidine-4-carboxamide, a poorly soluble developmental 
drug, with glutaric acid achieved 3-fold higher Cmax and plasma AUC for two different 
doses (5 and 50 mg/kg) in dogs.42  An investigation of the dissolution rate of cocrystal by 
rotating disk showed that dissolution rate was 18-fold higher for cocrystal than crystalline 
drug.  Bak et al. showed similar results for a 1:1 cocrystal of an Amgen compound 
AMG517 with sorbic acid, where cocrystal demonstrated an 8 to 10-fold increase in Cmax 
and plasma AUC relative to an equivalent dose (500 mg/kg) of the crystalline drug in 
rats.43  The AMG517-sorbic acid cocrystal was shown to achieve 10-fold higher drug 
concentrations after 1 hour of powder dissolution in fasted-state simulated intestinal fluid 
(FaSSIF) relative to the crystalline drug, despite the crystalline drug having a smaller 
average particle size.  Additional cocrystals that have demonstrated higher Cmax and 
plasma AUC relative to pure drug include a 1:2 cocrystal of Merck L-883555 and L-
tartaric acid in monkeys, and a 1:1 cocrystal of indomethacin and saccharin in dogs.44, 45 
 However, not all attempts have been successful in selecting a cocrystal with 
improved pharmacokinetics relative to drug based on a favorable dissolution rate.  A 1:1 
cocrystal of carbamazepine and saccharin did not exhibit statistically significant 
differences in Cmax and plasma AUC when compared to the marketed form of 
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carbamazepine (Form III) in dogs.46  A pharmacokinetic study of two 1:1 cocrystals of 
lamotrigine with nicotinamide (anhydrous and monohydrate) showed lower Cmax and 
plasma AUC for cocrystal relative to drug, despite having comparable powder dissolution 
rates in water and acidic media.47 
 Other studies have shown that cocrystal can achieve a range of dissolution rates, 
depending on coformer selection.  Remenar et al. showed that cocrystals of itraconazole 
(a poorly soluble antifungal agent) with four dicarboxylic acids (L-tartaric, maleic, 
succinic, and fumaric) achieved powder dissolution rates 4 to 20-fold that of the 
crystalline drug in 0.1 N HCl.48  The highest dissolution rates achieved were comparable 
to the amorphous form of itraconazole. 
 
Fusion properties 
 Melting point can be important for identification, processing in thermally 
sensitive environments, and is typically used as a gauge for solubility.  In general, 
cocrystals have melting points distinct from the solid cocrystal components.  Analysis of 
the melting temperatures of twenty-seven carbamazepine cocrystals indicates that 
cocrystal melting points can be either be between, less than, or greater than the melting 
points of the pure components.18, 49, 50  The differences in melting points between pure 
drug and cocrystal can be attributed to changes in intermolecular interactions, 
composition, and crystal structure.  Correlations between a cocrystal’s melting point and 
its aqueous solubility were attempted on a limited set of carbamazepine cocrystals in 
various organic solvents and water.49  The cocrystal melting point was shown to be a poor 
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indicator of cocrystal aqueous solubility, where solute-solvent interactions dominate over 
crystal lattice energies. 
 
Hygroscopicity 
 Sensitivity to water is an important consideration for any drug candidate.  For 
example, compounds that interact strongly with water are at risk of phase transformation 
from anhydrous solid into a hydrate.51-55  Cocrystals have been shown to prevent hydrate 
formation in cocrystals of the drug carbamazepine with coformers saccharin and 
nicotinamide.56, 57  Carbamazepine-saccharin and carbamazepine-nicotinamide showed 
no hydrate formation after 10 weeks at 98% RH and 3 weeks at 100% RH, whereas solid 
carbamazepine readily converted to the dihydrate form.  Similar results have been 
reported for caffeine and theophylline cocrystals with dicarboxylic acids.57 
 Deliquescent additives have been shown to induce solution-mediated 
transformations from solid reactants to cocrystal.53  Carbamazepine-saccharin cocrystals 
were formed in the presence of deliquescent additives sucrose, fructose, and citric acid at 
high relative humidities.  The formation of cocrystal relied on differential dissolution 
rates of solid coformer and drug in the sorbed moisture, which led to the solution 
becoming supersaturated with respect to cocrystal. 
 
Chemical stability 
 Cocrystallization can affect chemical stability through rearrangement of the 
molecules in the crystalline lattice.  Carbamazepine undergoes photodegradation and its 
mechanism is dependent on distances between azepine rings in the crystal lattice 
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(requires <4.1 Å).57, 58  Carbamazepine-saccharin and carbamazepine-nicotinamide 
cocrystals contain azepine ring distances long enough to disrupt the photodegradation 




 The response of pharmaceutical solids to mechanical stresses can impact 
formulation and processing strategies.  A series of paracetamol cocrystals were 
investigated for their tabletability and other mechanical properties.59  The coformers were 
selected based on crystal engineering principles that promote intended crystallographic 
features.  Two polymorphs of paracetamol were unable to be tabletted in their pure forms, 
while four cocrystals of paracetamol readily formed tablets. 
 The four cocrystals’ mechanical properties were characterized in terms of tensile 
strength, breaking force, and other elastic properties.  Each of the four cocrystals 
outperformed both paracetamol polymorphs in the mechanical properties tests.  The 
authors’ reasoning behind the improved tabletability is the successful formation of layers 
in the crystal structure that are critical for elasticity and strength.  These studies 
demonstrate the utility of cocrystallization in the design of pharmaceutical solids. 
 
Cocrystal solution chemistry 
Cocrystal solubility 
 Cocrystal solution phase behavior was first investigated by Higuchi, Connors, and 
coworkers, though their focus was on solution complexation between cocrystal 
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components.60-62  Their experiments showed that cocrystals adhered to solubility product 
behavior, where increasing coformer concentration led to decreasing drug concentration 
at equilibrium.  The mathematical models to explicitly describe cocrystal solubility in 
terms of cocrystal solubility product (Ksp) and solution complexation constant (K11) were 
introduced by Nehm et al.41 
 The chemical equilibria that describe cocrystal AB solubility, where A is drug and 








A B AB   (1.2) 
where Ksp and K11 are the cocrystal solubility product and the complexation constant for 
a 1:1 solution complex between A and B.  Ksp and K11 are given by 





  (1.4) 
under the assumption of dilute conditions where activities are approximated by 
concentrations.  By mass balance, where [A]T and [B]T are the total analytical 
concentrations of A and B, 







   (1.6) 
Equation (1.6) is an expression of the cocrystal solubility (in terms of drug concentration) 
as a function of the coformer concentration at equilibrium.  Figure 1.2 shows the 
solubility of a 1:1 cocrystal of carbamazepine and nicotinamide (CBZ-NCT) in three 
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organic solvents. Figure 1.2 shows that cocrystal solubility decreases as a function of 
coformer concentration.   
 
 
Figure 1.2.  Solubility of 1:1 CBZ-NCT cocrystal at 25 °C as a function of total NCT 
concentration in ethanol, 2-propanol, and ethyl acetate.41  The solid lines represent the 
predicted solubility according to Equation (1.6).  Filled symbols are experimental 
cocrystal solubility values in (■) ethanol, (▲) 2-propanol, and (●) ethyl acetate. 
 
For a 1:1 cocrystal, the cocrystal solubility in solutions containing stoichiometric solution 
concentrations of A and B, SAB, is given by 
AB T TS [A] [B]   (1.7) 
AB spS K  (1.8) 
if we assume K11Ksp << SAB. 
 
Measuring solubility of metastable cocrystal phases 
 Cocrystals are often selected for their high solubilities relative to the drug.  
Cocrystals that are highly soluble relative to drug can transform, sometimes very rapidly, 
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to the less soluble crystalline drug.  Equilibrium solubilities that use drug concentration 
as a measure of cocrystal solubility are confounded by such conversions, which can lead 
to underestimation of true cocrystal solubilities.  Kinetic solubility measurements are 
limited by the kinetics of transformation and depend highly on experimental conditions, 
which are often empirically selected. 
 A method was developed by Good et al. to measure cocrystal solubility under 
equilibrium conditions and use mathematical models to extrapolate the solubility under 
stoichiometric conditions.49  This method measured the solution composition where two 
solids (cocrystal and one of the cocrystal components) and a solution coexist at 
equilibrium.  According to Gibbs’ phase rule, at constant temperature (and pH) the 
solution concentrations of drug and coformer are independent of the ratios of solid 
components.  This point is known as a eutectic point or transition concentration.  Multiple 
eutectic points can exist depending on what solid phases coexist at equilibrium.  In the 
case of a cocrystal AB with no other stoichiometries or polymorphs, two eutectics exist; 
the first is between solid drug, cocrystal, and solution, and the second is between solid 
coformer, cocrystal, and solution. 
Figure 1.3 shows the schematic pathway to determine the solubility of cocrystal 
via the eutectic point.  The intersection of cocrystal and drug solubilities is the eutectic 
between solid drug, cocrystal, and solution.  From the concentrations of drug and 





Figure 1.3.  (a) Flowchart of method used to establish the invariant point and determine 
equilibrium drug and coformer eutectic concentrations.  (b) Schematic phase solubility 
diagram that illustrates two pathways to the eutectic point (marked X).49 
 
Cocrystal solubility dependence on coformer solubility 
 The solubilities of twenty-five cocrystals were studied and ranked according to 
their solubility advantage over drug.49  The cocrystals were various combinations of three 
drugs (carbamazepine, theophylline, and caffeine) and seven coformers (malonic acid, 
nicotinamide, salicylic acid, saccharin, succinic acid, glutaric acid, and oxalic acid) in 
four solvents (water, isopropyl alcohol, methanol, and ethyl acetate).  The measured 
cocrystal solubilities ranged from 0.1 to over 100-fold their respective drug solubilities 
and the coformer solubilities spanned several orders of magnitude, from 10-2 m to 101 m. 
 Figure 1.4 shows the cocrystal to drug solubility ratio for against the coformer to 
drug solubility ratio for each respective cocrystal.  The dependence was demonstrated to 
be linear, where larger coformer to drug solubility ratios resulted in cocrystals that were 
more soluble relative to the drug.  The work demonstrated that cocrystal solubility 
enhancement could be rationally selected based on knowledge of the coformer solubility, 
and that measuring the drug and coformer eutectic concentrations was a rapid and reliable 
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method of assessing cocrystal solubility, especially with cocrystals that were highly 
soluble relative to drug. 
 
 
Figure 1.4.  The ratio of coformer to drug solubility plotted against the cocrystal 
solubility ratio (filled circles) and the ratio of coformer to drug eutectic concentrations 
(open circles).49  All aqueous samples are shown in red.  Several cocrystals with the same 
coformers are labeled.  
 
Cocrystal systems with multiple stoichiometries 
 A study of carbamazepine-4-aminobenzoic acid (CBZ-4ABA) cocrystal in 
ethanol revealed that different cocrystal stoichiometries could be stable in the same 
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solvent depending on the solution concentration of coformer.63  Solid phase analysis 
showed that in pure solvent, 2:1 cocrystal transformed to the crystalline drug CBZ 
(marketed form III).  At low 4ABA concentrations, the 2:1 form was the most favorable 
while at high 4ABA concentrations the 1:1 form was most favorable. 
These findings were explained by investigation of the solubilities of CBZ-4ABA 
cocrystal (2:1 and 1:1 forms) and CBZ measured as a function of 4ABA concentration, 
shown in Figure 1.5.  Mathematical models were developed based on cocrystal solution 
phase chemistry that identified the solution concentrations of coformer where crystalline 
CBZ, 2:1 cocrystal, and 1:1 cocrystal were thermodynamically stable.  The work 
demonstrated that (1) the thermodynamically favorable cocrystal stoichiometry depended 
on solution concentrations of reactants, (2) a eutectic point existed where the solid phases 
at equilibrium were 2:1 and 1:1 forms of CBZ-4ABA, (3) eutectic points were essential 
in identifying the regions of stability for each cocrystal stoichiometry, and (4) 
transformation pathways of cocrystal could be predicted from mathematical models 





Figure 1.5.  Phase solubility diagram for CBZ−4ABA in ethanol at 25˚C showing 
reactant solution concentrations ([CBZ]T and [4ABA]T) at equilibrium with CBZ (◊), 2:1 
cocrystal (○), or 4ABA (♦).63  Measured solubility of CBZ(III) and 4ABA in neat ethanol 
are indicated by the points ‘a’ and ‘b’, respectively. Eutectic points c1, c2, and c3 are 
represented by (□). Dashed lines correspond to solution reactant stoichiometries equal to 
that of cocrystals.  Blue line refers to the 2:1 cocrystal, red line refers to 1:1 cocrystal, 
and green refers to CBZ. 
 
Role of additives in cocrystal research 
 Additives and excipients are commonplace in pharmaceutical research, testing, 
and processing.  Surfactants are particularly important additives that have multitudinous 
pharmaceutical applications as solubilizers, emulsifiers, detergents, foaming agents, 




In particular, Remenar et al. investigated the influence of surfactant (sodium 
lauryl sulfate, SLS) and polymer (polyvinylpyrollidone, PVP) mixtures on dissolution 
and phase stability of a 1:1 cocrystal of celecoxib and nicotinamide.20  Celecoxib-
nicotinamide cocrystal was suspended in aqueous media with varying pH, ionic strength, 
and SLS concentration for 5 minutes.  Cocrystal was found to transform to drug in all 
cases, but the presence of SLS resulted in transformation to different polymorphs of 
celecoxib under certain conditions.  This implies that excipients such as SLS can affect 
which solid forms are favorable in solution and the kinetics of transformation to those 
solid forms.  Similarly, dissolution of celecoxib-nicotinamide cocrystal into aqueous 
media (pH 6.5) containing 1% SLS demonstrated that a 5-minute “presuspension” 
process could lead to variable dissolution rates based on extent of transformation from 
cocrystal to drug, which could compromise a potential dosage form.  Thus, mixtures of 
cocrystal, PVP K-30, and SLS were formulated to inhibit the transformation to less 
soluble drug.  Dissolution of cocrystal, PVP, and SLS mixtures into aqueous media (pH 
6.5) containing 1% SLS exhibited dissolution rates comparable to amorphous form/PVP 
mixtures in the same media.  The authors attributed this behavior to transformation from 
cocrystal to amorphous mediated by PVP.  This investigation, while preliminary, clearly 
demonstrated that solution conditions (such as pH) and excipients (PVP, SLS) affected 
cocrystal solution phase behavior.  The major limitation of this work is the lack of 
quantitative theoretical treatments and mechanistic understanding of excipient effects on 




Bak et al. reported the serendipitous discovery of a 1:1 cocrystal of Amgen 
compound AMG517 with sorbic acid which precipitated in a suspending vehicle 
Oraplus®.43, 50  The suspending vehicle had a number of components, which included 
10% (w/v) Pluronic F108®, part of a class of block copolymer surfactants known to 
strongly solubilize hydrophobic drugs.67-70  The authors maintained the use of Pluronic 
F108® in cocrystal synthesis and administration to rats for pharmacokinetic study.  Cmax 
and plasma AUC were greatly increased for equivalent doses of cocrystal relative to 
crystalline drug, and showed that AMG517-sorbic acid cocrystal had higher solubility 
and dissolution than drug in fasted state simulated intestinal fluid (FaSSIF, which 
contains the biorelevant surfactant sodium taurocholate).  The authors noted the apparent 
contradictory nature of forming the cocrystal in certain surfactant solutions (Oraplus®) 
and obtaining improved solubility and dissolution characteristics over drug in other 
surfactant-containing solutions (FaSSIF).  As with Remenar and coworkers, the major 
challenge is constructing a theoretical framework that explains excipient effects on 
cocrystal solution chemistry, which can then be applied to other cocrystal systems. 
Others have investigated cocrystal dissolution in media that contains surfactants, 




Statement of dissertation research 
 The purpose of this dissertation is to investigate the influence of pH and micellar 
solubilization on cocrystal solubility, stability, and eutectic points.  The number of 
discovered cocrystals is increasing rapidly, and there is an emerging need for rational 
methods of selecting cocrystals and evaluating their physicochemical properties.  Studies 
on cocrystal dissolution and bioavailability often use empirically selected pH conditions 
and additive concentrations without considering the impact of ionization and micellar 
solubilization.  This creates a substantial risk of producing experimental results that are 
not generalizable to other solution conditions or cocrystal systems.  The objective of this 
work is to develop a theoretical framework that explains cocrystal solution chemistry in 
terms of experimentally accessible thermodynamic parameters.  The following chapters 
model and explain cocrystal solubility and stability by considering various solution phase 
equilibria. 
 Chapter 2 considers the contribution of ionization to cocrystal solubility.  Most 
cocrystals contain at least one ionizable component; this chapter demonstrates that an 
ionizable coformer imparts pH-dependent solubility to a cocrystal of a nonionizable drug.   
Mathematical equations are developed that describe cocrystal solubility in terms of 
thermodynamic parameters (solubility product Ksp and acid dissociation constant Ka) and 
solution [H+].  Cocrystal solubility is shown to increase as ionization increases, and can 
change by orders of magnitude when pH > pKa.  This can have important implications 
when selecting conditions to evaluate cocrystal solubility and dissolution. 
Chapter 3 investigates the role of micellar solubilization on cocrystal solubility 
and stability.  The objective of this chapter is to study the role of micellar surfactants in 
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changing cocrystal solubility and stability relative to drug.  Mathematical equations are 
developed based on cocrystal dissociation, component ionization, and micellar 
solubilization equilibria that describe cocrystal solubility as a function of thermodynamic 
parameters (Ksp, Ka, and micellar solubilization constant Ks) and solution [H
+].  This 
chapter demonstrates for the first time that cocrystal phase stability depends on micellar 
surfactant concentration, whose mechanism is identified as a differential solubilization 
between drug and coformer by the micelles.  Based on these equations, a novel concept 
called the critical stabilization concentration (CSC) is introduced that describes the 
surfactant concentration at which an otherwise unstable cocrystal (under stoichiometric 
conditions) achieves thermodynamic stability in micellar solutions. 
Chapter 4 investigates methods to engineer cocrystal solubility, stability, and 
pHmax by micellar solubilization.  This expands the theoretical framework introduced in 
the previous chapter to describe solubility and stability of cocrystals of different 
stoichiometry and ionization properties.  Additional mathematical equations are 
developed that predict CSC from experimentally accessible thermodynamic parameters.  
Several methods are developed to measure and/or estimate CSC for a cocrystal, based on 
cocrystal solubilities measured in pure water and thermodynamic constants describing 
ionization and micellar solubilization (Ka, Ks).  This chapter discusses and challenges the 
implications of the model’s predictions of cocrystal solubility and CSC with a series of 
cocrystals of the poorly soluble drug carbamazepine (CBZ). 
Chapter 5 considers the influence of micellar surfactants on cocrystal eutectic 
points.  Cocrystal eutectic points are points that describe where two solid phases and 
solution coexist at equilibrium; eutectic points demarcate regions of thermodynamic 
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stability for the cocrystal and its components in the phase diagram.  Mathematical 
equations based on cocrystal solution phase equilibria are developed that describe how 
the regions of cocrystal stability shift due to micellar solubilization of the cocrystal 
components.  This chapter investigates the contribution of micellar solubilization and 
ionization on the solution concentrations of cocrystal components at the eutectic point for 
a series of CBZ cocrystals.  The objective of this study is to identify and explain how 
micellar solubilization alters regions of cocrystal stability. 
The conclusions of this dissertation and future directions of this research are 
discussed in Chapter 6.  Several of the chapters in this dissertation are published.  The 
work in Chapter 2 is presented in Crystal Growth & Design 2009, 9(9), 3976-3988.  
Chapter 3 is the topic of a publication in Crystal Growth & Design 2010, 10(5), 2050-
2053.  Chapter 4 is a manuscript currently under review in Journal of Pharmaceutical 
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CHAPTER 2  
Customizing cocrystal solubility-pH dependence 
 
Introduction 
 Cocrystals have the potential to increase the solubility of a poorly soluble drug, 
which can then enhance delivery of solubility-limited pharmaceutical compounds.1-4  
Selecting coformers of different physicochemical nature than the drug can generate a 
wide variety of solid forms that have physicochemical properties distinct from the solid 
drug.  Though a preponderance of cocrystals reported in the literature includes ionizable 
components,5-7 the dependence of cocrystal solubility on ionization is rarely addressed.  
Literature on other multicomponent systems such as salts recognize the importance of pH 
in determining solubility and phase stability.8, 9 
Current mathematical models that describe cocrystal solubility consider the 
contributions of cocrystal dissociation and solution complexation.10  The solution 
chemistry of cocrystals has been shown to be critical in determining the solubility 
advantage of cocrystals and the solution conditions where cocrystal is the 
thermodynamically stable phase.7, 10, 11  This chapter provides a theoretical framework for 
considering the effect of ionization on cocrystal solubility.  Mathematical models are 
developed based on cocrystal solution phase chemistry that predict cocrystal solubility, 
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eutectic point, and the eutectic constant Keu as a function of pH based on experimentally 
accessible thermodynamic parameters (cocrystal Ksp and component pKa). 
The model is evaluated by a series of cocrystals of a poorly soluble nonionizable 
drug carbamazepine (CBZ).  The selected cocrystals include 1:1 carbamazepine-salicylic 
acid (CBZ-SLC), 1:1 carbamazepine-saccharin (CBZ-SAC), and 2:1 carbamazepine-4-
aminobenzoic acid monohydrate (CBZ-4ABA-HYD).  The cocrystals include the two 
most abundant stoichiometries and the coformers have ionization properties common 
among reported cocrystals.  Salicylic acid and saccharin are monoprotic weak acids; 
salicylic acid has a reported pKa of 3.0,
12 and saccharin has a range of reported pKa 
values between 1.8 and 2.2.13, 14  4-aminobenzoic acid is amphoteric with pKa values of 
2.6 and 4.8.15 
 
Theoretical 
Cocrystal solubility-pH dependence 
 Cocrystal solubility was previously shown to be governed by solubility product 
behavior and solution complexation constants (if applicable).10  The solubility of a 1:1 
cocrystal RHA, where R is a nonionizable hydrophobic drug and HA is a weakly acidic 
coformer, can be determined by considering the solution equilibria that affect R and HA.  
The derivations for all equations presented here can be found in the Appendix.  The 








HA A H   (2.2) 
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where Ksp is the cocrystal solubility product and Ka is the acid dissociation constant.  
Subscript aq indicates aqueous phase.  In this analysis, solution complexation is 
negligible.  Assuming dilute conditions where concentrations replace activities, the 
equilibrium constants are given by 








  (2.4) 
The cocrystal solubility in solutions containing the stoichiometric solution concentrations 
of cocrystal components (referred to as the cocrystal stoichiometric solubility), SRHA, is 
given by 
RHA,aq T TS [R] [A]   (2.5) 
where subscript T indicates total (unionized + ionized).  Therefore, 
RHA aq aq aqS [R] [HA] [A ]
    (2.6) 









  (2.7) 
Equation (2.7) indicates that cocrystal RHA solubility is dependent on the cocrystal 
solubility product Ksp, the Ka of the ionizable coformer, and solution [H
+].  The 





Figure 2.1.  Dependence of cocrystal stoichiometric solubility and drug solubility on pH 
according to Equation (2.7) for a hypothetical cocrystal RHA.  There exists a pHmax at the 
pH where cocrystal stoichiometric solubility equals drug solubility.  Ksp = 1 mM
2, pKa = 
3, SR,aq = 2 mM. 
 
Cocrystal solubility increases with increasing pH when the coformer is a weak acid.  
Cocrystal RHA achieves pH-dependent solubility while crystal R solubility remains 
unaffected by pH.  This analysis shows that an ionizable coformer imparts pH-dependent 
solubility to a cocrystal, even when the drug is nonionizable.  When pH = pKa, cocrystal 
solubility is 2 -fold higher than under unionized conditions, whereas a weak acid’s 
solubility under the same conditions is 2-fold greater than the intrinsic solubility of the 
acid. 
 Figure 2.1 predicts the existence of a pHmax, a pH where cocrystal stoichiometric 
solubility and drug solubility are equal.  A cocrystal with a pHmax is thermodynamically 
stable in nonionizing conditions and unstable in ionizing conditions. 
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 Cocrystal solubility as a function of coformer concentration (which includes 
nonstoichiometric solution concentrations of drug and coformer) is determined from the 
mass balance on each of the cocrystal components, 
T aq[R] [R]  (2.8) 
T aq aq[A] [HA] [A ]
   (2.9) 











The total drug concentration at equilibrium, [R]T, is inversely proportional to the total 
coformer concentration at equilibrium [A]T.  Thus, [R]T decreases with increasing [A]T, 
which is a consequence of cocrystal solubility product behavior. 
 Figure 2.2 shows the dependence of cocrystal solubility (given by [R]T) on 
coformer concentration and pH according to Equation (2.10).  Figure 2.2 shows that 
cocrystal solubility is predicted to increase with increasing ionization (pH > pKa) and 
decrease with increasing coformer concentration.  According to this analysis, drug and 
cocrystal can be equally soluble under certain solution conditions, which are denoted by 
the intersection between drug and cocrystal solubilities. 
 
Cocrystal eutectic point-pH dependence 
 These intersection points, referred to as the eutectic points (and also known as 
transition concentrations) have several main features.  At the eutectic point, two solid 
phases (i.e. cocrystal and one of the cocrystal components) and one liquid phase 
(solution) coexist in equilibrium.  At constant temperature and pH, the solution 
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composition is independent of the relative ratios of solid components, which makes 
eutectic point measurements an experimentally accessible method of evaluating cocrystal 
solubility regardless of the solubility relationship between cocrystal and its components.  
The eutectic point is characterized by the solution concentrations of drug and coformer 
and the solution pH at equilibrium.  In Figure 2.2 the intersections between the cocrystal 
and drug solubilities indicate the eutectic concentrations of drug and coformer of the 
cocrystal RHA, which demarcate the regions of thermodynamic stability and instability 
for the cocrystal.  A thorough discussion of cocrystal eutectic points is presented 
elsewhere.7, 16 
 At least two eutectic points exist for any given cocrystal.  For a cocrystal RHA, 
there exists a eutectic between solid drug, cocrystal, and solution (E1), and another 
between solid coformer, cocrystal, and solution (E2).  Other eutectic points exist 
depending on which solid phases coexist at equilibrium, such as cocrystals of two 
different stoichiometries.17  E1 is the focus for the work described here; E1 is relevant for 
cocrystals of poorly soluble drugs because it describes the minimum coformer 
concentration required for the cocrystal to be thermodynamically stable.  The maximum 
coformer concentration where the cocrystal is thermodynamically stable is given by E2, 






Figure 2.2.  Dependence of drug concentration ([R]T) on coformer concentration ([A]T) 
and pH for a hypothetical cocrystal RHA and solution at equilibrium according to 
Equation (2.10).  Blue/green surface indicates cocrystal solubility, red line indicates 
cocrystal stoichiometric solubility.  Yellow plane indicates drug solubility.  Eutectic 
points are given by the intersection of cocrystal and drug solubilities.  The intersection of 
the cocrystal stoichiometric solubility and drug solubility is the pHmax.  Ksp = 1 mM
2, pKa 
= 3, SR,aq = 2 mM. 
 
At the eutectic between solid drug, cocrystal, and solution (E1), the total concentration of 
drug at the eutectic point, [R]eu, is given by the solubility of R in the eutectic solution.  In 
the absence of solution complexation between drug and coformer, this is equivalent to the 
aqueous solubility of the drug crystal, 
eu R,aq[R] S  (2.11) 














Equations (2.11) and (2.12) predict that eutectic coformer concentrations increase with 
pH according to the pKa of the coformer, and that eutectic drug concentrations remain 
constant with respect to pH.  For cocrystal RHA, the predicted drug and coformer 
concentrations at the eutectic are shown in Figure 2.3. 
 
 
Figure 2.3.  Predicted dependence of drug and coformer eutectic concentrations ([R]eu 
and [A]eu) on pH according to Equations (2.11) and (2.12) for a hypothetical cocrystal 
RHA.  Intersection of [R]eu and [A]eu indicates pHmax, where cocrystal stoichiometric 
solubility is equal to the drug solubility. Ksp = 1 mM
2, pKa = 3 SR,aq = 2 mM. 
 
 Cocrystal solubilities for cocrystals of different stoichiometry and ionization 
properties are listed in Table 2.1.  The cocrystal and drug solubility-pH profiles for these 
cocrystals are shown in Figure 2.4.  These cocrystals represent the two most abundant 
cocrystal stoichiometries and the coformers have ionization properties common among 
reported cocrystals.  Figure 2.4 shows that a variety of cocrystal solubility-pH profiles 
 
40 
can be generated from combinations of drug/coformer ionization properties.  This allows 




Figure 2.4.  Cocrystal stoichiometric solubility-pH dependence for hypothetical 
cocrystals of different stoichiometry and ionization properties according to equations in 
Table 2.1.  Cocrystals represented are (a) HXHA (b) BHA (c) R2H2A (d) R2HAB. 
 
Eutectic constant Keu 







  (2.13) 
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where aA,eu and aR,eu are the activities of coformer and drug in solution at the eutectic 
point.  Eutectic constants have been discussed in the literature concerning enantiomeric 
purification and stability of racemic compounds but were recently applied to cocrystal 
systems.16, 18, 19 
 Keu in the context of cocrystals has been shown to describe cocrystal 
thermodynamic stability relative to drug.16  Keu is measured under equilibrium conditions, 
though it is not a true equilibrium constant.  Assuming dilute conditions where 







  (2.14) 
Under certain conditions, Keu can be related to the ratio of cocrystal to drug solubility.  
This can be accomplished when [R]eu,T = SR,T = [R]aq and [A]eu,T = [HA]aq + [A
-]aq.  If the 









   
 
 (2.15) 














2 2R H A,T




























S K 1 1
[H ] [H ] 
  
      
  
  (2.17) 
BHA 




















H A H A HA
sp a a a
3R H A 2
K K K K
S 1














3R HAB H AB
a














Table 2.2.  Equations that describe the dependence of drug and coformer eutectic concentrations on cocrystal Ksp, component Ka(s), 
drug aqueous solubility, and solution [H+]. 
Cocrystal Drug eutectic concentration Equation Coformer eutectic concentration Equation
RHA 
1:1 nonionizable : 
monoprotic acidic 
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2:1 nonionizable : 
diprotic acidic 
eu R,aq[R] S  (2.25) 
2 2H A H A HA
sp a a a
eu 2 2
eu
K K K K
[A] 1









2:1 nonionizable : 
amphoteric 

















Materials and Methods 
Materials 
 Anhydrous monoclinic carbamazepine (CBZ(III); lot #013K1381 USP grade) was 
purchased from Sigma Chemical Company (St. Louis, MO), stored at 5 °C over 
anhydrous calcium sulfate and used as received.  Saccharin (SAC; lot # 03111DD) (pKa = 
1.8), salicylic acid (SLC; lot #11111KC) (pKa = 3.0), and 4-aminobenzoic acid (4ABA; 
lot #05102HD) (pKa = 2.6, 4.8) were purchased from Sigma Chemical Company (St. 
Louis, MO) and used as received.  Water used in this study was filtered through a double 




 Cocrystals were prepared by the reaction crystallization method at room 
temperature by adding carbamazepine to nearly saturated solutions of coformer.11 CBZ-
SLC and CBZ-SAC were prepared in ethanol while CBZ-4ABA-HYD was prepared in 
water. Solid phases were isolated and characterized by XRPD. 
 
Measurement of cocrystal eutectic points 
 The eutectic concentrations of drug and coformer were measured by HPLC after 
equilibrating carbamazepine dihydrate and cocrystal in solution at various pH values and 
at ambient temperature 24±1°C).  Solid phases at equilibrium were CBZD and cocrystal.  
The pH of the solution was adjusted by the addition of small volumes of concentrated 
HCl or NaOH and the pH at equilibrium was measured.  The solid phases at equilibrium 
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were characterized by XRPD.  The system was determined to have reached equilibrium 
when two solid phases, drug and cocrystal, were confirmed by XRPD and the solution 
concentration remained constant over consecutive days. 
 Cocrystal solubilities were determined from eutectic concentrations of drug and 
coformer from the relations 







  (2.30) 
Equation (2.29) applies to 1:1 cocrystals and (2.30) to 2:1 cocrystals, and both consider 
ionization of the coformer. 
 
High performance liquid chromatography (HPLC) 
 The solution concentration of CBZ and coformer was analyzed by Waters HPLC 
(Milford, MA) equipped with a UV/Vis spectrometer detector.  Waters’ operation 
software, Empower, was used to collect and process the data.  A C18 Atlantis column 
(5µm, 4.6 x 250mm; Waters, Milford, MA) at ambient temperature was used to separate 
the drug and the coformer.  The mobile phase was composed of 55% methanol and 45% 
water with 0.1% trifluoroacetic acid and the flow rate was 1mL/min using an isocratic 
method.  Injection sample volume was 20µL or 50µL.  Absorbance of CBZ, SAC, 
4ABA, and SLC was monitored at 284, 260, 284, and 303nm, respectively.    
  
X-ray powder diffraction (XRPD) 
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 XRPD patterns of solid phases were collected with a bench top Rigaku Miniflex 
X-ray Diffractometer (Danvers, MA) using Cu-Kα radiation (λ = 1.54Å), a tube voltage 
of 30 kV, and a tube current of 15 mA. Data were collected from 2 to 40° at a continuous 
scan rate of 2.5° min−1. 
 
Results 
 The theoretical framework presented earlier explains the contributions of drug and 
coformer ionization to cocrystal solubility.  A cocrystal of a nonionizable drug can 
achieve pH-dependent solubility if the coformer is ionizable.  This is demonstrated for a 
series of cocrystals of carbamazepine (CBZ, a nonionizable drug with low aqueous 
solubility), which include 1:1 cocrystals with monoprotic weakly acidic coformers 
salicylic acid and saccharin (CBZ-SLC and CBZ-SAC) and a 2:1 cocrystal monohydrate 
with an amphoteric coformer 4-aminobenzoic acid (CBZ-4ABA-HYD). 
 Because these cocrystals are reported to transform to CBZD in water, cocrystal 
stoichiometric solubility is determined from the solution concentrations of drug and 
coformer at the eutectic point (where CBZD, CBZ cocrystal, and solution coexist in 
equilibrium at constant temperature and pH) according to equations in Table 2.1.  Table 
2.3 summarizes the eutectic points measured for CBZ-SLC, CBZ-SAC, and CBZ-4ABA-
HYD measured in water as a function of pH, and their estimated cocrystal solubilities 
under stoichiometric solution conditions according to Equations (2.29) and (2.30).  The 
pH-dependent solubilities of the CBZ cocrystals are shown in Table 2.3. 
 According to Equations (2.7) and (2.20), cocrystal solubility increases as 
ionization increases; cocrystal RHA (CBZ-SLC and CBZ-SAC) solubility increases with 
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increasing pH and cocrystal R2HAB (CBZ-4ABA-HYD) solubility forms a U-shape 
solubility-pH profile where solubility reaches a minimum at a certain pH and cocrystal 
solubility increases away from that pH. 
 Figure 2.3 shows the predicted and experimental cocrystal stoichiometric 
solubility-pH dependence for CBZ cocrystals according to Equations (2.7) and (2.20).  
Ksp and Ka values used in predictions are found in  
Table 2.4, which are either reported in literature or determined from linear regression of 
the coformer eutectic concentrations as a function of pH (Figure 2.7). Figure 2.3 shows 
that experiments are in excellent agreement with predicted behavior.  CBZ-SLC and 
CBZ-SAC have dramatically increased solubilities at pH > pKa (3.0 and 1.8, 
respectively).  CBZ-4ABA-HYD solubility, due to the coformer’s acidic and basic 
properties, achieves a minimum between pH 3 and 4 and increases as pH > 4.8 (pKa
HAB) 
and pH < 2.6 (pKa
HABH+). 
CBZ cocrystal stoichiometric solubilities were higher than the aqueous solubility 
of CBZD (0.53 mM REF) at all pH values, thus no pHmax exists for the cocrystals 
investigated.  CBZ-SLC solubility ranged from 1.3 to 6.3-fold that of CBZD between pH 
1.0 and 3.9, while CBZ-SAC solubility ranged from 2.3 to 14.4-fold that of CBZD 
between pH 1.1 and 3.0. CBZ-4ABA-HYD solubility ranged from 2.5 to 9.3-fold that of 
CBZD between pH 4.0 and 1.1.  This shows that a cocrystal’s solubility advantage over 
drug crystal is highly dependent on pH, where high cocrystal solubilities can be achieved 
in environments that favor high levels of coformer ionization. 
   CBZ eutectic concentrations are expected to remain constant because CBZ is 
nonionizable while SLC, SAC, and 4ABA eutectic concentrations are expected to 
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increase with increasing ionization according to their respective pKa values.  [CBZ]eu 
measured in this study varies between 0.59±0.04 mM for CBZ-4ABA-HYD to 0.69±0.03 
mM for CBZ-SAC.  This value is slightly higher than the reported aqueous solubility of 
CBZD (0.53 mM20).  By contrast, Figure 2.6 shows the experimental coformer eutectic 
concentrations and their predicted dependences according equations in Table 2.2.  The 
experiments confirm the expected behavior that coformer eutectic concentrations increase 
at pHs where ionization is favorable.  Thermodynamic values used in predictions of drug 
and coformer eutectic concentration pH-dependence are listed in  
Table 2.4. 
The eutectic constant Keu (the ratio of coformer to drug concentrations at the 
eutectic) increases as the eutectic solution composition becomes more enriched with 
coformer.  Keu is a critical parameter that is proportional to the cocrystal to drug 
solubility ratio in a manner dependent on cocrystal stoichiometry.16  The pH-dependence 
of Keu (Figure 2.6) is evidence that the cocrystal to drug solubility ratio increases as 
ionization increases, thereby increasing the cocrystal solubility advantage but also 
making the cocrystal more thermodynamically unstable in solution. 
 The model equations that predict cocrystal solubility and eutectic concentrations 
of drug and coformer in Figure 2.5 and Figure 2.6 assume that the thermodynamic 
parameters (Ksp, Ka) are independent of solute concentration.  The excellent agreement 
between experimental and predicted cocrystal solubilities and eutectic concentrations 
indicates that this assumption is reasonable for the cocrystals studied.  Improving the 
prediction power of the model can be achieved by introducing corrections for activity 
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when ionic strength is significant or when deviations from Henderson-Hasselbalch 
behavior is observed for the ionizable compound(s).21-23 
 If the stated assumptions are justified, cocrystal solubility-pH dependence can be 
estimated for a wide range of pH conditions based on a single eutectic point measurement 
at a single pH.  This can provide a good first approximation for cocrystal solubility and 




Table 2.3.  Eutectic concentrations of drug and coformer and Keu for CBZ-SLC, CBZ-
SAC, and CBZ-4ABA-HYD in water at various pH values.  Values in bold measured 










CBZ-SLC 1.04a 0.40 1.10 2.75 0.66 
 1.05 0.53 1.19 2.24 0.80 
 1.07 0.58 1.22 2.12 0.84 
 1.94a 0.63 1.10 1.75 0.83 
 1.98 0.58 1.40 2.40 0.90 
 2.16 0.54 1.47 2.73 0.89 
 2.87 0.58 2.62 4.53 1.23 
 2.90 0.60 2.30 3.83 1.17 
 2.96 0.59 2.79 4.75 1.28 
 3.76 0.57 12.25 21.49 2.64 
 3.78 0.59 12.40 20.91 2.71 
 3.87a 0.78 14.10 18.08 3.32 
      
CBZ-SAC 1.07 0.61 2.43 3.99 1.21 
 1.10a 0.70 2.10 3.00 1.21 
 1.17 0.57 2.45 4.28 1.19 
 1.98 0.65 9.17 14.09 2.44 
 2.08 0.57 8.88 15.45 2.26 
 2.12a 0.69 8.60 12.46 2.44 
 2.54 0.68 27.52 40.53 4.32 
 2.58 0.62 24.85 39.89 3.93 
 2.77 0.74 46.63 63.19 5.87 
 2.80a 0.83 30.30 36.51 5.01 
 2.84 0.69 46.52 67.60 5.66 
 2.95a 0.90 65.10 72.33 7.65 
      
CBZ-4ABA-HYD 1.08 0.93 138.15 148.55 4.93 
 1.52 0.67 55.75 83.21 2.93 
 3.93 0.59 6.70 11.36 1.33 
 4.75 0.46 10.20 22.17 1.63 
 5.28 0.57 29.05 50.96 2.11 
 5.33 0.54 22.22 41.48 1.89 
 5.34 0.54 22.29 41.58 1.86 
 5.36 0.55 24.40 44.60 1.85 
 5.36 0.53 24.08 45.22 1.94 
 5.37 0.54 24.24 44.93 1.92 
 5.39 0.55 22.11 39.89 1.90 
a Courtesy of Sarah Bethune, University of Michigan24 
b Stoichiometric solubilities calculated according to Equations(2.29) for 1:1 cocrystals 





Figure 2.5.  Experimental and predicted cocrystal stoichiometric solubilities for (a) CBZ-
SLC, (b) CBZ-SAC, and (c) CBZ-4ABA-HYD.  Predictions according to Equations (2.7) 






Figure 2.6.  Experimental and predicted eutectic concentrations of drug and coformer 
and Keu for (a) CBZ-SLC, (b) CBZ-SAC, and (c) CBZ-4ABA-HYD.  Predictions 
according to Equations (2.12) and (2.28), using Ksp and Ka values listed in  





Table 2.4.  Thermodynamic parameters used in predictions of cocrystal solubility and 
eutectic points.  Ka values were obtained from literature.  Ksp values were calculated from 








(mM2 or mM3) 
CBZ-SLC 3.0a 1.87±0.04 0.60±0.03 1.13±0.06 
CBZ-SAC 1.8b 4.18±0.03 0.68±0.03 2.84±0.13 
CBZ-4ABA-HYD 2.6, 4.8c 3.87±0.01 0.58±0.04 2.24±0.15 
a from reference 12 
b from references 13, 14 
c from reference 15 





Figure 2.7.  Linear regression of CBZ cocrystal eutectic concentrations to determine Ksp 
for (a) CBZ-SLC, (b) CBZ-SAC, and (c) CBZ-4ABA-HYD.  Slope = Ksp/[R]eu for 1:1 
cocrystals and slope = Ksp/([R]eu





 Investigation of several CBZ cocrystals of various stoichiometries and ionization 
properties demonstrates that cocrystals of nonionizable drugs can achieve pH-dependent 
solubilities when the coformer is ionizable.  A mathematical model based on a 
mechanistic understanding of cocrystal dissociation and ionization is developed that 
predicts cocrystal solubility, eutectic points, and Keu from cocrystal Ksp, component 
Ka(s), and solution [H
+].  pH is shown to be a powerful variable in determining cocrystal 
solubility and the solution compositions where cocrystal is thermodynamically stable. 
The findings presented here are valuable to (1) estimate cocrystal solubility-pH 
dependence with a minimum number of critical experiments, (2) guide selection of 
coformers to achieve pH-dependent cocrystal solubilities, and (3) determine the pH 






Explanation of terms 
Subscript aq – aqueous  
Subscript T – total 
Subscript eu – eutectic 
R – nonionizable drug 
HA – monoprotic weakly acidic coformer (nonionized) 
HAB – amphoteric coformer (nonionized) 
Ksp – cocrystal solubility product 
Ka – acid dissociation constant 
Keu – eutectic constant 
S – solubility 
 
RHA (1:1 nonionizable drug R, monoprotic weakly acidic coformer HA) 








HA A H   (2A.2) 
and the associated equilibrium constants are given by 










  (2A.4) 
 
Solubility-pH dependence of cocrystal RHA 
Mass balance on R is given by 
T aq[R] [R]  (2A.5) 
Mass balance on A is given by the sum of unionized and ionized A. 
T aq aq[A] [HA] [A ]
   (2A.6) 







  (2A.7) 
























Stoichiometric solubility for cocrystal RHA, SRHA, is given by SRHA = [R]T = [A]T, so 












Eutectic drug and coformer concentration pH-dependence of cocrystal RHA 
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The eutectic point, where solid drug, cocrystal, and solution coexist in equilibrium, is 
described by 
solid solid aq aqRHA R R HA   (2A.11) 
The concentrations of R and A at the eutectic point, [R]eu and [A]eu, are special solutions 












At the eutectic point, [R]eu is equal to the solubility of R in the eutectic solution.  A 
simplifying assumption is that the solubility of R is unaffected by the presence of 
coformer, thus [R]eu is given by the aqueous solubility of R. 
eu R,aq[R] S  (2A.13) 













HXHA (1:1 monoprotic weakly acidic drug HX, monoprotic weakly acidic coformer HA) 














HA A H   (2A.17) 
Associated equilibrium constants are given by 
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  (2A.20) 
 
Solubility-pH dependence of cocrystal RHA 
Mass balance on X is given by the sum of unionized and ionized X. 
T aq aq[X] [HX] [X ]
   (2A.21) 
Mass balance on A is given by the sum of unionized and ionized A. 
T aq aq[A] [HA] [A ]
   (2A.22) 































[A] [H ] [H ] 
  
    
  
 (2A.25) 
Stoichiometric solubility for cocrystal HXHA, SHXHA, is given by SHXHA = [X]T = [A]T, 







S K 1 1
[H ] [H ] 
  




Eutectic drug and coformer concentration pH-dependence of cocrystal HXHA 
The eutectic point, where solid drug, cocrystal, and solution coexist in equilibrium, is 
described by 
solid solid aq aqHXHA HX HX HA   (2A.27) 
The concentrations of X and A at the eutectic point, [X]eu and [A]eu, are special solutions 







[A] [H ] [H ] 
  
    
  
 (2A.28) 
At the eutectic point, [X]eu is equal to the solubility of X in the eutectic solution.  A 
simplifying assumption is that the solubility of X is unaffected by the presence of 

























BHA (1:1 monoprotic weakly basic drug B, monoprotic weakly acidic coformer HA) 
















HA A H   (2A.33) 
Associated equilibrium constants are given by 
















  (2A.36) 
 
Solubility-pH dependence of cocrystal BHA 
Mass balance on B is given by the sum of unionized and ionized B. 
T aq aq[B] [B] [BH ]
   (2A.37) 
Mass balance on A is given by the sum of unionized and ionized A. 
T aq aq[A] [HA] [A ]
   (2A.38) 































K [H ] K
[B] 1 1




    
  
 (2A.41) 
Stoichiometric solubility for cocrystal BHA, SBHA, is given by SBHA = [B]T = [A]T, so 















Eutectic drug and coformer concentration pH-dependence of cocrystal BHA 
The eutectic point, where solid drug, cocrystal, and solution coexist in equilibrium, is 
described by 
solid solid aq aqBHA B B HA   (2A.43) 
The concentrations of B and A at the eutectic point, [B]eu and [A]eu, are special solutions 





K [H ] K
[B] 1 1




    
  
 (2A.44) 
At the eutectic point, [B]eu is equal to the solubility of B in the eutectic solution.  A 
simplifying assumption is that the solubility of B is unaffected by the presence of 


























R2H2A (2:1 monoprotic weakly basic drug R, diprotic weakly acidic coformer H2A) 
Relevant equilibria are given by 
sp
2 2 solid aq 2 aq
K
R H A 2R H A  (2A.47) 
2H A
a
2 aq aq aq
K







    (2A.49) 
Associated equilibrium constants are given by 
2
sp aq 2 aqK [R] [H A]  (2A.50) 
2 aq aqH A
a
2 aq














  (2A.52) 
 
Solubility-pH dependence of cocrystal R2H2A 
Mass balance on R is given by 
T aq[R] [R]  (2A.53) 
Mass balance on A is given by the sum of unionized and ionized A. 
2
T 2 aq aq aq[A] [H A] [HA ] [A ]
     (2A.54) 









  (2A.55) 
and (2A.51) and (2A.52) into (2A.55), 
2 2H A H A HA
a a a
T 2 aq 2
K K K
[A] [H A] 1




    
 
 (2A.56) 
Combining Equations (2A.55) and (2A.56), 
 
2 2H A H A HA
sp a a a2
T 2
T
K K K K
[R] 1




    
 
 (2A.57) 
Stoichiometric solubility for cocrystal R2H2A, 
2 2R H A
S , is given by 
2 2R H A T T
S 0.5[R] [A]   (because cocrystal contains 2 moles of drug per mole of 
cocrystal), so Equation (2A.57) becomes 
2 2H A H A HA
sp a a a3
RHA 2
K K K K
S 1








Eutectic drug and coformer concentration pH-dependence of cocrystal R2H2A 
The eutectic point, where solid drug, cocrystal, and solution coexist in equilibrium, is 
described by 
2 2 solid solid aq 2 aqR H A R R H A   (2A.59) 
The concentrations of R and A at the eutectic point, [R]eu and [A]eu, are special solutions 
to Equation (2A.57), where [R]eu = [R]T and [A]eu = [A]T, 
2 2H A H A HA
sp a a a2
eu 2
eu
K K K K
[R] 1









At the eutectic point, [R]eu is equal to the solubility of R in the eutectic solution.  A 
simplifying assumption is that the solubility of R is unaffected by the presence of 
coformer, thus [R]eu is given by the aqueous solubility of R. 
eu R,aq[R] S  (2A.61) 
According to Equation (2A.60) [A]eu is given by 
2 2H A H A HA
sp a a a
eu 2 2
R,aq
K K K K
[A] 1








R2HAB (2:1 monoprotic weakly basic drug R, amphoteric coformer HAB) 
Relevant equilibria are given by 
sp
2 solid aq aq
K
R HAB 2R HAB  (2A.63) 
2H AB
a
2 aq aq aq
K
H AB HAB H






HAB AB H   (2A.65) 
Associated equilibrium constants are given by 
2
sp aq aqK [R] [HAB]  (2A.66) 
















  (2A.68) 
 
Solubility-pH dependence of cocrystal R2HAB 
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Mass balance on R is given by 
T aq[R] [R]  (2A.69) 
Mass balance on AB is given by the sum of unionized and ionized A. 
T aq 2 aq aq[AB] [HAB] [H AB ] [AB ]
     (2A.70) 







  (2A.71) 













    
 
 (2A.72) 














    
 
 (2A.73) 
Stoichiometric solubility for cocrystal R2HAB, 
2R HAB
S , is given by 
2R HAB T T
S 0.5[R] [AB]   (because cocrystal contains 2 moles of drug per mole of 

















Eutectic drug and coformer concentration pH-dependence of cocrystal R2HAB 




2 solid solid aq aqR HAB R R HAB   (2A.75) 
The concentrations of R and A at the eutectic point, [R]eu and [AB]eu, are special 













    
 
 (2A.76) 
At the eutectic point, [R]eu is equal to the solubility of R in the eutectic solution.  A 
simplifying assumption is that the solubility of R is unaffected by the presence of 
coformer, thus [R]eu is given by the aqueous solubility of R. 
eu R,aq[R] S  (2A.77) 




eu 2 H AB
R,aq a
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Effect of micellar solubilization on cocrystal solubility and stability 
 
Introduction 
 Cocrystals are part of the broader class of multicomponent solids that offer the 
ability to generate materials that exhibit different physicochemical properties than their 
constituents.1-6  There are several advantages for developing cocrystal forms of a drug.   
Among the most important is aqueous solubility higher than the parent drug, which can 
translate to higher bioavailability for BCS Class II drugs (low aqueous solubility and high 
permeability).7, 8  Cocrystal forms with higher solubilities are however characterized by 
conversion to a less soluble form of the drug when exposed to solvent or solution, and 
deliberate efforts are required to prevent such transformations.  This represents a 
challenge for dosage form development and drug delivery.  Current approaches aim at 
delaying the conversion to drug but may require high additive levels to achieve transient 
stability.  We have discovered that micellar additives with different solubilization 
capacity for cocrystal components, such as surfactants, impart thermodynamic stability to 
otherwise unstable cocrystal phases.  This chapter presents the mechanism for cocrystal 
stabilization and a rational basis for surfactant or stabilizer selection. 
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 Cocrystal eutectic points, where two solid phases are in equilibrium with solution, 
are key indicators of cocrystal solubility.9  Recently the effect of ionization on cocrystal 
solubility was demonstrated through the measurement and prediction of eutectic points.10 
The effect of micellar solubilization and pH on cocrystal solubility and eutectic points is 
modeled based on solution phase chemistry.  A preliminary analysis based on a 
pseudophase model of micellar solubilization is proposed that predicts cocrystal 
solubility and eutectic points in surfactant solutions.  Solubilization is considered as the 
equilibrium of solute or solutes between the aqueous and micellar pseudophases.  The 
concept of differential solubilization, where micelles interact preferentially with one of 
the components in solution, is applied for the first time to cocrystal solubility and 
stability relative to its constituents.  Pharmaceutical cocrystals generally comprise a 
hydrophobic drug and a relatively hydrophilic coformer, and different 
affinities/solubilities in micellar nanophases with hydrophobic cores are to be expected in 
aqueous solutions.  Differential solubilization has been previously discussed by others in 
the context of binary oil mixtures and extraction of oil components from membranes.11   
 
Theoretical 
 Cocrystal stabilization is related to several equilibria between the cocrystal solid 
phase and its components in the aqueous and micellar psueodophases as illustrated in 
Figure 3.1.  The effect of differential solubilization on cocrystal solubility is modeled by 
examining the homogeneous and heterogeneous reaction equilibria that have previously 
described cocrystal solubility product behavior and ionization of cocrystal components.10, 
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12  In this work it is convenient to refer to the cocrystal components as drug and coformer, 
although its applicability is not limited to pharmaceutical compounds. 
 
 
Figure 3.1.  Schematic illustration of the equilibria between cocrystal phase and its 
components in the aqueous and micellar subphases.  This scheme represents micellar 
solubilization of one cocrystal component (for instance drug) leading to excess coformer 
in the aqueous pseudophase and in this way stabilizing the cocrystal phase. 
 
 The relevant equilibria for a 1:1 cocrystal RHA, where R represents a 



















HA A H   (3.4) 
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and their associated equilibrium constants are
 



























Subscript aq denotes species in the aqueous phase.  Subscript m refers to species in the 
micellar phase.  Ksp is the cocrystal solubility product.  Ks
R and Ks
HA are the equilibrium 
constants for the solubilization of R and HA, respectively.  This way of defining the 
solubilization constants is in agreement with the mass action model where solubilization 
is treated as a stepwise addition of solute molecules to the micelles.  Ka is the ionization 
constant for the coformer HA.  Activities are replaced by concentrations as a first 
approximation applicable to dilute solutions. 
 The total solubility of cocrystal RHA, SRHA,T = Saq + Sm, is derived by considering 
the above equilibria and mass balances on R and HA, 
 R HA aRHA,T sp s s KS K 1 K [M] 1 K [M] [H ]
 
    
 
 (3.9) 
where the micellar surfactant concentration [M] is the total surfactant concentration 
minus the critical micellar concentration (CMC).  The CMC is assumed to be constant in 
the range of concentrations and solubilizations reported here.  Large extent of micellar 
solubilization and higher solute concentrations will not justify this assumption.  Equation 
(3.9) applies to cocrystal solubility in solutions of stoichiometric concentrations 
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(equimolar concentration of cocrystal components in this case), and assumes that 
partitioning of ionized coformer is negligible compared to unionized species.  This 
relationship may serve as a guide for surfactant selection and concentration to meet a 
target cocrystal solubility.  Ks and Ka values are often available from the literature and it 
will only require a single measurement of cocrystal Ksp and solution pH. 
 The concept of micellar solubilization has been known for over a century and is 
generally applied to solubilize hydrophobic drugs over the surrounding aqueous media.11, 
13-18  Figure 2 compares the solubility of a hydrophobic drug and a more water soluble 
cocrystal of that drug, whose solubility is calculated from Equation (3.9).  The total 
solubility of the crystalline drug, SR,T, increases linearly in surfactant solutions above the 
CMC according to 
 RR,T R,aq sS S 1 K [M]   (3.10) 
where SR,aq is the aqueous solubility of R in the absence of surfactant.  The cocrystal 
solubility SRHA,T, by contrast, is nonlinear with respect to micellar surfactant 
concentration, when the components are differentially solubilized by the surfactant.  This 
nonlinear behavior is dependent on the relative magnitude of Ks
R and Ks
HA.  
Consequently, the thermodynamic stability of cocrystal relative to drug is dependent on 
micellar concentration. 
 Figure 3.2 shows that there is a concentration of surfactant at which the solubility 
curves of cocrystal and pure drug intersect.  At this surfactant concentration, crystalline 
drug and cocrystal are thermodynamically stable.  We are calling this the critical 
stabilization concentration (CSC).  At surfactant concentrations above the CSC, cocrystal 
is thermodynamically stable with respect to the drug, and cocrystal persists in aqueous 
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suspensions.  The CSC exists due to the differential solubilization of R compared to HA; 
if R and HA have equal Ks, Equation (3.9) predicts that no CSC exists.  It can be seen 
that the CSC, like the cocrystal solubility, depends on the relative magnitude of Ks
R and 
Ks
HA.  The effectiveness of a surfactant in stabilizing cocrystals is based on lowering the 
CSC, and is related to higher Ks




Figure 3.2.  Schematic representation of the cocrystal (RHA) and drug (R) solubility 
with respect to the total surfactant concentration according to Equations (3.9) and (3.10).  
Differential solubilization of cocrystal components represented by the relative values of 
Ks
HA and Ks
R leads to nonlinear cocrystal solubility dependence and to intersection of the 
cocrystal and drug solubility curves. CSC refers to the critical stabilization concentration 
at which both cocrystal and drug are thermodynamically stable. 
 
 The phase stability of cocrystal, drug, and coformer can be described by its 
eutectic points E1 and E2, as shown in Figure 3.  The eutectic points are isothermal 
invariant points where two solid phases are in equilibrium with the solution.  E1, the 
eutectic between cocrystal, solid drug, and solution, is the more relevant eutectic for 
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incongruently saturating cocrystals of drugs with low aqueous solubility.  Micellar 
solubilization shifts these eutectics in a predictable manner based on Equations (3.9) and 
(3.10), which can result in cocrystal becoming the thermodynamically stable phase at the 
stoichiometric ratio of components. 
 
 
Figure 3.3.  Hypothetical triangular phase diagram showing how differential 
solubilization of cocrystal components changes the eutectic points and cocrystal stability 
regions. E1 and E2 are the cocrystal eutectic points.  Subscript aq refers to aqueous and 
subscript T refers to total (aqueous + micellar).  Differential solubilization of the drug 
compared to the coformer shifts the cocrystal stability region to cross the 1:1 
stoichiometric composition line (dotted), which results in a congruently saturating 
cocrystal. 
 
 In the interest of forming cocrystals from solutions of stoichiometric composition, 
it is common to select a solvent in which the solubilities of the components are similar.19, 
20  This condition can be achieved by the addition of surfactants with very different Ks 
values for cocrystal components or differential solubilization such that the cocrystal 
becomes congruently saturating. 
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 Although the focus of this work is on E1, the concept of differential solubilization 
is equally applicable to E2.  E2 describes the equilibrium between solid coformer, 
cocrystal, and solution, whereas E1 describes the equilibrium between solid drug, 
cocrystal, and solution.  The composition at E2 depends on the solubilization of the 
cocrystal relative to the solubilization of the coformer.  A CSC can theoretically exist for 
E2.  However, due to the generally low magnitudes of Ks
HA and the high aqueous 
solubility of coformers for most cocrystals, the calculated CSCs may not be 
experimentally accessible. 
 
Materials and Methods 
Materials 
Anhydrous monoclinic carbamazepine (CBZ(III); lot no. 057K11612 USP grade) 
was purchased from Sigma Chemical Company (St. Louis, MO), stored at 5 °C over 
anhydrous calcium sulfate and used as received.  Salicylic acid (SLC; lot no. 09004LH) 
and sodium lauryl sulfate (SLS; lot no. 104H0667) were purchased from Sigma Chemical 
Company (St. Louis, MO) and used as received.  Water used in this study was filtered 
through a double deionized purification system (Milli Q Plus Water System from 
Millipore Co., Bedford, MA).  
 
Cocrystal synthesis 
Carbamazepine-salicylic acid cocrystal (CBZ-SLC) was prepared by reaction 
crystallization at 24±1 °C.21  Carbamazepine and salicylic acid were added in 
stoichiometric amounts to near saturated solutions of salicylic acid in acetonitrile.  
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Carbamazepine dihydrate (CBZD) was prepared in water from anhydrous carbamazepine 
(CBZ).  Solid phases were analyzed by X-ray powder diffraction (XRPD). 
 
Cocrystal stability in aqueous SLS solutions 
Excess CBZ-SLC was suspended in pure water or in a 1% w/w (35 mM) aqueous 
SLS solution for 24 hours at room temperature (24±1 °C).  Solid phases were analyzed by 
XRPD. 
 
Measurement of cocrystal eutectic points 
The eutectic point between cocrystal and solid drug was measured using methods 
described previously.9  Two solids, cocrystal and drug, were equilibrated in either pure 
water or in 1% w/w aqueous SLS solution.  Samples were maintained at 25±0.1 °C for up 
to 3 days.  Solid phases were analyzed by XRPD and the solution concentrations were 
analyzed by high performance liquid chromatography (HPLC). 
 
Measurement of Ks 
Excess solid was equilibrated in varying concentrations of aqueous SLS solution.  
Samples were maintained at 25±0.1 °C for the duration of 24 hours.  Solid phases were 
analyzed by XRPD and the solution concentrations by HPLC. 
Ks
R was calculated from Equation (3.10).  Ks




S S 1 K [M]
[H ]
 
   
 
, where SA,aq is the total solubility of acid, SHA,aq is the 
intrinsic solubility of the acid, and [M] is micellar surfactant.  Ks
CBZ was calculated from 




High performance liquid chromatography (HPLC) 
 Solution concentrations were analyzed using a Waters Alliance 2695 autosampler 
equipped with a Waters 2996 photodiode array UV/vis detector.  A C18 Thermo Electron 
Corp. column (5 μm, 4.6 x 250 mm) at room temperature was used for separation.  
Mobile phase consisted of 55% methanol, 45% water and 0.1% trifluoroacetic acid in an 
isocratic method.  Flow rate was 1 mL/min.  CBZ and SLC were analyzed at 284 nm and 
304 nm respectively. 
 
X-ray powder diffraction (XRPD) 
 XRPD patterns were collected with a benchtop Rigaku Miniflex X-ray 
Diffractometer (Danvers, MA) with Cu Kα (λ = 1.54 Å) radiation, 30 kV tube voltage, 




 Predictions based on the micellar solubilization models presented were tested for 
the carbamazepine-salicylic acid (CBZ-SLC) cocrystal in aqueous solutions of sodium 
lauryl sulfate (SLS).  SLS is a commonly used anionic surfactant with a CMC reported at 
8 mM (0.24%).23  Carbamazepine (CBZ) is a nonionizable, low aqueous solubility drug 
and its anhydrous crystal quickly transforms to carbamazepine dihydrate (CBZD) in 
water.  Salicylic acid (SLC) is weakly acidic with a reported pKa of 3.0 and a reported 
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aqueous solubility of 14 mM at pH 3, approximately 26 times more soluble than 
CBZD.22, 24, 25 
 
Table 3.1.  Eutectic point and eutectic constant (±SE) for the equilibrium of CBZ-SLC 
and CBZD at 25 °C in water with and without SLS. 




(mM) Keu (exp.) Keu (pred.)* 
0 3.0 ± 0.1 0.61 ± 0.03 2.88 ± 0.04 4.75 ± 0.17 - 
35 3.2 ± 0.1 9.38 ± 0.07 5.25 ± 0.03 0.56 ± 0.01 0.59 
* Calculated from theoretical solubility dependence of cocrystal and drug on surfactant 
concentration.  Ks
CBZ = 0.6 mM-1 calculated from literature values between 0 and 17 mM 
SLS.22  Ks
SLC = 0.06 mM-1 (measured from solubility between 0 and 69 mM SLS). 
 
 Table 3.1 shows the eutectic concentrations at E1 for CBZ-SLC in pure water and 
in aqueous solutions of SLS.  CBZ-SLC cocrystal has been shown to be more soluble 
than CBZD in water and at pH values between 1 and 7.10   It can be seen that addition of 
surfactant reverses this solubility relationship. [CBZ]eu and [SLC]eu denote the total 
analytical concentrations of drug  and coformer at the eutectic point.  In the absence of 
surfactant, [SLC]eu is higher than [CBZ]eu, indicating that the cocrystal requires excess 
coformer to be at equilibrium with pure drug.  This situation is reversed in the 35 mM 
(1%) SLS solution, where [CBZ]eu is higher than [SLC]eu. 
 The utility of the eutectic constant Keu has been described recently for 
cocrystals.26  The eutectic constant was introduced in the context of chiral mixtures 
containing racemic compounds.27  For cocrystals, Keu is defined as the ratio of activities 
of coformer to drug at the eutectic point (Keu = acoformer,eu/adrug,eu ≈ [coformer]eu/[drug]eu). 
 Keu values are important indicators of cocrystal stability.
26  Keu > 1 for a 1:1 
cocrystal indicates that cocrystal is thermodynamically unstable with respect to drug 
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under stoichiometric solution conditions.   Observed Keu values for CBZ-SLC cocrystal 
decrease from 4.75 in water to 0.56 in 35 mM SLS, evidence of an unstable cocrystal in 
water becoming stable by addition of SLS.  A decrease to Keu below the cocrystal 
stoichiometric ratio, e.g., < 0.5 for a 2:1 cocrystal or < 1 for a 1:1 cocrystal (from Keu > 
cocrystal stoichiometric ratio) indicates a reversal in the thermodynamic stability, where 
cocrystal is more stable than drug.  In instances where activities are not well 
approximated by concentrations, the Keu where the activities of drug and coformer at the 
eutectic are equal may deviate from the stoichiometric ratio.  Therefore, the Keu at which 
the thermodynamic stability of drug and cocrystal reverse may shift depending on 
solution nonidealities. 
 Predicted Keu values, based on Equations (3.9) and (3.10) using experimental Ks 
values for the solubilization of pure drug and coformer in aqueous SLS solutions, are in 
excellent agreement with observed Keu values.  Results in Table 1 also imply that there is 





Figure 3.4.  X-ray powder diffraction patterns of solid phases after suspending CBZ-SLC 
cocrystal in aqueous solutions with and without surfactant for 24 h at pH 3 and 24 °C.  (a) 
0 mM SLS, (b) 35 mM SLS, (c) CBZD reference, (d) CBZ-SLC reference. 
 
 XRPD patterns in Figure 3.4 show that CBZ-SLC cocrystal converts to CBZD in 
water, whereas in 35 mM SLS solution, cocrystal is the only solid phase detected after 24 
hours. These results are in agreement with the cocrystal phase stability dependence on 
surfactant concentration observed and predicted by Keu values. Without knowledge of 
eutectic points, solid phase analysis alone is not sufficient to determine whether 
stabilization is of a kinetic or a thermodynamic nature. 
 
Conclusions 
 The findings presented here have broad implications for cocrystals in general and 
for pharmaceutical cocrystals in particular.  The selection of additives that prevent 
cocrystal conversions has been mostly an empirical exercise, requiring extensive 
experimentation and resources. A mechanism for cocrystal stabilization is presented 
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whereby additives with different solubilization capacities for cocrystal components 
impart thermodynamic stability to cocrystal phases exposed to solvent.  A mathematical 
model that describes the dependence of cocrystal solubility on micellar solubilization of 
cocrystal components explains the stabilization of CBZ-SLC cocrystal in aqueous SLS 
solutions.  Extension of this model to other cocrystal/surfactant systems is the subject of 
the next chapter. 
 Results show that cocrystal solubility and Keu are controlled by micellar 
solubilization of cocrystal components.  The effectiveness of the surfactant to stabilize 
cocrystals is associated with different micellar solubilization of cocrystal components.  
This stabilization mechanism is not limited to micellar solubilization, but is applicable to 
other processes involving differential affinities of components such as complexation, 
adsorption, etc.  These findings serve as a guide for surfactant selection to control 
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Engineering cocrystal solubility, stability, and pHmax by micellar solubilization  
 
Introduction  
The ability to engineer the aqueous solubility of inherently insoluble 
pharmaceutical compounds by cocrystal formation has important implications for the 
development of drug delivery systems.   Cocrystals owe their large solubility range to the 
numerous structures, diverse molecular characteristics of cocrystal components and 
solution phase behavior.1, 2  One of the fundamental consequences related to the nature of 
cocrystal components and their solution phase behavior is the ability to tailor the 
solubility-pH dependence of cocrystals of nonionizable or ionizable drugs by the careful 
selection of coformers and control of solution conditions.  The contributions of ionization 
and complexation of cocrystal components to cocrystal solubility have been reported and 
quantitative models have been developed that allow for tailoring cocrystal solubility 
behavior.3-5  While surfactants are commonly used in cocrystal dissolution studies and 
formulations,6-9 and the role of micelles on drug solubilization is widely appreciated in 
the literature,10-15 their role on cocrystal solubility has been virtually unexplored.    
 Cocrystals that are more soluble than the parent drug can transform, sometimes 
very rapidly, to the less soluble drug upon contact with solution.16-19  Thus, understanding 
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and controlling cocrystal thermodynamic stability is essential if they are to become 
pharmaceutical products. 
 We recently showed that surfactants can impart thermodynamic stability to 
cocrystals that are otherwise unstable in solution.20  A surfactant critical stabilization 
concentration (CSC) was discovered where cocrystal and drug phases become 
thermodynamically stable in micellar solutions.   Below CSC, cocrystal is 
thermodynamically unstable whereas at the CSC and above, cocrystal is 
thermodynamically stable.  A theoretical treatment predicted that the stabilizing effect of 
micellar surfactants is related to their differential solubilization of cocrystal components.  
In other words, when a surfactant system has superior solubilization power for the least 
soluble cocrystal component, its effectiveness as a cocrystal stabilizer increases.  
 The work presented here establishes the contributions of micellar solubilization 
and ionization of cocrystal components on cocrystal solubility, develops mathematical 
models that predict cocrystal solubility behavior in terms of thermodynamic parameters 
that are readily available in the literature or experimentally accessible, and provides a 
mechanistic basis for tailoring cocrystal CSC and pHmax to meet solubility and stability 
requirements.  
 This work shows for the first time that micellar solubilization can induce a pHmax 
for cocrystals that do not have one otherwise.  Mathematical models are derived that 
describe the dependence of cocrystal solubility, CSC, and pHmax on cocrystal Ksp, 
component Ks(s) and Ka(s), and micellar surfactant concentration.   
 The predictive power of the models is evaluated from studies that examine the 
influence of a surfactant (sodium lauryl sulfate, SLS) and coformer ionization on 
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cocrystal solubility, stability, and CSC for a range of cocrystals of a hydrophobic, 
nonionizable drug (carbamazepine, CBZ) and hydrophilic coformers with several 
ionization properties and stoichiometries.  The cocrystals studied include the following: 
1:1 carbamazepine-salicylic acid (CBZ-SLC), 1:1 carbamazepine-saccharin (CBZ-SAC), 
2:1 carbamazepine-succinic acid (CBZ-SUC), and 2:1 carbamazepine-4-aminobenzoic 
acid monohydrate (CBZ-4ABA-HYD).  The selected cocrystals cover the two most 
abundant stoichiometries and the coformers have ionization properties common among 
reported cocrystals.  Salicylic acid and saccharin are monoprotic weak acids; salicylic 
acid has a reported pKa of 3.0,
21 saccharin has a range of reported pKa values between 1.8 
and 2.2.22, 23  Succinic acid is a diprotic weak acid with pKa values of of 4.1 and 5.6.
24 4-
aminobenzoic acid is amphoteric with pKa values of 2.6 and 4.8.
25   
 
Theoretical 
 This section describes the theoretical basis of our quantitative approach to predict 
cocrystal solubilization and thermodynamic stability from solution phase properties of 
cocrystal components and micellar surfactants.  We first present the solution phase 
equilibria that govern the solubilization properties of cocrystals in micellar solutions.  
Relatively simple equations to calculate cocrystal solubility are derived by considering 
the contributions of ionization and micellar solubilization of cocrystal components.  
Several important physicochemical factors are identified that can be used to make 
cocrystal solubility and stability predictions.   
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 The interested reader is directed to the appendix for derivations of the equations 
presented in this section. The analysis can be generalized to mixed micelles and other 
solubilization mechanisms, although they may be of a different nature. 
 
Cocrystal solubilization and thermodynamic stabilization in micellar solutions 
 A micellar solution phase in equilibrium with a solid cocrystal phase consists of 
molecules of cocrystal components and surfactant in several states of self-association, 
complexation, and ionization.  Surfactants self-assemble in solution at a critical micellar 
concentration (CMC) and provide a means to solubilize cocrystal components.  The 
solubility of a cocrystal (RHA) composed of the nonionized forms of its components, a 
nonionizable drug (R) and an ionizable coformer, in this case a monoprotic weak acid 
(HA), is described by the equilibria for cocrystal dissociation, ionization, complexation 
and micellar solubilization. For the sake of simplicity solution complexation of cocrystal 

























    (4.5) 
where subscripts m and aq refer to micellar and to aqueous pseudophases, respectively. 
Ksp is the cocrystal solubility product and Ka is the dissociation constant for the acidic 
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coformer. M is the micellar surfactant.  Ks
R, Ks
HA, and Ks
A- are the micellar solubilization 
constants for cocrystal components and their ionized forms.  
 The cocrystal solubility, SRHA,T, under stoichiometric conditions, is equal to the 
total concentration of each cocrystal component in equilibrium with solution, SRHA,T = 
[R]T = [A]T. The contributions of ionization and micellar solubilization of each cocrystal 
component to the solubility of a cocrystal RHA,  is given by  
RHA,T aq m aq aq m mS [R] [R] [HA] [A ] [HA] [A ]
        (4.6) 
 An expression for cocrystal solubility in terms of experimentally accessible 
solution properties is obtained  
  a aR HA ARHA,T sp s s s
K K
S K 1 K [M] 1 K [M] K [M]




     
 
 (4.7) 
by combining Equation (4.6) with the equilibrium constant equations below 































  (4.12) 
where the terms in brackets refer to concentrations with the recognition that under dilute 
solution conditions they approximate activities.   
 Equation (4.7) can be further simplified to 
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  aR HARHA,T sp s s
K
S K 1 K [M] 1 K [M]
[H ]
 





A-, and the micellar solubilization of ionized species negligibly affects 
total solubility unless present at very high concentrations.26-28 Equation (4.13) predicts 




+], and surfactant micellar concentration, [M]. 
 It is evident from Equations (4.7) and (4.13) that cocrystal solubility is not 
linearly dependent on micellar concentration.  This is in contrast to the well-known linear 
dependence of the micellar solubilization of a single-component solid phase of a 
nonionzable drug R 
 RR,T R,aq sS S 1 K [M]   (4.14) 
where SR,aq is the solubility of crystal R in the aqueous pseudophase.  In this analysis, Ks 
values are assumed to be independent of solute and surfactant concentrations.   
 Equations (4.13) and (4.14) are shown graphically in Figure 1 for the case of a 
nonionizable, hydrophobic drug and its cocrystal with an ionizable, hydrophilic, coformer 
where Ks
HA = 0.   This plot reveals that cocrystal and drug solubility surfaces intersect 
along a curve of given surfactant concentration and pH values and identifies stability 
regions for cocrystal or drug by two critical parameters.  The first is the CSC, or the 
surfactant concentration where cocrystal and drug solid phases are in equilibrium with 
solution.  The second is the pHmax, or the pH value at the CSC.  Above the CSC or below 
pHmax the cocrystal becomes the stable phase relative to the drug phase.  When one or 
more cocrystal components ionize, both CSC and pHmax are necessary to describe the 
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solution conditions under which cocrystal and/or drug solid phase are thermodynamically 
stable. 
 
Figure 4.1.  Cocrystal RHA (blue/green surface) and drug R (yellow surface) solubility 
dependence on surfactant concentration and pH.  The intersection of the cocrystal and 
drug solubility surfaces represents the surfactant concentrations (CSC) and pH values 
(pHmax), where cocrystal and drug are in thermodynamic equilibrium with solution.  
Solubilities were calculated from Equations (4.13) and (4.14) with  Ksp = 1 mM
2 
(SRHA,aq/SR,aq = 5), SR,aq = 0.2 mM, pKa = 4, Ks
R = 1 mM-1, Ks
HA = 0, and CMC = 8 mM. 
  
 The existence of a CSC and a pHmax (in the case of ionizable cocrystal 
component) is a consequence of the slower rate of increase of cocrystal solubility with 
surfactant concentration compared to that of drug solubility.  It is evident from Equations 
(4.13) and (4.14) that cocrystal solubility depends on [M]  (when Ks
HA = 0) whereas 




Estimation of cocrystal solubilization from drug solubilization 
 A useful estimate of the surfactant influence on cocrystal solubilization can be 





  (4.15) 
This expression is obtained by combining Equations (4.13) and (4.14) for a nonionizable 
drug R when Ks
R is unaffected by the coformer and Ks
HA = 0.  A surfactant concentration 
that increases drug solubility by 100-fold is predicted to increase cocrystal solubility by 
10-fold.  Equation (4.15) implies that a surfactant will increase the solubility of all 1:1 
cocrystals of a drug by the same ratio as long as the stated assumptions are justified.   





R X ,T R,T




   
 
 (4.16) 
for a nonionizable drug R and coformer X.  The solubility increase for a 2:1 cocrystal is 
predicted to be 1002/3 or 21.5-fold its aqueous solubility, when the drug solubility is 
increased by 100-fold.  Thus cocrystal stoichiometries richer in hydrophobic drug will 
exhibit a weaker dependence of total cocrystal solubility on micellar solubilization, 
leading to higher CSC or pHmax values. 
 
Mechanism by which micelles stabilize cocrystals 
 The influence of micellar solubilization on cocrystal thermodynamic stability and 
CSC can be explained by considering the species distribution in micellar solutions at 
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equilibrium with cocrystal and/or drug solid phases.  Figure 4.2 shows the distribution of 
the drug in micellar and aqueous environments for a crystal of a hydrophobic drug R and 





Figure 4.2.  Distribution of drug (R) between the aqueous and micellar environments in 
surfactant solutions at equilibrium with cocrystal (RHA) and crystal (R).  The cocrystal 
thermodynamic stability relative to the drug decreases with surfactant concentration.  A 
thermodynamically unstable cocrystal in pure solvent becomes stable at the CSC where 
all curves intersect.  Cocrystal is more soluble than drug below the CSC, cocrystal is 
equally soluble to drug at the CSC, and cocrystal is less soluble than drug above the CSC.  
Subscripts aq, m, and t, refer to aqueous, micellar and total.  Solubilities and drug 




HA = 0 mM-1, SR,aq = 0.5 mM, and CMC = 8 mM.  
 
 When drug crystal phase (R) is in equilibrium with micellar solution, the drug 
concentration in the aqueous environment, [R]R,aq, remains constant with increasing 
surfactant concentration. At surfactant concentrations above the CMC, the drug 
concentration in the micellar environment, [R]R,m, increases linearly.  For cocrystal 
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(RHA) in equilibrium with micellar solution (where drug is solubilized by the micelle 
and the coformer is not) the drug concentration in the aqueous environment, [R]RHA,aq, is 
not constant but decreases with increasing surfactant concentration above the CMC.  
Because the coformer is not solubilized by the micelle, the aqueous phase becomes 
enriched with coformer and [R]RHA,aq decreases to maintain a constant solubility product 
as described by the cocrystal dissociation equilibrium.  This imbalance of cocrystal 
components in the aqueous environment leads to a decrease in the rate of cocrystal 
solubilization as drug solubilized by the micelle increases with surfactant concentration.  
A CSC where cocrystal is in equilibrium with drug is reached as indicated by the 
intersection of the total drug concentration curves, [R]RHA,T = [R]R,T, as well as the 
speciation in the aqueous and micellar environments [R]RHA,m = [R]R,m and [R]RHA,aq = 
[R]R,aq. 
 
CSC and pHmax dependence on cocrystal and surfactant properties 
 Cocrystals of higher solubilities in water are predicted to exhibit higher CSC 
values as illustrated in Figure 4.3.  For cocrystals of the same drug, aqueous solubilities 
can be altered by different coformers or by coformer ionization behavior in solution (by 





Figure 4.3.  Influence of surfactant solubilization on cocrystal solubility and CSC for 
cocrystals of the same drug with different aqueous solubilities.   More soluble cocrystals 
relative to drug require higher surfactant concentration to achieve the CSC.  Total 
solubilities of cocrystal RHA (SRHA,T) and drug (SR,T) were calculated from Equations 
(4.13) and (4.14) with cocrystal Ksp = 1 and 4 mM
2 (SRHA,aq/SR,aq = 5 and 10), SR,aq = 0.2 
mM, Ks
R = 1 mM-1, Ks
HA = 0, and CMC = 8 mM.  
 













    (4.17) 
by solving for the surfactant concentration at which SRHA,T = SR,T from Equations (4.13) 
and (4.14).  This expression applies to a 1:1 cocrystal with no micellar solubilization of 




 The influence of drug and coformer micellar solubilization on the CSC has been 
recently presented.20  The basis for the existence of the CSC for cocrystal and drug was 
described from the differential micellar solubilization of drug and coformer. The greater 
the drug micellar solubilization, Ks
R, relative to that of the coformer, Ks
HA, the lower is 
the CSC value.  In the case of pharmaceutical cocrystals drugs are generally much more 
hydrophobic than coformers and Ks
R >> Ks
HA.    
 Figure 4.4 shows the dependence of CSC on drug micellar solubilization (Ks
R) 
and cocrystal aqueous solubility, as predicted by Equation (4.17).  CSC is inversely 
proportional to drug micellar solubilization and directly proportional to cocrystal aqueous 
solubility.  This equation allows for estimation of the required Ks
R to achieve the CSC for 
cocrystal and its drug component, and in this way provide guidance for the rational 
selection of surfactant and concentration. 
 
Figure 4.4.  The CSC increases with increasing cocrystal to drug solubility ratio in pure 
water (or below CMC) and with decreasing drug micellar solubilization Ks
R.  CSC 
calculated from Equation (4.17) with Ks




 Micellar solubilization of cocrystal components can also impart a pHmax to a 
cocrystal that otherwise does not have one as shown in Figure 4.5.  The solubility-pH 
dependence for a cocrystal RHA of a nonionizable drug and a weakly acidic coformer, 
where the cocrystal is more soluble than drug R at all pH values, is presented in Figure 
4.5(a).  Many CBZ cocrystals, including CBZ-SAC, CBZ-SLC and CBZ-4ABA-HYD, 
have been shown to exhibit this behavior and consequently have no pHmax in aqueous 
solutions.4, 29, 30  This behavior, however, is changed by micellar solubilization and 
ionization of cocrystal components (Figure 4.5(b)) where the cocrystal and drug 
solubility curves intersect at a given pH, or  pHmax.  The surfactant concentration at this 
intersection is the CSC.  The drug micellar solubilization leading to coformer enrichment 
in the aqueous environment is responsible for the CSC and pHmax. 
 
 
Figure 4.5.  pHmax of a cocrystal can be tailored by micellar solubilization of cocrystal 
components.  Solubility-pH dependence for a cocrystal RHA and drug R (a) in water and 
(b) in a micellar solution.  Calculations are based on Equation (4.18) with Ksp = 1 mM
2 
(SRHA,aq/SR,aq = 5),  SR,aq = 0.2 mM, [M] = 99 mM (SR,T/SR,aq = 100 and SRHA.T/SRHA,aq = 
10), pKa = 4, and Ks




 Considering the contributions of coformer solubilization and ionization in 





















where [H+] represents [H+]max.  According to Equation (4.18), the CSC for a 1:1 cocrystal 




HA.   
This equation can also be solved for [H+] to predict the pHmax dependence on micellar 
surfactant concentration and other cocrystal and surfactant properties. Equation (4.18) 
and Figure 4.6 show that if a CSC exists, there also is a pHmax value associated with that 
CSC and vice versa.  CSC is predicted to increase as ionization increases.  Higher levels 
of ionization increase cocrystal solubility, and thus more surfactant is required to achieve 
the CSC.  Equation (4.18) can also be used to engineer a cocrystal’s pHmax based on 





Figure 4.6.  CSC dependence on pHmax according to Equation (4.18) for a cocrystal 
RHA.  CSC increases greatly at pH above the coformer pKa (i.e. increased ionization).  
Calculations are based on Equation (4.18) with Ksp = 1 mM
2, SR,aq = 0.2 mM, Ks
R = 1 
mM-1, Ks
HA = 0, pKa = 4, and CMC = 8 mM. 
 
 Table 4.1 summarizes the equations that describe cocrystal solubility and CSC for 
several common classes of cocrystals, with varying stoichiometries and component 
ionization properties.  
 The theoretical treatment of cocrystal micellar solubilization suggests that the 
CSC, where cocrystal and drug phases are in thermodynamic equilibrium, is most readily 
achieved by (1) preferential drug solubilization (Ks
R >> Ks
HA), (2) cocrystals of lower 
aqueous solubility relative to drug, and (3) cocrystal stoichiometries that are higher in 
coformer. 
 
Surfactant selection to achieve CSC 
 The CSC is a consequence of differential solubilization where drug is more highly 
solubilized than coformer.  From Equation (4.18) a criterion can be obtained that 
determines if a particular surfactant, which has a given Ks
R and Ks
HA for the cocrystal 







  (4.19) 
This expression is obtained by examining Equation (4.18) for which positive values can 
be obtained (denominator > 0).  Equation (4.19) relates the dimensionless parameter 
Ksp/SR,aq
2 to the ratio of drug to coformer Ks, thus providing simple guidelines to select 




2 for a 1:1 cocrystal RHA in the absence of ionization and micellar 








   
 
 (4.20) 
If a surfactant is chosen such that Equation (4.19) is satisfied, there exists a CSC and 
pHmax for that cocrystal and surfactant combination.  Cocrystals that are more soluble 
relative to drug (higher Ksp/SR,aq
2) require surfactants with more highly differential 
solubilization (higher Ks
R/Ks
HA) to achieve CSC.  Equation (4.19) is not indicative of the 
magnitude of CSC and does not guarantee that the CSC and pHmax are within reasonably 






Table 4.1.  Equations that describe cocrystal solubility and CSC as a function of cocrystal Ksp, component Ka and Ks, solution [H
+],  
micellar surfactant concentration [M] and CMC. 
Cocrystal Solubility Equation CSC Equation
RHA 
1:1 nonionizable : 
monoprotic acidic 
  aR HARHA,T sp s s
K
S K 1 K [M] 1 K [M]
[H ]
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Materials and Methods 
Materials 
Anhydrous monoclinic carbamazepine (CBZ(III); lot no. 057K11612 USP grade) 
was purchased from Sigma Chemical Company (St. Louis, MO), stored at 5 °C over 
anhydrous calcium sulfate and used as received.  Salicylic acid (SLC; lot no. 09004LH), 
saccharin (SAC; lot no. 03111DD), succinic acid (SUC; lot no. 037K0021), 4-
aminobenzoic acid (4ABA; lot no. 068K0698), and sodium lauryl sulfate (SLS; lot no. 
104H0667) were purchased from Sigma Chemical Company (St. Louis, MO) and used as 
received.  Water used in this study was filtered through a double deionized purification 
system (Milli Q Plus Water System from Millipore Co., Bedford, MA). 
 
Cocrystal Synthesis 
Cocrystals were prepared by the reaction crystallization method at room 
temperature by adding CBZ to nearly saturated solutions of coformer.17  CBZ-SLC was 
prepared in acetonitrile, CBZ-SAC and CBZ-SUC were prepared in ethanol, and CBZ-
4ABA-HYD was prepared in water.  CBZ dihydrate (CBZD) was prepared in water.  
Solid phases were characterized by XRPD.   
 
CSC measurement from solid phase stability (Method 1) 
Cocrystal was suspended in aqueous solutions of different SLS concentrations.  
Suspensions were seeded with ~5% w/w of CBZD after several hours.  30-40 mg of 
CBZ-SLC or CBZ-SAC were added to 3 mL of aqueous SLS solution.  70-80 mg of 
CBZ-SUC or CBZ-4ABA-HYD were added to 3 mL of aqueous SLS solution.  Samples 
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were maintained at 25 ± 0.1 °C for the duration of 3 days, when the solids were recovered 
and analyzed by XRPD.  Examination of the XRPD patterns revealed that 24 hours was 
sufficient for samples to reach equilibrium.  The CSC was determined to be above the 
highest SLS concentration where CBZD is detected and below the lowest concentration 
where CBZD is no longer detected in the solid phase. 
 
CSC predicted from cocrystal aqueous solubility and micellar solubilization of cocrystal 
components (Method 2) 
CSC was predicted from model equations in Table 4.1 (Equations (4.18), (4.26), 
(4.28)), with thermodynamic parameters measured in pure water or obtained from 
literature.  Ksp was calculated from cocrystal aqueous solubilities according to the model 
equations in Table 4.1 (Equations (4.13), (4.25) and (4.27) when [M]=0); cocrystal 
aqueous solubilities were determined by measuring eutectic concentrations of drug and 
coformer in pure water at 25 ± 0.1°C.  50-100 mg of cocrystal and 25-50 mg of CBZD 
were suspended in 3 mL of pure water up to 3 days.  pH at equilibrium was measured but 
not independently modified.  The equations to determine cocrystal aqueous solubility 







  for 1:1 and 2:1 cocrystals, respectively.  Equations are 
specific to cocrystal stoichiometry but general to cocrystal ionization properties.  The 
evaluation of cocrystal solubilities and stabilities via eutectic points has been discussed 
thoroughly elsewhere.4, 29, 31  At the eutectic or transition point the solution is saturated 
with respect to two solid phases, in this case cocrystal and CBZD.  This method allows 
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for cocrystal solubility measurement under thermodynamic equilibrium that may not 
otherwise be accessible due to transformation to less soluble forms. 
Micellar solubilization constants (Ks) for cocrystal components were determined 
by linear regression of the measured solubilities of the individual components as a 
function of micellar SLS concentration at 25 ± 0.1°C.  Ka values were obtained from 
literature.  Drug and coformer concentrations were analyzed by HPLC.  Solid phases at 
equilibrium were confirmed by XRPD.  
 
CSC measurement of cocrystal solubility in SLS solutions (Method 3) 
The CSC was evaluated by measuring cocrystal and drug solubilities as a function 
of SLS concentration in water at 25 ± 0.1°C.  Cocrystal solubilities were obtained from 
measuring eutectic concentrations of drug and coformer in aqueous SLS solutions at 25 ± 
0.1°C.   50-100 mg of cocrystal and 25-50 mg of CBZD were suspended in 3 mL of pure 
water up to 3 days.  pH at equilibrium was measured but not independently modified.  







  for 1:1 and 2:1 cocrystals, respectively.  Equations are specific 
to cocrystal stoichiometry but general to cocrystal ionization properties.  CBZD 
solubilities were measured as a function of SLS concentration in water at 25 ± 0.1°C and 
are consistent with reported values.32  Drug and coformer concentrations were analyzed 
by HPLC.  Solid phases at equilibrium were confirmed by XRPD. 
 
High Performance Liquid Chromatography (HPLC) 
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The solution concentrations of CBZ and coformer were analyzed by Waters 
HPLC (Milford, MA) equipped with a UV/vis spectrometer detector.  Waters’ operation 
software, Empower 2, was used to collect and process the data.  A C18 Thermo Electron 
Corporation column (5 μm, 250 x 4.6 mm) at ambient temperature (24 °C) was used.  
The mobile phase was composed of 55% methanol and 45% water with 0.1% 
trifluoroacetic acid and the flow rate was 1 mL/min using an isocratic method. Injection 
sample volume was 20 or 40 μL.  Absorbance of CBZ, SLC, SUC, and 4ABA was 
monitored at 284, 303, 230, and 284 nm, respectively. 
 
X-ray Powder Diffraction (XRPD) 
XRPD diffractograms of solid phases were collected with a benchtop Rigaku 
Miniflex X-ray diffractometer (Danvers, MA) using CuKα radiation (λ = 1.54 Å), a tube 
voltage of 30 kV, and a tube current of 15 mA. Data were collected from 5 to 40 ° at a 
continuous scan rate of 2.5°/min. 
 
Results 
The equations presented above for cocrystal solubility in terms of micellar 
solubilization and ionization of cocrystal components, suggest that cocrystal CSC and 
pHmax in micellar solutions can be a priori calculated from knowledge of cocrystal and 
drug solubilities in water, pKa and Ks values of cocrystal components, and surfactant 
CMC.  At the CSC, cocrystals otherwise unstable in aqueous media will become 
thermodynamically stable.   To evaluate the predictive power of the model, the solubility 
and stability of cocrystals of a nonionizable drug (carbamazepine) with coformers of 
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different ionization properties and stoichiometries were investigated as a function of SLS 
solution concentration.  These included 1:1 cocrystals where coformers are monoprotic 
weak acids (CBZ-SLC and CBZ-SAC), and 2:1 cocrystals with a diprotic weak acid 
(CBZ-SUC) or with an amphoteric coformer (CBZ-4ABA-HYD).   The cocrystal 
aqueous solubilities range from 1.32 mM for CBZ-SLC to 2.38 mM for CBZ-SUC 
(expressed in terms of drug concentration) at 25 °C, or 2.5 to 4.5 times the solubility of 
CBZD (0.53 mM).32   Cocrystal solubilities in pure water are in agreement with those 
reported in previous studies.29 
 For cocrystals with ionizable components, the CSC is dependent on pH and while 
the pH was not independently adjusted in these studies, the pH of surfactant solutions at 
equilibrium with solid phases was measured.  The pH at the CSC corresponds to the 
pHmax, where two solid phases (cocrystal and drug in this case) are in equilibrium with 
solution.  
 The cocrystal CSCs were evaluated by three methods: (1) measurement of solid 
phase stability and pH as a function of SLS solution concentration, (2) calculation from 
cocrystal and drug solubility measurement in pure water, in conjunction with values of 
cocrystal component ionization (Ka), micellar solubilization (Ks), surfactant CMC, and 
solution pH, and (3) measurement of cocrystal solubility, drug solubility and pH as a 
function of SLS solution concentration.   Further, the dependence of CSC on pHmax was 
estimated from the evaluation of CSC at a single pH. 
 
CSC from measurement of solid phase stability (Method 1) 
 
112 
Evaluation of the CSC from cocrystal phase stability measurements was done by 
XRPD analysis of solid phases after suspension in aqueous solutions of varying SLS 
concentration for 72 hours, though 24 hours was sufficient for equilibration to occur.  
Figure 4.7 shows that cocrystal conversion to drug (CBZD) decreases and becomes 
undetectable as surfactant concentration increases.  The incremental variation of SLS 
concentrations for each cocrystal studied led to the following range of CSC values: CBZ-
SLC 15 mM < CSC ≤ 20 mM, CBZ-SAC 50 mM < CSC ≤ 55 mM, CBZ-4ABA-HYD 69 
mM < CSC ≤ 104 mM, and CBZ-SUC 120 mM < CSC ≤ 140 mM.  The solution pH 
value associated with each CSC measurement is reported in the legend of Figure 4.7.  
The CSC range for CBZ-SLC is in agreement with previous results where cocrystal was 
found to be stable in 35 mM (1% w/v) SLS.20 
 While the solid phase analysis approach is convenient for a quick assessment of 
the CSC range, it must be recognized that its accuracy is limited by the changes of 
solution composition from initial to equilibrium states as solid phase(s) dissolve and 
crystallize.  It is also not sufficient to establish whether the stabilization achieved is of a 
thermodynamic or kinetic nature.  These issues may be resolved by measuring the 
changes in solution composition that result from equilibration of cocrystal and solid drug 
with the solution phase, and/or calculating the CSC according to the equations presented 





Figure 4.7.  XRPD patterns showing the influence of SLS concentration on the cocrystal 
to drug conversion at 25 °C for (a) CBZ-SLC at pH 3.0 (b) CBZ-SAC at pH 2.2 (c) CBZ-
4ABA-HYD at pH 4.0, and (d) CBZ-SUC at pH 3.1.  pH was not independently adjusted 
and represents the values measured at 24 h before solid phase recovery for XRPD 
analysis.   Initial solid phase consisted of cocrystal and a small fraction of CBZD.  Peaks 
associated with SLS are indicated by *.   
 
CSC from measured cocrystal solubility in pure water (Method 2) 
Figure 4.8 shows the calculated cocrystal and drug solubilities in micellar SLS 
solutions according to Equations (4.13), (4.25) and (4.27) for cocrystal and Equation 
(4.14) for drug, from thermodynamic parameter values presented in Table 4.2. The CSC 
where cocrystal and CBZD are in equilibrium with solution is given by the SLS 
concentration and pH at the intersection of the solubility curves. CSC is strongly 
influenced by pH and the calculations were done for pH values measured at saturation.  
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This pH value changed by 0.2 units or less at the concentrations of SLS studied.   The pH 
at the CSC is the pHmax, where two solid phases (cocrystal and drug in this case) are in 
equilibrium with solution. 
 Predicted CSC values for these cocrystals range from 20 to 187 mM which are in 
reasonably good agreement with the experimentally measured values listed in Table 4.3.  
Results of CSC measurement according to method 3, from solubility measurement in 
surfactant solutions are described in the next section.   
 The range of measured CSCs for each cocrystal by direct experimental 
measurement (methods 1 and 3) can be narrowed by examining smaller increments of 
SLS concentrations, and by approaching equilibrium from above and below saturation 
with respect to cocrystal and drug phases.   Estimation of the CSC from thermodynamic 
properties of cocrystal and surfactant solutions (such as solubility in water, Ks, Ka and 
CMC) provides useful guidance for the selection of surfactant, its concentration and 





Figure 4.8.  Calculated solubility and CSC of CBZ cocrystals in SLS aqueous solutions 
from measured solubility in water and values of Ks, Ka and pH listed in Table 4.2.  
Values of solution pH measured at equilibrium with solid phases are indicated.  Dashed 
line shows the SLS concentration at the CSC, where cocrystal and drug are 
thermodynamically stable.  The solid lines represent solubility predictions for cocrystal 
and drug, according to Equations (4.13), (4.14), (4.25) and (4.27).  The CMC value of 6 
mM for SLS measured at saturation with CBZD was used in these calculations. 
 
 Table 4.2 presents the thermodynamic parameter values for the CBZ cocrystals 
studied.  Cocrystal Ksp in water and the corresponding solubility and pH are within 30% 
of those reported in previous studies.20, 29  Coformer Ka values were obtained from the 
literature.  Surfactant CMC and Ks values for drug and coformer were determined from 
solubility measurements of individual components (drug or coformer) in SLS solutions.   
The CMC of SLS was experimentally measured to be 6 mM in solutions saturated with 
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CBZ and is used in these calculations unless otherwise specified.  The reported CMC 
value for SLS in water (8.3 mM33) is higher than the value measured in this study and 
those reported for carbamazepine solutions without coformer (5.3 mM32).   The purity, 
ionic strength, and interactions with solutes are well documented to induce changes in the 
CMC of ionic surfactants.10, 34-36   Ks values for hydrophobic compounds have been 
reported to be influenced by solute and surfactant concentration10, 37-41  Ks values as well 
as the concentration ranges in which they were measured are shown in Table 4.2.  An 
expression that describes the Ks dependence on surfactant concentration could also be 





Table 4.2.  Cocrystal Ksp and drug solubilities in water, pKa and Ks values for cocrystal components in SLS solutions used in 
calculation of CSC and pHmax. 
Solid phase 
Ksp 
























6.15 4.1, 5.6d 0.49f 0g 2.38±0.02 
pH 3.1 
CBZD n/a n/a 
0.49 (0 to 140 mM) 
0.58 (0 to 50 mM) 
n/a 0.53±0.01h 
a from reference 21 
b from reference 22 
c from reference 25  
d from reference 24 
e average Ks in lower concentrations of SLS (0 to 50 mM) 
f average Ks in higher concentrations of SLS (0 to 140 mM) 
g Ks values <0.010 mM-1 are considered to = 0. 




Table 4.3.  CSCs and solubilities of CBZ cocrystals in SLS aqueous solutions. 
Cocrystal pH 
Scocrystal/Sdrug       
in terms of  
CBZ mM 
CSC measured from 
solid phase stability 
in SLS solutions (1) 
SLS mM 
CSC calculated from 
measured cocrystal 
solubility in water (2) 
SLS mM 
CSC measured from 
cocrystal solubility 




3.0 2.5 15 < CSC ≤ 20 
23 (CMC = 9 mM) 
20 (CMC = 6 mM) 
18 < CSC < 27 
CBZ-SAC 
(1:1) 
2.2 4.5 50 < CSC ≤ 55 44 35 < CSC < 50 
CBZ-4ABA-HYD 
(2:1) 
4.0 3.5 69 < CSC ≤ 104 92 70 < CSC < 140 
CBZ-SUC 
(2:1) 
3.1 4.5 120 < CSC ≤ 140 187 140 < CSC 
· (Method 1) CSCs determined from XRPD analysis of the solid phase in Figure 4.7.  The lower boundary is the highest concentration 
of SLS where CBZD is detected in the solid phase, and the upper boundary is the lowest concentration of SLS where no CBZD is 
detected in the solid phase. 
· (Method 2) CSCs calculated according to Equations (4.18), (4.26), (4.28) from Ksp, pKa, and Ks values in Table 4.2. 
· (Method 3) CSCs determined from measurement of cocrystal and drug solubilities in SLS solutions (Figures 4.9-4.11). 
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CSC from measured cocrystal solubility in SLS solutions (Method 3) 
Figure 4.9 shows the experimental and predicted cocrystal solubility dependence 
on surfactant concentration and pH.  The pH was not independently adjusted and 
experimental measurements represent the narrow pH range of micellar solutions saturated 
with cocrystal.   Changes in pH, however, can profoundly affect cocrystal solubility as 
indicated by the surfaces predicted from Equations (4.13), (4.14), (4.25) and (4.27) using 
parameter values in Table 4.2.   Coformer ionization, in this case determines the shape of 
the curves, since the drug is not ionizable and coformer is not solubilized by micelles.  
The solubility of cocrystals with acidic coformers increases with pH, whereas solubility 
decreases and increases with an amphoteric coformer.   The contribution of coformer 
ionization to cocrystal solubility is consistent with the behavior in water that we 





Figure 4.9.  Influence of pH and surfactant concentration on cocrystal solubility for (a) 
CBZ-SLC (b) CBZ-SAC (c) CBZ-4ABA-HYD (d) CBZ-SUC.  Points refer to cocrystal 
solubilities measured in surfactant solutions, while surfaces represent cocrystal 
solubilities calculated from Equations (4.13), (4.25) and (4.27) using measured cocrystal 
solubility in water at a given pH and thermodynamic values listed in Table 4.2. 
 
 Figures 4.10 and 4.11 show the predicted and measured cocrystal and drug 
solubilities as a function of surfactant concentration.  The CMC for SLS was constant at 6 
mM for cocrystals in Figure 4.9, whereas a CMC of 9 mM was estimated from solubility 
of CBZ-SLC cocrystal (Figure 4.10).  Results show very good agreement between 
predicted and experimental cocrystal solubility and CSC behavior.   The largest 
deviations were observed with the CBZ-SUC cocrystal at high SLS concentration and 
may be a result of changes in Ks with SLS and coformer concentration.  CSC values 
obtained by the three methods are listed in Table 4.3 and show very good agreement 
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between the predicted (method 2) and experimentally measured CSC values (methods 1 
and 3).   A small variation in the CMC of SLS, such as from 6 mM to 9 mM for CBZ-
SLC, has a relatively minor impact on the CSC (20 mM to 23 mM).   
 Improving the predictive power of the model requires more rigorous consideration 
of various solution interactions on equilibrium constants (such as Ka and Ks) and on 
surfactant properties (such as CMC).  The model equations assume that solubilization of 
one cocrystal component is unaffected by the presence of the other; that is, Ks for a 
component under pure conditions is a good approximation for the Ks in the presence of 
cocrystal.  Factors that cause Ks, Ka, and CMC to change (such as ionic strength) 
influence the predictions and these differences may be considered by measuring the 
parameters as a function of solution composition.  A 0.2 unit pH or pKa change when pH 
≈ pKa (e.g. CBZ-SAC) can lead to errors in the CSC on the order of 15-30%, and even 
greater errors when pH > pKa.  A 10% error in Ks
CBZ (e.g. CBZ-SUC) leads to an error in 
the CSC of 10%. 
 An alternative approach would have been to fit the models to the experimental 
data and evaluate the corresponding parameters.  Given that this is the first manuscript on 
this topic, we chose to use thermodynamic parameter values reported in the literature or 
measured for single components of cocrystals, to evaluate the predicted cocrystal 






Figure 4.10.  Experimental and predicted influence of SLS on drug (CBZD) solubility 
and CBZ cocrystal solubilities for (a) CBZ-SAC, (b) CBZ-4ABA-HYD, and (c) CBZ-
SUC.  The experimental solubilities were measured in unbuffered surfactant aqueous 
solutions.  The pH measured at equilibrium is indicated.  Predicted drug and cocrystal 
solubilities were calculated according to Equations (4.13), (4.14), (4.25) and (4.27) with 
thermodynamic values in Table 2.  The CSC is indicated by the SLS concentration 






Figure 4.11.  Influence of SLS on the solubility of CBZ-SLC and CBZD.  The lines 
represent predictions according to Equations (4.13) and (4.14) from two different CMC 
values (a) 9 mM and (b) 6 mM. The points are experimental values.   
 
 
CSC and pHmax dependence on cocrystal and surfactant properties 
The treatment developed in the theoretical section is based on cocrystal 
component ionization and micellar solubilization. This treatment identified the existence 
of a CSC and the factors that determine its value:  (1) cocrystal Ksp and solubility relative 
to drug, (2) ionization of cocrystal components, (3) micellar solubilization of cocrystal 
components, (4) cocrystal stoichiometry, and (5) surfactant CMC.   CSC is predicted to 
increase with increasing cocrystal solubility, ionization, coformer Ks, and surfactant 
CMC and with decreasing drug Ks. 
For this series of CBZ cocrystals, the magnitude of the CSC is mostly influenced 
by the cocrystal Ksp, stoichiometry, and coformer ionization.   Between cocrystals of the 
same stoichiometry such as CBZ-SLC and CBZ-SAC, the experiments confirm the 
prediction that higher solubility relative to drug results in a higher CSC (Table 4.3).  
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These have similar % ionized (since pH ≈ pKa of the coformer), and Ks
HA << Ks
R.   The 
CSC is mainly determined by cocrystal solubility relative to drug.  Similar behavior is 
observed for the 2:1 cocrystals CBZ-4ABA-HYD and CBZ-SUC.   These cocrystals have 
low levels of ionization under the pH conditions studied (10-20% of the coformer 
ionized), and negligible coformer solubilization.  The experiments also show that the 2:1 
cocrystal CBZ-SUC has a higher CSC than the 1:1 cocrystal CBZ-SAC of equal 
solubility (in terms of CBZ moles).  The higher CSC of drug rich stoichiometries is a 
consequence of the higher surfactant concentrations required to solubilize more drug to 
achieve the same level of coformer enrichment in the aqueous pseudo phase as a 1:1 
cocrystal.  
 The pH value at the CSC is the pHmax, where cocrystal and drug (in this case) are 
in equilibrium with solution.  The predicted CSC and pHmax values for the CBZ 
cocrystals studied are plotted in Figure 12.  These were calculated from Equations (4.18), 
(4.26), and (4.28) using values presented in Table 4.2.  CSC is shown to be strongly 
dependent on pH and follows the coformer ionization behavior.   It is recognized that 
these calculations assume that ionized components do not interact with the micelles and 





Figure 4.12.  Calculated CSC (mM SLS) and pHmax for CBZ cocrystals according to 
Equations (4.18), (4.26), and (4.28) using measured values presented in Table 4.2.   CSC 




A theoretical treatment that considers the contributions of cocrystal dissociation, 
component ionization, and micellar solubilization, demonstrates that surfactants can 
impart thermodynamic stability to cocrystals that otherwise convert to parent drug solid 
in aqueous solutions.  The CSC and pHmax represent the surfactant concentration and 
solution pH, where cocrystal is in thermodynamic equilibrium with solid drug and 
solution phases.   Therefore, both CSC and pHmax (in the case of ionizable cocrystal 
components) are key indicators of cocrystal stability.  This behavior is confirmed by the 
stabilization of several CBZ cocrystals in SLS micellar solutions.   
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 How effective a surfactant is in changing the thermodynamic stability of a 
cocrystal, CSC and pHmax, is determined mostly by the differential solubilization of 
cocrystal components by micelles.  Such differential solubilization of cocrystal 
components leads to a slower rate of solubility increase with surfactant micellar 
concentration for the cocrystal, compared to that of the drug solubility increase (when the 
drug has the superior micellar solubilization of coocrystal components).   
 For cocrystals of nonionzable, hydrophobic drugs with ionizable, hydrophilic 
coformers, the theoretical treatment predicts that surfactant CSC is decreased by: (1) 
preferential drug solubilization (Ks
R >> Ks
HA), (2)  low ionization of coformer, (3) low 
cocrystal aqueous solubility relative to drug, and (4) cocrystal stoichiometries that are 
lower in drug than coformer.    This generalization assumes that there is no additional 
solution complexation, and that ionized coformer is not solubilized by the micelles.  The 
relationship between CSC and pHmax is determined by the ionization behavior of the 
coformer, with CSC changing orders of magnitude at pH values where coformer ionizes.   
Acidic coformers exhibit an increase in pHmax with increasing surfactant concentration, 
whereas amphoteric coformers exhibit pHmax decrease and increase.    
 CSC and pHmax for cocrystals in micellar solutions are quantitatively predicted by 
mathematical models from solution phase properties of cocrystal (Ksp), cocrystal 
components (Ks and Ka) and surfactant (CMC).  CSC, pHmax, and cocrystal solubility 
predicted by the models are in very good agreement with experimental measurements.  
The proposed models provide a rational basis for selecting additives and solution 
conditions to achieve desired cocrystal solubility/stability from parameter values that are 
generally available in the literature or experimentally accessible.   Since cocrystals owe 
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their solubility to the ionization and association of their components in solution, it is 
essential to consider the influence of solution conditions such as pH, presence of 






Derivation of equations 
Explanation of terms: 
Subscript aq – aqueous  
Subscript m – micellar  
Subscript T – total (aqueous + micellar) 
R – nonionizable drug 
HA – monoprotic weakly acidic coformer (nonionized) 
H2A – diprotic weakly acidic coformer (nonionized) 
HAB – amphoteric coformer (nonionized) 
M – micellar surfactant 
Ksp – cocrystal solubility product 
Ka – acid dissociation constant 
Ks – micellar solubilization constant 
Keu – eutectic constant 
S – solubility 
CMC – critical micellar concentration 
CSC – critical stabilization concentration 
 
RHA (1:1 nonionizable drug R, monoprotic weakly acidic coformer HA) 



























    (4A.5) 
Associated equilibrium constants are given by 































  (4A.10) 
 
Cocrystal RHA total solubility in micellar solutions 
Mass balance on R is given by 
T aq m[R] [R] [R]   (4A.11) 
Substituting (4.8) and (4.10) into (4A.11) gives 
 sp RT s
aq
K
[R] 1 K [M]
[HA]
   (4A.12) 
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Mass balance on A is given by 
T aq aq m m[A] [HA] [A ] [HA] [A ]
      (4A.13) 
Substituting (4.9), (4.11), and (4.12) into (4A.13) gives 
a aHA A
T aq s s
K K
[A] [HA] 1 K [M] K [M]




    
 
 (4A.14) 
Combining (4A.12) and (4A.14) gives 
 sp a aR HA AT s s s
T
K K K
[R] 1 K [M] 1 K [M] K [M]




     
 
 (4A.15) 
Cocrystal solubility in micellar solutions containing stoichiometric solution 
concentrations of cocrystal components, in the absence of solution complexation, is given 
by 
RHA,T T TS [R] [A]   (4A.16) 
Substituting (4A.16) into (4A.15), 
  a aR HA ARHA,T sp s s s
K K
S K 1 K [M] 1 K [M] K [M]









A-, then (4A.17) can be simplified to 
  aR HARHA,T sp s s
K
S K 1 K [M] 1 K [M]
[H ]
 




Solubility of drug R in micellar solutions 
Relevant equilibria are given by 







R M R   (4A.20) 







  (4A.21) 
According to mass balance on R, 
T aq m[R] [R] [R]   (4A.22) 
 RT aq s[R] [R] 1 K [M]   (4A.23) 
In this case, SR,T = [R]T and [R]aq = SR,aq so 
 RR,T R,aq sS S 1 K [M]   (4A.24) 
 
Solubility enhancement of cocrystal is related to solubility enhancement of drug 
From (4A.18), the ratio of cocrystal solubility in micellar solutions to pure water is given 
by 

























   (4A.26) 









Critical stabilization concentration (CSC) of cocrystal RHA 
At the CSC, 
RHA,T R,TS S  (4A.28) 





















CSC is given by 






















In the absence of micellar solubilization, cocrystal RHA aqueous solubility, according to 










Combining (4A.31) and (4A.32), with the assumption that Ks

















HXHA (1:1 monoprotic weakly acidic drug HX, monoprotic weakly acidic coformer HA) 






































    (4A.40) 
Associated equilibrium constants are given by 


















































  (4A.47) 
 
Cocrystal HXHA total solubility in micellar solutions 
Mass balance on X is given by 
T aq aq m m[X] [HX] [X ] [HX] [X ]
      (4A.48) 
Substituting (4A.41), (4A.42), (4A.44), and (4A.46) into (4A.48) gives 
HX HX




[X] 1 K [M] K [M]




     
 
 (4A.49) 
Mass balance on A is given by 
T aq aq m m[A] [HA] [A ] [HA] [A ]
      (4A.50) 
Substituting (4A.43), (4A.45), and (4A.47) into (4A.50) gives 
a aHA A
T aq s s
K K
[A] [HA] 1 K [M] K [M]




    
 
 (4A.51) 
Combining (4A.49) and (4A.51) gives 
HX HX HA HA
sp a a a aHX X HA A
T s s s s
T
K K K K K
[X] 1 K [M] K [M] 1 K [M] K [M]
[A] [H ] [H ] [H ] [H ]
 
   
  
          
  
 (4A.52) 
Cocrystal solubility in micellar solutions containing stoichiometric solution 
concentrations of cocrystal components, in the absence of solution complexation, is given 
by 
HXHA,T T TS [X] [A]   (4A.53) 
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Substituting (4A.52) into (4A.53), 
HX HX HA HA
a a a aHX X HA A
HXHA,T sp s s s s
K K K K
S K 1 K [M] K [M] 1 K [M] K [M]
[H ] [H ] [H ] [H ]
 
   
  







A- then (4A.54) can be simplified to 
HX HA
a aHX HA
HXHA,T sp s s
K K
S K 1 K [M] 1 K [M]
[H ] [H ] 
  




Solubility of drug HX in micellar solutions 
Relevant equilibria are given by 

















    (4A.59) 




























According to the mass balance on X, 
T aq aq m m[X] [HX] [X ] [HX] [X ]
      (4A.63) 
Substituting (4A.60)-(4A.62) into (4A.63) gives 
HX HX
a aHX X
T aq s s
K K
[X] [HX] 1 K [M] K [M]














[X] [HX] 1 K [M]
[H ]
 
    
 
 (4A.65) 





S S 1 K [M]
[H ]
 




CSC of cocrystal HXHA 
At the CSC, 
HXHA,T X,TS S  (4A.67) 

















   
        
   

 (4A.68) 
CSC is given by 



















   
        




BHA (1:1 monoprotic weakly basic drug B, monoprotic weakly acidic coformer HA) 






































    (4A.77) 
Associated equilibrium constants are given by 


















































  (4A.84) 
 
Cocrystal BHA total solubility in micellar solutions 
Mass balance on B is given by 
T aq aq m m[B] [B] [BH ] [B] [BH ]
      (4A.85) 
Substituting (4A.78), (4A.79), (4A.81), and (4A.83) into (4A.85) gives 
sp B BH
T s sB B
aq a a
K [H ] [H ]




     
 
 (4A.86) 
Mass balance on A is given by 
T aq aq m m[A] [HA] [A ] [HA] [A ]
      (4A.87) 
Substituting (4A.80), (4A.82), and (4A.84) into (4A.87) gives 
a aHA A
T aq s s
K K
[A] [HA] 1 K [M] K [M]




    
 
 (4A.88) 
Combining (4A.86) and (4A.88) gives 
HA HA
sp a aB BH HA A
T s s s sB B
T a a
K [H ] [H ] K K
[B] 1 K [M] K [M] 1 K [M] K [M]










Cocrystal solubility in micellar solutions containing stoichiometric solution 
concentrations of cocrystal components, in the absence of solution complexation, is given 
by 
BHA,T T TS [B] [A]   (4A.90) 
Substituting (4A.89) into (4A.90), 
HA HA
a aB BH HA A
BHA,T sp s s s sB B
a a
[H ] [H ] K K
S K 1 K [M] K [M] 1 K [M] K [M]












A- then (4A.91) can be simplified to 
HA
aB HA
BHA,T sp s sB
a
[H ] K









Solubility of drug B in micellar solutions 

















    (4A.96) 


























  (4A.99) 
 
According to the mass balance on B, 
T aq aq m m[B] [B] [BH ] [B] [BH ]
      (4A.100) 
Substituting (4A.97)-(4A.99) into (4A.100) gives 
B BH
T aq s sB B
a a
[H ] [H ]














[B] [B] 1 K [M]
K
 
    
 
 (4A.102) 





S S 1 K [M]
K
 




CSC of cocrystal BHA 
At the CSC, 
BHA,T B,TS S  (4A.104) 









K K [H ]
1 1







   
        
   

 (4A.105) 
CSC is given by 
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K K [H ]
1 1







   
        




R2H2A (2:1 monoprotic weakly basic drug R, diprotic weakly acidic coformer H2A) 
Relevant equilibria are given by 
sp
2 2 solid aq 2 aq
K
R H A 2R H A  (4A.108) 
2H A
a
2 aq aq aq
K












R M R   (4A.111) 
2H A
s
2 aq 2 m
K














    (4A.114) 
Associated equilibrium constants are given by 
2
sp aq 2 aqK [R] [H A]  (4A.115) 
2 aq aqH A
a
2 aq























  (4A.118) 


























  (4A.121) 
 
Cocrystal R2H2A total solubility in micellar solutions 
Mass balance on B is given by 
T aq m[R] [R] [R]   (4A.122) 
Substituting (4A.115) and (4A.118) into (4A.122) gives 
 2sp2 RT s
2 aq
K
[R] 1 K [M]
[H A]
   (4A.123) 
Mass balance on A is given by 
2 2
T 2 aq aq aq 2 m m m[A] [H A] [HA ] [A ] [H A] [HA ] [A ]
          (4A.124) 
Substituting (4A.116), (4A.117), and (4A.119)-(4A.121) into (4A.124) gives 
2 2 2 2
2
2
H A H A H A H AHA HA
a a a a a aH A HA A
T 2 aq s s s2 2
K K K K K K
[A] [H A] 1 K [M] K [M] K [M]
[H ] [H ] [H ] [H ]
 
 
   
 








2 2 2 2
2
2
H A H A H A H AHA HA
2sp a a a a a aH A2 R HA A
T s s s s2 2
T
K K K K K K K
[R] 1 K [M] 1 K [M] K [M] K [M]
[A] [H ] [H ] [H ] [H ]
 
 
   
 




Cocrystal solubility in micellar solutions containing stoichiometric solution 
concentrations of cocrystal components, in the absence of solution complexation, is given 
by 




   (4A.127) 
Substituting (4A.126) into (4A.127), 
 




H A H A H A H AHA HA
2sp a a a a a aH AR HA A
3R H A,T s s s s2 2
K K K K K K K
S 1 K [M] 1 K [M] K [M] K [M]
4 [H ] [H ] [H ] [H ]
 
 
   
 




When 2H A HAs sK K











H A H A HA
2sp a a a H AR
3R H A,T s s2
K K K K
S 1 K [M] 1 K [M]









Solubility of drug R in micellar solutions 
Relevant equilibria are given by 





R M R   (4A.131) 







  (4A.132) 
According to mass balance on R, 
T aq m[R] [R] [R]   (4A.133) 
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 RT aq s[R] [R] 1 K [M]   (4A.134) 
In this case, SR,T = [R]T and [R]aq = SR,aq so 
 RR,T R,aq sS S 1 K [M]   (4A.135) 
 
CSC of cocrystal R2H2A 
At the CSC, 
2 2R H A,T R,T
2S S  (4A.136) 
Substituting (4A.129) and (4A.135) into (4A.136) and solving for [M] gives 
2 2
2
H A H A HA







2K K K K
1 1













CSC is given by 




H A H A HA






2K K K K
1 1














R2HAB (2:1 monoprotic weakly basic drug R, amphoteric coformer HAB) 
Relevant equilibria are given by 
sp
2 solid aq aq
K





2 aq aq aq
K
H AB HAB H











R M R   (4A.143) 
2H AB
s
2 aq 2 m
K
H AB M H AB













    (4A.146) 
Associated equilibrium constants are given by 
2
sp aq aqK [R] [HAB]  (4A.147) 























  (4A.150) 





[H AB ] [M]






















Cocrystal R2HAB total solubility in micellar solutions 
Mass balance on B is given by 
T aq m[R] [R] [R]   (4A.154) 
Substituting (4A.147) and (4A.150) into (4A.154) gives 
 2sp2 RT s
aq
K
[R] 1 K [M]
[HAB]
   (4A.155) 
Mass balance on AB is given by 
T aq 2 aq aq m 2 m m[AB] [HAB] [H AB ] [AB ] [HAB] [H AB ] [AB ]
          (4A.156) 




a aH ABHAB AB
T aq s s sH AB H AB
a a
[H ] K [H ] K
[AB] [HAB] 1 K [M] K [M] K [M]






       
 
 (4A.157) 




2sp a aH AB2 R HAB AB
T s s s sH AB H AB
T a a
K [H ] K [H ] K
[R] 1 K [M] 1 K [M] K [M] K [M]






        
 
 (4A.158) 
Cocrystal solubility in micellar solutions containing stoichiometric solution 
concentrations of cocrystal components, in the absence of solution complexation, is given 
by 




   (4A.159) 




2sp a aH ABR HAB AB
3R HAB,T s s s sH AB H AB
a a
K [H ] K [H ] K
S 1 K [M] 1 K [M] K [M] K [M]






        
 
 (4A.160) 
When 2H ABHABs sK K

  and HAB ABs sK K








3R HAB,T s sH AB
a
K [H ] K










Solubility of drug R in micellar solutions 
Relevant equilibria are given by 





R M R   (4A.163) 







  (4A.164) 
According to mass balance on R, 
T aq m[R] [R] [R]   (4A.165) 
 RT aq s[R] [R] 1 K [M]   (4A.166) 
In this case, SR,T = [R]T and [R]aq = SR,aq so 
 RR,T R,aq sS S 1 K [M]   (4A.167) 
 
CSC of cocrystal R2HAB 
At the CSC, 
2 2R H A,T R,T
2S S  (4A.168) 



























CSC is given by 




























Coformer solubilities as a function of SLS concentration 
Table 4A.1.  CBZD and coformer solubilities (±SE) measured as a function of SLS 
concentration, from which Ks values were calculated. 
Cocrystal 
component 
[SLS] (mM) Concentration (mM)
CBZ 8 1.00±0.01 
 10 1.86±0.05 
 15 3.58±0.12 
 17 3.97±0.05 
 20 5.10±0.03 
 35 9.30±0.29 
 51 13.43±0.41 
 67 17.35±0.19 
 100 24.81±1.13 
 140 33.53±0.85 
   
SLC, pH 3.0 35 34.01±0.46 
 52 43.44±0.97 
 69 50.32±0.63 
   
SAC, pH 2.2 35 26.15±0.10 
 52 28.89±0.07 
 69 30.46±0.46 
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Engineering cocrystal eutectic points and stability regions by micellar 
solubilization and ionization  
 
Introduction 
 The ability to engineer the thermodynamic stability of cocrystals has important 
implications for the control and use of cocrystals in various industries and for the 
development of drug delivery systems in the pharmaceutical industry.  Though 
surfactants have been widely investigated as a means to increase the solubility of 
hydrophobic drugs,1-4 we recently demonstrated that surfactants can impart 
thermodynamic stability to cocrystals relative to drug crystal, and this behavior is 
dependent on surfactant concentration and pH.5-7  Surfactants that have differential 
affinities for the cocrystal components have the potential to reverse the thermodynamic 
stabilities of cocrystal and drug at a surfactant concentration called the critical 
stabilization concentration (CSC).  The underlying mechanism for the CSC is the 
enrichment of the aqueous phase with the most soluble component (i.e. coformer) as the 
least soluble cocrystal component (i.e. drug) is preferentially solubilized by the micelles.  
A model was developed that explained cocrystal solubility, CSC, and pHmax based on 
cocrystal dissociation, component ionization, and micellar solubilization equilibria.7 
 The purpose of this work is to understand the role of micellar solubilization and 
ionization in altering cocrystal stability regions and to develop mathematical equations 
that predict cocrystal eutectic point behavior from experimentally accessible 
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thermodynamic parameters; this enables fine-tuning cocrystal phase behavior based on a 
mechanistic understanding of cocrystal solution chemistry. 
 Eutectic points, also referred to as transition concentrations, offer an 
experimentally accessible method to assess cocrystal solubility and stability regardless of 
the solubility relationship between cocrystal and drug..5, 9, 10  A cocrystal eutectic point is 
a point where two solids (one of which is cocrystal) and solution coexist in equilibrium.   
 The solution conditions that favor transformation from cocrystal to drug (and vice 
versa) can be quantified by examining the solution concentrations of drug and coformer 
at the eutectic point as a function of micellar surfactant.  Equations are developed that 
describe the eutectic concentrations of drug and coformer in micellar solutions by 
considering the equilibria of the partitioning of drug and coformer between aqueous and 
micellar pseudophases.  The eutectic concentrations of drug and coformer in micellar 
solutions are a function of their respective eutectic concentrations in pure water (or in 
submicellar surfactant concentrations), component pKa(s), solution pH, and Ks for the 
individual cocrystal components. 
 A eutectic constant Keu (ratio of coformer to drug concentration at the eutectic) 
can be calculated that describes cocrystal thermodynamic stability relative to drug.11  
Eutectic constants are commonly applied to mixtures of racemic compounds with 
enantiomer but were recently adapted to cocrystal systems.12, 13 This work extends the 
theoretical framework for eutectic points and Keu to micellar systems and demonstrates 




 Model equations are derived for cocrystals of CBZ (nonionizable, hydrophobic 
drug) with several ionization properties and stoichiometries.  These cocrystals include 1:1 
carbamazepine-salicylic acid (CBZ-SLC), 1:1 carbamazepine-saccharin (CBZ-SAC), 2:1 
carbamazepine-succinic acid (CBZ-SUC), and 2:1 carbamazepine-4-aminobenzoic acid 
monohydrate (CBZ-4ABA-HYD).  Salicylic acid and saccharin are monoprotic weak 
acids; salicylic acid has a reported pKa of 3.0, saccharin has a range of reported pKa 
values between 1.8 and 2.2.14-16  Succinic acid is a diprotic weak acid with pKa values of 
of 4.1 and 5.6.17  4-aminobenzoic acid is amphoteric with pKa values of 2.6 and 4.8.
18   
 
Theoretical 
 The work presented here develops a model to predict the dependence of cocrystal 
eutectic points on ionization and micellar solubilization.  This identifies the solution 
conditions where cocrystal is thermodynamically stable by considering the partitioning of 
drug and coformer into micelles.  It is based on relatively simple solution phase equilibria 
and equilibrium constants for the cocrystal components that are experimentally accessible 
or available in the literature.  A quantitative model for cocrystal solubility was presented 
previously and demonstrated that cocrystal solubility relative to drug crystal is a function 
of surfactant concentration.7  Knowledge of cocrystal eutectic points is of critical 
importance during cocrystal synthesis, processing, and performance. 
 
Cocrystal eutectic point dependence on micellar solubilization 
 Eutectic points as critical indicators of cocrystal solubility have been discussed 
thoroughly elsewhere. The solution composition at the eutectic is independent of the 
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mass of each phase at equilibrium, which has several important features:  (1) indicates the 
thermodynamic stability of cocrystal relative to drug crystal, (2) enables estimation of 
cocrystal solubility in solution compositions where cocrystal is unstable, and (3) provides 
insight into solute-solute or solute-solvent interactions between drug, coformer, and 
solvent. 
 At least two eutectic points exist for a cocrystal, which are differentiated by the 
phases at equilibrium.  E1 refers to the eutectic between solid drug, cocrystal, and 
solution, and E2 refers to the eutectic between solid coformer, cocrystal, and solution.  
Other eutectic points have been reported in the literature, such as between cocrystals of 
different stoichiometry.10  The focus of this work is on E1, which is of particular 
importance to cocrystals of poorly soluble drugs in aqueous solutions because it describes 
the conditions under which a cocrystal can transform to a less soluble crystalline drug 
form.  The analyses presented here can be generalized to other solubilization mechanisms 
such as mixed micelles or complexation, though the equations may be of a different 
nature. 
 For a 1:1 cocrystal RHA whose components are R (nonionizable drug) and HA 
(monoprotic, weakly acidic coformer), E1 is described by 
solid solid aq aqRHA R R HA   (5.1) 
and E2 by 
solid solid aq aqRHA HA R HA   (5.2) 




























    (5.7) 
where aq refers to aqueous and m refers to micellar.  Ksp is the cocrystal solubility 




A- are the micellar solubilization constants for R, HA, and A- respectively.  For the sake 
of simplicity this model assumes no solution complexation between drug and coformer, 
though theoretical treatments of such equilibria have been addressed elsewhere.11, 19, 20 
 The equilibrium constants that describe Equations (5.3)-(5.7) are given by 































  (5.12) 
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where brackets refer to concentrations with recognition that under dilute solution 
conditions they approximate activities.  Ks and Ka values are assumed to be independent 
of solution composition. 
 Total cocrystal solubility SRHA,T, in terms of the total drug concentration at 
equilibrium [R]T, is given by the sum of aqueous and micellar drug in solution, 
RHA,T T aq mS [R] [R] [R]    (5.13) 
By considering the equilibrium constants in Equations (5.8) and(5.10), Equation (5.13) 
becomes 
 sp RT s
aq
K
[R] 1 K [M]
[HA]
   (5.14) 
The mass balance on coformer is given by 
T aq aq m m[A] [HA] [A ] [HA] [A ]
      (5.15) 
Substituting Equations (5.9), (5.11) and (5.12) into (5.15), 
HA HA
a aHA A
T aq s s
K K
[A] [HA] 1 K [M] K [M]




     
 
 (5.16) 
Combining Equations (5.14) and (5.16), 
 
HA HA
sp a aR HA A
RHA,T T s s s
T
K K K
S [R] 1 K [M] 1 K [M] K [M]




       
 
 (5.17) 
If the ionized species interacts more favorably with the aqueous environment than the 
micellar environment such that Ks
HA >> Ks




RHA,T T s s
T
K K
S [R] 1 K [M] 1 K [M]
[A] [H ]
 
      
 
 (5.18) 
unless the ionized species is present at very high concentrations.21, 22 
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 The total cocrystal solubility in a solution of stoichiometric concentrations of drug 




RHA,T sp s s
K
S * K 1 K [M] 1 K [M]
[H ]
 
     
 
 (5.19) 
A detailed discussion of micellar solubilization and ionization effects on cocrystal 
stoichiometric solubilities was presented previously.5, 7 
 At eutectic point E1 the solution is saturated with drug and cocrystal.  E1 is 
characterized by the solution concentrations of drug and coformer and is another special 
case of Equation (5.18) when [R]T = SR,T.  The concentration of drug at the eutectic point, 
[R]eu,T, is given by 
eu,T R,T[R] S  (5.20) 
where SR,T is the solubility of drug R in the eutectic micellar solution.  Assuming that the 
coformer does not affect the solubilization mechanisms of drug (and vice versa), then 
SR,T is simply the solubility of the drug R in a micellar solution. 
 The influence of micellar surfactant concentration on solubilization of 
hydrophobic drugs is well documented in the literature and is given by 
 RR,T R,aq sS S 1 K [M]   (5.21) 
where SR,aq is the aqueous solubility of drug R.
1-4, 23, 24  Therefore, by combining 
Equations (5.20) and (5.21), 
 Reu,T R,aq s[R] S 1 K [M]   (5.22) 
 The total concentration of coformer at the eutectic point, [A]eu,T, is obtained by 








[A] 1 K [M]
S [H ]
 
    
 
 (5.23) 
Cocrystal stoichiometric solubility can be related to the eutectic solution concentrations  
of drug and coformer by combining Equations (5.19), (5.22), and (5.23) to give 
RHA,T eu,T eu,TS * [R] [A]  (5.24) 
Equation (5.24) is specific to cocrystal stoichiometry (1:1) but general for ionization and 
micellar solubilization properties.  For a 2:1 cocrystal (e.g. R2H2A with drug R and 







  (5.25) 
 [R]eu,T and [A]eu,T at a chosen [H
+] (denoted by [H+]T) can be rewritten in terms of 
the drug and coformer concentrations and [H+] at the eutectic in water (denoted by 
[R]eu,aq, [A]eu,aq, and [H
+]aq).  Thus 























Equations (5.26) and (5.27) show that the full dependence of the cocrystal eutectic point 
on pH and surfactant concentration can be calculated from a eutectic point measurement 
in pure water at a single pH, provided Ks and Ka for the cocrystal components are known.  
Eutectic concentrations of drug and coformer for cocrystals of different stoichiometries 





Figure 5.1.  Eutectic concentrations of drug ([R]eu,T) and coformer ([A]eu,T) as a function 
of surfactant concentration under nonionizing conditions.  Predicted according to 
Equations (5.26) and (5.27) for cocrystal RHA at eutectic point E1.  The CSC for a 1:1 
cocrystal is given by the surfactant concentration where [R]eu,T = [A]eu,T.  Ksp = 1 mM
2 
(SRHA,aq/SR,aq = 5), [R]eu,aq = 0.2 mM, [A]eu,aq = 5 mM, Ks
R = 1 mM-1, Ks
HA = 0, CMC = 8 
mM. 
 
 Figure 5.1 shows the predicted dependence of drug and coformer eutectic 
concentrations on surfactant concentration for a cocrystal RHA according to Equations 
(5.26) and (5.27).  Different dependencies of [R]eu,T and [A]eu,T on surfactant 
concentration are a consequence of differential solubilization of the cocrystal components 
(Ks
R >> Ks
HA).  The surfactant concentration where [R]eu,T = [A]eu,T indicates the critical 
stabilization concentration (CSC) for cocrystal RHA.  At the CSC, a liquid phase of equal 
molar ratio as the cocrystal is necessary for cocrystal to be thermodynamically stable.  At 
the CSC for a 2:1 cocrystal, 0.5*[R]eu,T = [A]eu,T.  Drug-rich stoichiometries require more 
drug to be solubilized by the micelles to achieve the coformer enrichment in the aqueous 
phase that is responsible for the CSC. 
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 Though E2 is less discussed in the pharmaceutical cocrystal literature than other 
eutectic points, similar methods can be used to calculate its dependence on surfactant 
concentration from Equation (5.18).  At E2, Equation (5.20) no longer applies because 
drug crystal is not one of the solid phases at equilibrium.  Instead, the relevant solution 
condition at E2 is that the total coformer concentration at the eutectic [A]eu,T is equal to 
the total solubility of the coformer in the eutectic micellar solution SA,T 
eu,T A,T[A] S  (5.28) 
Assuming the solubilization mechanisms of drug and coformer are mutually independent, 





S S 1 K [M]
[H ]
 
    
 
 (5.29) 
where SHA,aq is the intrinsic solubility of the weakly acidic coformer.  Equations (5.28) 





[A] S 1 K [M]
[H ]
 
    
 
 (5.30) 
Substituting (5.30) into (5.18) gives [R]eu,T at E2. 
 sp Reu,T s
HA,aq
K
[R] 1 K [M]
S
   (5.31) 
If Equations (5.30) and (5.31) are rewritten in terms of [R]eu,aq and [A]eu,aq at E2, then the 
same equations as (5.26) and (5.27) are obtained.  Thus, equations (5.26) and (5.27) apply 






Table 5.1.  Equations that describe drug and coformer eutectic concentrations in micellar solutions at [H+]T, in terms of drug and 
coformer eutectic concentrations in pure water at [H+]aq, Ka and Ks of the cocrystal components, and micellar surfactant concentration 
[M]. 
Cocrystal Drug eutectic concentration Eqn Coformer eutectic concentration Eqn 
RHA 
1:1 nonionizable : 
monoprotic acidic 























































































































2:1 nonionizable : 
diprotic acidic 




H A H A HA
a a a H A
s2
T T

















   





2:1 nonionizable : 
amphoteric 


























   




* Subscript aq represents values measured in submicellar concentrations of surfactant.
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Eutectic constant Keu 







  (5.40) 
where aA,eu and aR,eu are the activities of coformer and drug in solution at the eutectic 
point.  Eutectic constants have been discussed in the literature concerning enantiomeric 
purification and stability of racemic compounds but were recently applied to other 
cocrystal systems.11-13 
 Keu in the context of cocrystals has been shown to describe cocrystal 
thermodynamic stability relative to drug.11  Keu is determined under equilibrium 
conditions, though it is not a true equilibrium constant (such as Equations (5.3)-(5.7)).  







  (5.41) 
Keu can be related to the ratio of cocrystal stoichiometric solubility to drug solubility.  
This can be accomplished when [R]eu,T = SR,T = [R]aq + [R]m and 
[A]eu,T = [HA]aq + [A
-]aq + [HA]m + [A
-]m, indicating that ionization and micellar 
solubilization are the only mechanisms of solubilization.  For a 1:1 cocrystal (e.g. RHA) 
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2 2R H A,T
S *  is cocrystal R2H2A solubility under stoichiometric conditions in terms of 
drug concentration. 
 Keu ≤ 1 indicates that cocrystal is thermodynamically stable in stoichiometric 
solutions of drug and coformer. Likewise, 2:1 cocrystals achieve thermodynamic stability 
at Keu ≤ 0.5.  The surfactant concentration and pH that achieve Keu = 1 for a 1:1 cocrystal 
(Keu = 0.5 for a 2:1 cocrystal) are the CSC and pHmax respectively. 
 Keu in micellar solutions (Keu,T) at [H
+]T can be expressed in terms of Keu 
measured in pure water (Keu,aq) at [H
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where Keu,aq = [R]eu,aq/[A]eu,aq, or the Keu of the cocrystal in water at [H
+]aq.  Equation 
(5.45) predicts that Keu,T can either increase or decrease (as does the cocrystal to drug 
solubility ratio) as a function of surfactant concentration, depending on Ks
R and Ks
HA. 
 Figure 5.2 shows the dependence of the cocrystal to drug solubility ratio and Keu,T 
on surfactant concentration in the absence of ionization effects.  The parameter values 
used in this simulation are typical of cocrystals of hydrophobic drugs such as CBZ. 
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 Figure 5.2 shows that if the reduction in Keu,T is sufficient, a CSC exists where 
Keu,T = 1.  Equations that describe CSC as a function of Keu is discussed in a subsequent 
section.  It is notable that micellar solubilization is most effective in reducing the 
cocrystal to drug solubility ratio at surfactant concentrations very close to the CMC.  
Therefore, consideration of Keu,T plays an important role in micellar solutions even at 
surfactant concentrations far below the CSC.  
 
 
Figure 5.2.  Dependence of cocrystal to drug solubility ratio and Keu on surfactant 
concentration according to Equations (5.43) and (5.45) for a 1:1 cocrystal RHA.  Keu,T 
decreases as surfactant concentration increases, indicating that the cocrystal to drug 
solubility ratio is decreasing.  CSC can be estimated from Keu,aq and Ks for the cocrystal 
components.  Simulated under nonionizing conditions, with no interactions beyond 
micellar solubilization.  Ksp = 1 mM
2, Keu,aq = 25 (SRHA,aq/SR,aq = 5), SR,aq = 0.2 mM, Ks
R 
= 1 mM-1, Ks
HA = 0, and CMC = 8. 
 
 Keu,T depends on two main factors:  cocrystal solubility relative to drug in water 
(calculated from Keu,aq) and micellar solubilization of cocrystal components (Ks
R and 
Ks
HA).  Figure 5.3 shows the predicted influence of cocrystal aqueous solubility and Ks
R 
on Keu,T and the cocrystal to drug solubility ratio according to Equations (5.43) and (5.45)
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.  Figure 5.3 shows that (1) cocrystals with higher aqueous solubilities relative to drug, or 
larger Keu,aq, require higher surfactant concentrations to achieve the CSC, (2) cocrystals 
with high Ks
R require lower surfactant concentrations to achieve the CSC, and (3) 
cocrystals highly soluble relative to drug and/or have high Ks
R values are the most 
susceptible to changes in Keu,T in small concentrations of micellar surfactant.  Changes in 
Keu,aq (Figure 5.3(a)) can be the result of pH or selection of a different coformer whose 
cocrystal is more soluble.  Changes in Ks




Figure 5.3.  Influence of cocrystal aqueous solubility and micellar solubilization on Keu,T 
and CSC. (a) impact of cocrystal aqueous solubility (Keu,aq = 4 and 25) when drug 
solubilization is constant (Ks
R = 1 mM-1), (b) impact of drug solubilization (Ks
R = 1 and 5 
mM-1) when cocrystal aqueous solubility is constant (Keu,aq = 25).  Curves generated 
according to Equations (5.43) and (5.45) for a 1:1 cocrystal RHA with Ks






Figure 5.4.  Dependence of Keu,T on total surfactant concentration and pH.  Multicolored 
surface represents Keu,T for a cocrystal RHA according to Equation (5.45).  Yellow 
surface represents Keu,T = 1, where cocrystal and drug are equally soluble.  The 
intersection points indicate CSC and pHmax, values that describe the conditions where 
cocrystal and drug are thermodynamically stable without excess of either component in 
solution.  Keu,aq (pH 1.0) = 4, pKa = 3.0, Ks
R = 1 mM-1, and CMC = 8 mM. 
  
 Figure 5.4 shows the predicted Keu,T dependence on total surfactant concentration 
and pH for cocrystal RHA according to Equation (5.45), where a cross-section at constant 
pH is represented by Figure 5.2.  Keu,T increases as a function of pH (which is a 
consequence of Keu,aq increasing) and decreases as a function of surfactant concentration.  
The intersection of surfaces indicates the CSC and pHmax, or the surfactant concentrations 
and pHs where the cocrystal stoichiometric solubility is equal to the drug solubility.  
Together, the CSC and pHmax values identify the solution conditions where cocrystal and 
drug are the thermodymically stable phases.  Solving Equation (5.45) for [M] when Keu,T 
= 1 gives the micellar surfactant concentration at the CSC.  Thus, the CSC at [H+]T (in 
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this case, [H+]T = [H
+]max) for a 1:1 cocrystal RHA can be written in terms of Keu,aq at 









































HA, which is typical for hydrophobic drugs and hydrophilic coformers, 
and the pH in micellar solution and water are equal ([H+]T = [H









   (5.47) 
Keu,aq and [H
+]aq also refers to values in solutions of submicellar surfactant 
concentrations. Equations that predict Keu,T and CSC at [H
+]T from measurement of Keu,aq 
at [H+]aq for cocrystals of different stoichiometry and ionization properties are presented 







Table 5.2.  Equations that allow for calculation of Keu,T and CSC at [H
+]T from Keu,aq at [H
+]aq, and Ka and Ks values for cocrystal 
components. 
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Table 5.2 (cont’d).  Equations that allow for calculation of Keu,T and CSC at [H
+]T from Keu,aq at [H
+]aq, and Ka and Ks values for 
cocrystal components. 
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* Subscript aq represents values measured in submicellar concentrations of surfactant.
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Effect of micellar solubilization on cocrystal phase stability regions 
 Micellar solubilization has the ability to shift the regions of cocrystal stability by 
differentially solubilizing drug relative to coformer.  The presented model allows 
prediction of such changes in the phase diagram via the eutectic points.  Figure 5.5 
illustrates how differential solubilization of cocrystal components results in a shift in the 
cocrystal stability region.  The points designated by E1 and E2 are the cocrystal eutectic 
points that identify the range of solution compositions where cocrystal is stable in water 
(subscript aq) and in a micellar solution (subscript T).  Line E1,aq-E1,T, which is generated 
according to Equations (5.26) and (5.27), shows that increasing surfactant concentration 
leads to the eutectic point E1 becoming more enriched with drug.   
 At the CSC, the eutectic point E1 intersects the stoichiometric composition line, 
indicating that RHA becomes congruently saturating.  This shows that a system that is 
incongruently saturating in pure water can achieve congruent saturation in micellar 
solutions.  Figure 5.5 shows that micellar solubilization can shift or even widen the range 
of solution compositions where cocrystal is the thermodynamically stable phase.     
 E2, like E1, becomes more enriched with drug at the eutectic as a function of 
surfactant concentration due to the differential solubilization of drug over coformer.  
Equations (5.26) and (5.27) are applicable to both E1 and E2.  E1 is governed by the drug 
solubility (Equation (5.21)) and E2 by the coformer solubility (Equation (5.29)).  In 
principle micellar solubilization can cause E2 to intersect the stoichiometric composition 
line at a certain concentration of surfactant, which causes an otherwise congruently 
saturating cocrystal to become incongruently saturating.  In instances where micellar 
solubilization is highly differential in favor of drug, the concentrations of surfactant 
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required to destabilize a congruently saturating cocrystal may not be experimentally 
achievable. 
 Figure 5.5 illustrates a simple system where only one cocrystal stoichiometry 
exists.  The solid phase(s) at equilibrium (cocrystal, drug, or coformer) is controlled by 
how E1 and E2 respond to micellar solubilization.  Cocrystal systems that have more than 
one stoichiometry can have multiple CSCs, which describe the conditions where each 
cocrystal stoichiometry becomes congruently saturating.  Cocrystals of different 
stoichiometry are influenced differently by the micelles, such that more drug-rich 
stoichiometries are solubilized to a much greater extent than coformer-rich 
stoichiometries.  As such, the eutectic point between cocrystals of different 
stoichiometries is expected to change as a result of micellar solubilization.  Our 
mathematical models indicate that coformer-rich stoichiometries become more 
thermodynamically favorable than drug rich stoichiometries as surfactant concentration 
increases (provided drug is preferentially solubilized relative to coformer).  Therefore, 
micellar solubilization can be a tool not only to thermodynamically stabilize cocrystals 





Figure 5.5.  Schematic triangular phase diagram of cocrystal RHA and its components 
illustrating the influence of micellar solubilization on eutectic points and phase stability 
regions.  Differential solubilization of R results in the solution composition at the eutectic 
becoming enriched with drug as surfactant concentration increases.  Cocrystals that are 
incongruently saturating in the absence of micelles can become congruently saturating in 
micellar solutions.  Dotted line indicates stoichiometric ratio of cocrystal components. 
 
Materials and Methods 
Materials 
Anhydrous monoclinic carbamazepine (CBZ(III); lot no. 057K11612 USP grade) 
was purchased from Sigma Chemical Company (St. Louis, MO), stored at 5 °C over 
anhydrous calcium sulfate and used as received.  Salicylic acid (SLC; lot no. 09004LH), 
saccharin (SAC; lot no. 03111DD), succinic acid (SUC; lot no. 037K0021), 4-
aminobenzoic acid (4ABA; lot no. 068K0698), and sodium lauryl sulfate (SLS; lot no. 
104H0667) were purchased from Sigma Chemical Company (St. Louis, MO) and used as 
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received.  Water used in this study was filtered through a double deionized purification 
system (Milli Q Plus Water System from Millipore Co., Bedford, MA). 
 
Cocrystal Synthesis 
Cocrystals were prepared by the reaction crystallization method at room 
temperature by adding CBZ to nearly saturated solutions of coformer.25  CBZ-SLC was 
prepared in acetonitrile, CBZ-SAC and CBZ-SUC were prepared in ethanol, and CBZ-
4ABA-HYD was prepared in water.  CBZ dihydrate (CBZD), the most stable form of 
CBZ in water, was prepared from anhydrous CBZ in water.  Solid phases were 
characterized by XRPD.   
 
Measurement of cocrystal eutectic points 
Cocrystal eutectic points were measured as a function of SLS concentration in 
water at 25 ± 0.1°C.  A detailed discussion of eutectic point measurements has been 
discussed elsewhere.9, 11  50-100 mg of cocrystal and 25-50 mg of CBZD were suspended 
in 3 mL of aqueous SLS solution up to 3 days.  pH at equilibrium was measured but not 
independently modified.  Cocrystal stoichiometric solubilities were determined from 
Equations (5.43) and (5.44).  Drug and coformer concentrations were analyzed by HPLC.  
Solid phases at equilibrium were confirmed by XRPD. 
 
High Performance Liquid Chromatography (HPLC) 
The solution concentrations of CBZ and coformer were analyzed by Waters 
HPLC (Milford, MA) equipped with a UV/vis spectrometer detector.  Waters’ operation 
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software, Empower 2, was used to collect and process the data.  A C18 Thermo Electron 
Corporation column (5 μm, 250 x 4.6 mm) at ambient temperature (24 °C) was used.  
The mobile phase was composed of 55% methanol and 45% water with 0.1% 
trifluoroacetic acid and the flow rate was 1 mL/min using an isocratic method. Injection 
sample volume was 20 or 40 μL.  Absorbance of CBZ, SLC, SUC, and 4ABA was 
monitored at 284, 303, 230, and 284 nm, respectively. 
 
X-ray Powder Diffraction (XRPD) 
XRPD diffractograms of solid phases were collected with a benchtop Rigaku 
Miniflex X-ray diffractometer (Danvers, MA) using CuKα radiation (λ = 1.54 Å), a tube 
voltage of 30 kV, and a tube current of 15 mA. Data were collected from 5 to 40 ° at a 
continuous scan rate of 2.5°/min. 
 
Results 
 The model equations presented above predict the dependence of cocrystal eutectic 
points on micellar solubilization, which identifies and enables engineering of the solution 
compositions where cocrystal is thermodynamically stable.  Eutectic concentrations of 
drug and coformer at E1 in micellar solutions are predicted from eutectic concentrations 
in water, Ka and Ks values for the cocrystal components, solution pH, and surfactant 
CMC.  The work discussed here focuses on E1 (solid phases at equilibrium are CBZ 
cocrystal, CBZD, and solution) because it is the relevant eutectic point in aqueous media, 
since it describes the cocrystal tendency to transform to the less soluble drug.  The 
concepts discussed in the context of E1 are relevant to other eutectic points, but E1 better 
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addresses the challenges of cocrystals whose purpose is to increase the solubility of a 
hydrophobic drug.  However, consideration of all eutectic points in a cocrystal system is 
necessary for complete understanding of the phase diagram and control of crystallization 
outcomes. 
 The predictions are evaluated for a series of CBZ cocrystals of different 
stoichiometries and ionization properties in aqueous solutions.  The cocrystals include 1:1 
cocrystals with monoprotic acids (CBZ-SLC and CBZ-SAC) and 2:1 cocrystals with a 
diprotic acid (CBZ-SUC) and an amphoteric coformer (CBZ-4ABA-HYD).  The 
cocrystal stoichiometric solubilities in pure water were reported previously, and ranged 
from 1.32 mM for CBZ-SLC at pH 3.0 to 2.38 mM for CBZ-SUC at pH 3.1 (in terms of 
CBZ concentration), or 2.5 to 4.5-fold the aqueous solubility of CBZD (0.53 mM).7, 26 
 pH was not independently adjusted for the studies presented here but the pH of 
the eutectic solutions at equilibrium were measured.  pH varied by less than 0.2 units 
between eutectics measured in water and in SLS solutions. 
 
Drug and coformer eutectic concentration dependence on SLS concentration 
 Figure 5.6 shows the solution concentrations of drug and coformer at the eutectic 
point E1 as a function of SLS concentration for the CBZ cocrystals.  Figure 5.6 shows 
that drug and coformer concentrations increase at different rates with respect to SLS 
concentration.  The CBZ eutectic concentration increases at a faster rate than the 
coformer with respect to SLS concentration, such that there is a reversal in the relative 
eutectic concentrations from coformer-rich in low surfactant concentrations to drug-rich 
in high surfactant concentrations.  This is in agreement with predicted behavior according 
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to Equations (5.26) and (5.27), which predict that eutectic concentrations of drug and 
coformer increase according to their respective Ks values. 
 
 
Figure 5.6.  Dependence of eutectic concentrations of CBZ and coformer on SLS 
concentration in aqueous solutions.  Solid phases at equilibrium are CBZ cocrystal and 
CBZD.  (a) CBZ-SLC pH 3.0 (b) CBZ-SAC pH 2.2 (c) CBZ-4ABA-HYD pH 4.0 (d) 




 Figure 5.7 shows the predicted and experimental drug and coformer eutectic 
concentrations for each cocrystal as a function of SLS concentration.  The predicted lines 
were generated by linear regression according to equations in Table 5.1 where Ks values 
and surfactant CMC were allowed to vary; drug and coformer eutectic concentrations in 
pure water, solution [H+], and Ka values remained fixed.  Figure 5.7 shows very good 
correlation between experimental and predicted behavior. 
 The Ks values generated by linear regression (Table 5.3), are a measure of the 
drug and coformer Ks values in the eutectic solution, and represent the influence of 
coformer on Ks.  There is good agreement between these and the Ks values of the separate 
cocrystal components in aqueous SLS solutions, suggesting that the presence of coformer 
negligibly affected drug solubilization and vice versa.  This finding is supported by 
Figure 5.8, which compares the CBZD solubilities at the eutectic and in the absence of 
coformer as a function of SLS concentration.  The excellent agreement between CBZ 
eutectic concentrations and CBZD solubilities in Figure 5.8 shows that the coformers had 
minimal impact on the solubilization of CBZ. 
 The CMC value of 6 mM SLS for CBZ-SAC, CBZ-4ABA-HYD, and CBZ-SUC 
are in good agreement with reported CMC of SLS in saturated CBZ solutions (5.3 mM 
SLS26).  CBZ-SLC has a fitted CMC value 8 mM.  Our previous cocrystal solubility 
studies indicate that SLC exhibits a weak effect on the CMC of SLS in saturated CBZ 
solutions, which was reported as 9 mM SLS.7  In these studies the magnitude of the 
changes in CMC as a result of solutes and solution conditions are generally small relative 
to the total surfactant concentrations. 
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 When drug, coformer, and surfactant exhibit solution interactions that affect 
ionization or micellar solubilization, using parameters measured for the separate 
components (Ka, Ks, and CMC) in the model equations may not be justified.  If 
necessary, more rigorous expressions that describe the thermodynamic parameters as a 




Figure 5.7.  Eutectic concentrations of drug and coformer at E1 in aqueous SLS solutions 
for (a) CBZ-SLC pH 3.0 (b) CBZ-SAC pH 2.2 (c) CBZ-4ABA-HYD pH 4.0 (d) CBZ-
SUC pH 3.1.  Lines represent linear regression from equations in Table 5.1, where Ks and 
CMC values are allowed to vary (Table 5.3, Ks values denoted by “cocrystal+drug”), 
eutectic concentrations measured in aqueous solutions without SLS, and all other 






Table 5.3.  Comparison of Ks values for the drug and coformer measured at saturation when the solid phases at equilibrium are (a) 




















CBZ-SLC 0.605 ± 0.023 0.576 ± 0.017c 0.107 ± 0.010 0.060 ± 0.005 8 
CBZ-SAC 0.541 ± 0.020 0.576 ± 0.017c 0.027 ± 0.002 0.013 ± 0.002 6 
CBZ4-ABA-HYD 0.470 ± 0.009 0.494 ± 0.012d 0.007 ± 0.001 <0.010 6 
CBZ-SUC 0.484 ± 0.009 0.494 ± 0.012d 0.001 ± 0.020e <0.010 6 
a Ks and CMC determined by linear regression of eutectic concentrations as a function of SLS concentration (Figure 5.7) according to 
equations in Table 5.1, where Ks and CMC were allowed to vary and all other parameters remained fixed. 
b Ks determined by linear regression of measured solubilities of pure drug or coformer at saturation as a function of SLS concentration 
according to Equations (5.21) and (5.29).  CBZ Ks demonstrated a weak dependence on SLS concentration, so Ks values were 
determined in a range of SLS concentrations similar to those used in eutectic point experiments (Figure 5.7). 
c Ks measured between 0 mM and 50 mM SLS 
d Ks measured between 0 mM and 140 mM SLS 




Figure 5.8.  Comparison of CBZD solubility as a function of SLS concentration (■) in 
the absence of coformer and (○) at the eutectic for four CBZ cocrystals (CBZ-SLC, CBZ-
SAC, CBZ-4ABA-HYD, CBZ-SUC).  Eutectic concentrations show that CBZD 
solubility is unaffected by the presence of coformer.  Predicted line is drawn according to 
Equation (5.21), SR,aq = 0.53 mM, Ks = 0.49 mM
-1, CMC = 6 mM. 
 
 The CSC can be calculated from the eutectic concentrations of drug and coformer 
as a function of SLS concentration in Figure 5.7 where the molar ratios of drug and 
coformer at E1 are equal to the cocrystal stoichiometry.  The CSC indicates the minimum 
surfactant concentration such that no excess coformer in solution is required for the 
cocrystal to be thermodynamically stable, thereby creating unfavorable conditions for 
cocrystal to transform to drug.  The CSCs for the 1:1 cocrystals CBZ-SLC and CBZ-SAC 
are indicated by the surfactant concentration where [drug]eu = [coformer]eu, illustrated by 
the intersection of the drug and coformer eutectic concentration dependencies.  For the 
2:1 cocrystals CBZ-4ABA-HYD and CBZ-SUC, 0.5*[drug]eu = [coformer]eu at the CSC. 
 
Keu dependence on SLS concentration 
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 The ratio of coformer to drug activities at the eutectic, known as the eutectic 
constant Keu, is an indicator of the thermodynamic stability of cocrystal and cocrystal 
component solid phases.  Under dilute conditions where activities are replaced by 
concentrations, Keu values can be calculated from drug and coformer eutectic 
concentrations in SLS solutions (Figure 5.7).  Keu > 1 for 1:1 cocrystals (> 0.5 for 2:1 
cocrystals) indicates that cocrystal is thermodynamically unstable and Keu ≤ 1 for 1:1 
cocrystals (≤ 0.5 for 2:1 cocrystals) indicates cocrystal is thermodynamically stable.  The 
surfactant concentration and pH where Keu = 1 for 1:1 cocrystals (= 0.5 for 2:1 
cocrystals) are the CSC and pHmax. 
 Figure 5.9 shows the predicted and experimental Keu dependence on SLS 
concentration according to the model equations (Table 5.2) using Ks and CMC values in 
Table 5.3 and Keu measured in pure water (Keu,aq).  Measured Keu values decrease as a 
function of SLS concentration, indicating that the cocrystal becomes more stable relative 
to drug as SLS concentration increases.  If we assume that solution interactions other than 
ionization and micellar solubilization are negligible, decreasing Keu values can be related 
to decreasing cocrystal to drug solubility ratios (Equations (5.43) and (5.44)).  The 
experimental Keu dependence on SLS concentration is in excellent agreement with the 
predicted behavior.  This demonstrates that solution conditions where cocrystal is stable 
(pH and additive concentration) cannot be generalized to other solution conditions 
without considering ionization and micellar solubilization equilibria, even at low micellar 





Figure 5.9.  Dependence of Keu on SLS concentration in water for (a) CBZ-SLC pH 3.0 
(b) CBZ-SAC pH 2.2 (c) CBZ-4ABA-HYD pH 4.0 (d) CBZ-SUC pH 3.1. Predicted 
curves and CSCs are generated according to equations in Table 5.2 using the Keu 
measured in pure water and the Ks values for drug and coformer found in Table 1.  Keu 
dependence shows that cocrystal to drug solubility ratios decrease with increasing 
surfactant concentration.  Keu values below the horizontal dotted line (≤1 for 1:1 
cocrystals and ≤0.5 for 2:1 cocrystals) indicate the solution contains SLS concentration 
above the cocrystal’s CSC. 
 
 In this work CSC is evaluated by three methods: (1) Keu measured as a function of 
SLS concentration, (2) calculated from Keu,aq, [H
+]aq, Ks and Ka for the separate 
components, and surfactant CMC according to equations in Table 5.2, and (3) calculated 
according to the linear regressions of the eutectic drug and coformer concentrations in 
Figure 5.7.  These three methods are complementary to other methods of evaluating CSC 
 
188 
which were studied previously.7  Method (1) determines a CSC range between the highest 
concentration of surfactant where Keu > 1 and the lowest concentration of surfactant 
where Keu ≤ 1 for a 1:1 cocrystal (from Keu > 0.5 to Keu ≤ 0.5 for 2:1 cocrystals).  The 
surfactant concentrations in Figure 5.9 were not selected for the purpose of narrowing 
this range, as the kinetics of reaching equilibrium become slow at concentrations near the 
CSC.  Method (2) is a calculation based on a eutectic point measured in water with Ks 
values measured separately in surfactant solutions.  Method (3) is a calculation similar to 
Method (2) but is more appropriate for Ks values that are dependent on solute-solute and 
solute-solvent interactions. 
 CSC values predicted from Keu,aq measurements are in good agreement with CSC 
values measured in micellar solutions for three cocrystals (CBZ-SLC, CBZ-SAC, and 
CBZ-4ABA-HYD).  CBZ-SUC shows deviation between the two methods which may be 
due to Keu decreasing very slowly at surfactant concentrations near the CSC.  In Figure 
5.9(d) the rate of change of Keu with respect to SLS concentration is predicted to be very 
low near the CSC; this indicates that cocrystal and drug have very similar solubilities, 
which could limit the kinetics of transformation between phases. 
 The previous chapter evaluated three other methods of determining CSC based on 
solid phase analysis of cocrystal phase transformations, calculation from cocrystal 
stoichiometric solubilities in water, and measurement from cocrystal stoichiometric 
solubilities in SLS solutions.7  The six methods presented are in good agreement with 
each other.  Inconsistencies between individual methods may be due to the influence of 
solutes (surfactant, drug or coformer) on the Ks and Ka of the components, which the six 
methods consider in varying degrees.
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Table 5.4.  CSC values determined from (a) measured Keu dependence on SLS, (b) 
calculated according to equations in Table 5.2 using measured Keu,aq, and (c) calculated 
according to linear regression of eutectic drug and coformer concentrations. 
Cocrystal pH 
CSC range measured 












CBZ-SLC 3.0 9 < CSC < 18 19 16 
CBZ-SAC 2.2 50 < CSC < 55 42 56 
CBZ4-ABA-HYD 4.0 50 < CSC < 60 64 88 
CBZ-SUC 3.1 160 < CSC 142 172 
a Range of CSC determined by SLS concentrations where Keu>1 to Keu≤1 for 1:1 
cocrystals and where Keu>0.5 to Keu≤0.5 for 2:1 cocrystals. 
b Predictions according to equations in Table 5.2 using measured Keu,aq (Figure 5.9) and 
Ks values for the separate components in SLS solutions (Table 5.3). 
c Predictions according to linear regressions in Figure 5.7, where [R]eu,T = [A]eu,T for 1:1 
cocrystals and 0.5*[R]eu,T = [A]eu,T for 2:1 cocrystals. 
 
Engineering cocrystal stability regions 
 Micellar solubilization provides a mechanism to engineer the stability regions for 
cocrystal and drug.  Figure 5.10 shows phase diagrams with the predicted and 
experimental eutectic points of CBZ cocrystals as a function of SLS concentration in a 
triangular phase diagram.  Predicted lines are generated according to equations in Table 
5.1 with Ks and CMC values in Table 5.3 and Keu measured in pure water.  The predicted 
E1 lines shown are analogous to the E1,aq-E1,T line in Figure 5.5. 
 In Figure 5.10, the eutectic solution composition at E1 becomes more enriched in 
CBZ as micellar solubilization increases.  The predicted lines are generated from 
equations in Table 5.1 and Ks values in Table 5.3.  The experimental E1 values are in 
excellent agreement with the predicted behavior.  The intersection of the predicted E1 
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dependence with the equimolar composition line of components (dotted line) is the CSC, 
which describes a solution composition where drug, cocrystal, and micellar solution are 
in equilibrium with no excess of either cocrystal component in solution.  An 
incongruently saturating cocrystal below CSC becomes congruently saturating above 
CSC. 
 Triangular phase diagrams such as Figure 5.10 have utility in designing solution 





Figure 5.10.  Triangular phase diagram showing predicted and experimental dependence 
of eutectic point E1 on SLS concentration for (a) CBZ-SLC (b) CBZ-SAC (c) CBZ-
4ABA-HYD (d) CBZ-SUC.  Surfactant concentrations increase towards the base of the 
triangle.  Predicted lines generated according to equations in Table 5.1, Ks values in 
Table 5.3, and eutectic concentrations of cocrystal components measured in pure water.  
Micellar solubilization alters the cocrystal regions of stability such that cocrystal is 




 The work presented here describes the mechanisms by which cocrystal eutectic 
points can be fine-tuned via micellar solubilization and ionization of cocrystal 
components. Quantitative models developed allow for a priori calculation of cocrystal 
eutectic points in micellar solutions from a single eutectic point in pure water, Ks and Ka 
values of cocrystal components, and solution pH. The sensitivity of eutectic points and 
phase diagrams to the choice of surfactant and pH is shown for several carbamazepine 
cocrystals in aqueous solutions of sodium lauryl sulfate.   
 Increasing the magnitude of micellar solubilization for one of the cocrystal 
components is found to confer greater thermodynamic stability to the cocrystal and 
expand its stability region.   This brings a shift in eutectic points and phase stability 
regions to solutions of stoichiometry equal to the cocrystal (there is no excess 
concentration of either cocrystal component).  Thus, cocrystals which are otherwise 
unstable can achieve thermodynamic stability at a given surfactant concentration and pH, 
regarded as CSC and pHmax.     
 The eutectic constant Keu is an important parameter obtained from the solution 
composition at the eutectic and is an indicator of cocrystal solubility and thermodynamic 
stability relative to drug.  The CSC can be determined from Keu measured in micellar 
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solutions or can be predicted from Keu measured in pure water (and its associated solution 
pH) and Ks values for the cocrystal components.  
 The variation of Keu with surfactant concentration shows that cocrystal to drug 
solubility ratio decreases fastest close to the CMC.  Applications that rely on a large 
cocrystal solubility advantage over drug must be cognizant of reductions in the cocrystal 
to drug solubility ratio that can result from differential solubilization of cocrystal 
components.    
 The concepts developed are applicable to other solubilization mechanisms that 
exhibit differential affinities for cocrystal components.  Understanding the sensitivity of 
cocrystal thermodynamic stability to solution chemistry is critical for our ability to 





Derivation of equations 
Explanation of terms: 
Subscript aq – aqueous  
Subscript m – micellar  
Subscript T – total (aqueous + micellar) 
R – nonionizable drug 
HA – monoprotic weakly acidic coformer (nonionized) 
H2A – diprotic weakly acidic coformer (nonionized) 
HAB – amphoteric coformer (nonionized) 
M – micellar surfactant 
Ksp – cocrystal solubility product 
Ka – acid dissociation constant 
Ks – micellar solubilization constant 
Keu – eutectic constant 
S – solubility 
CMC – critical micellar concentration 




RHA (1:1 nonionizable drug R, monoprotic weakly acidic coformer HA) 


























    (5A.60) 
Associated equilibrium constants are given by 































  (5A.65) 
 
Solubility of cocrystal RHA 
Mass balance on R is given by 
T aq m[R] [R] [R]   (5A.66) 
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Substituting (5A.61) and (5A.63) into (4A.11) gives 
 sp RT s
aq
K
[R] 1 K [M]
[HA]
   (5A.67) 
Mass balance on A is given by 
T aq aq m m[A] [HA] [A ] [HA] [A ]
      (5A.68) 
Substituting (5A.62), (5A.64), and (5A.65) into (4A.13) gives 
HA
a aHA A
T aq s s
K K
[A] [HA] 1 K [M] K [M]




     
 
 (5A.69) 
Combining (4A.12) and (4A.14) gives the  
 
HA
sp a aR HA A
T s s s
T
K K K
[R] 1 K [M] 1 K [M] K [M]




      
 
 (5A.70) 
Where [R]T and [A]T are the total concentrations of drug and coformer when cocrystal 
and solution are in equilibrium.  When Ks
HA >> Ks







[R] 1 K [M] 1 K [M]
[A] [H ]
 




Eutectic solution concentrations of drug and coformer of cocrystal RHA 
At eutectic point E1, solid drug, cocrystal, and solution coexist in equilibrium. 
solid solid aq aqRHA R R HA   (5A.72) 
[R]eu,T and [A]eu,T, the total concentrations of drug and coformer at the eutectic, are 
special solutions to Equation (5A.71) when the following condition is satisfied: 
T R,T[R] S  (5A.73) 
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where SR,T is the solubility of R in the eutectic solution.  When drug and solubilization is 
mutually unaffected by coformer (and vice versa), then SR,T is equivalent to the drug 
solubility in micellar solution (no coformer), which is given by: 
R,T T aq mS [R] [R] [R]    (5A.74) 
 RR,T R,aq sS S 1 K [M]   (5A.75) 
where SR,aq is the drug aqueous solubility.  Thus, 






[A] 1 K [M]
S [H ]
 
    
 
 (5A.77) 
The eutectic concentrations in water (no micellar solubilization) are found when [M] = 0, 









   
 
 (5A.79) 
Combining Equations (5A.76) to (5A.79), [R]eu,T and [A]eu,T at [H
+] = [H+]T can be 
expressed in terms of [R]eu,aq and [A]eu,aq at [H
+] = [H+]aq. 

























E2, the eutectic between solid coformer, cocrystal, and solution, is described by 
solid solid aq aqRHA HA R HA   (5A.82) 
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At E2, [R]eu,T and [A]eu,T are special solutions to Equation (5A.71) when the following 
condition is satisfied: 
T A,T[A] S  (5A.83) 
When drug and solubilization is mutually unaffected by coformer (and vice versa), then 
SA,T is equivalent to the pure coformer solubility in micellar solution (no drug), which is 
given by the total coformer concentration in the aqueous and micellar environments: 
A,T T aq aq mS [A] [HA] [A ] [HA]





S S 1 K [M]
[H ]
 
   
 
 (5A.85) 
where SHA,aq is the coformer intrinsic solubility.  Solving for [R]eu,T and [A]eu,T according 
to Equation (5A.71) for E2 yields the same expressions as (5A.80) and (5A.81).   
 
Eutectic constant Keu of cocrystal RHA 







  (5A.86) 







  (5A.87) 
Assuming there are no solution interactions aside from ionization and micellar 





















           
 
 (5A.88) 
where Keu,T is the total Keu in micellar solution at [H
+] = [H+]T, and Keu,aq is the Keu in 
pure water at [H+] = [H+]aq. 
 
CSC of cocrystal RHA 
The CSC at [H+]T can be expressed as a function of Keu,aq at [H
+]aq.  The CSC is 


























































































HXHA (1:1 monoprotic weakly acidic drug HX, monoprotic weakly acidic coformer HA) 






































    (5A.97) 
Associated equilibrium constants are given by 


















































  (5A.104) 
 
Solubility of cocrystal HXHA 
Mass balance on X is given by 
T aq aq m m[X] [HX] [X ] [HX] [X ]
      (5A.105) 
Substituting (2A.18), (2A.19), (4A.44), and (4A.46) into (4A.48) gives 
HX HX




[X] 1 K [M] K [M]




     
 
 (5A.106) 
Mass balance on A is given by 
T aq aq m m[A] [HA] [A ] [HA] [A ]
      (5A.107) 
Substituting (2A.20), (4A.45), and (4A.47) into (4A.50) gives 
HA HA
a aHA A
T aq s s
K K
[A] [HA] 1 K [M] K [M]




     
 
 (5A.108) 
Combining (4A.49) and (4A.51) gives 
HX HX HA HA
sp a a a aHX X HA A
T s s s s
T
K K K K K
[X] 1 K [M] K [M] 1 K [M] K [M]
[A] [H ] [H ] [H ] [H ]
 
   
  
          
  
 (5A.109) 
Where [X]T and [A]T are the total concentrations of drug and coformer when cocrystal 




A-, then Equation 
(4A.52) can be simplified to 
HX HA




[X] 1 K [M] 1 K [M]
[A] [H ] [H ] 
  
    
  




Eutectic solution concentrations of drug and coformer of cocrystal HXHA 
At eutectic point E1, solid drug, cocrystal, and solution coexist in equilibrium. 
solid solid aq aqHXHA HX HX HA   (5A.111) 
[X]eu,T and [A]eu,T, the total concentrations of drug and coformer at the eutectic, are 
special solutions of Equation (5A.110) when the following condition is satisfied: 
T X,T[X] S  (5A.112) 
where SX,T is the solubility of X in the eutectic solution.  When drug and solubilization is 
mutually unaffected by coformer (and vice versa), then SX,T is equivalent to the pure drug 
solubility in micellar solution (no coformer), which is given by the total drug 
concentration in the aqueous and micellar environments: 
X,T T aq aq mS [X] [HX] [X ] [HX]





S S 1 K [M]
[H ]
 
   
 
 (5A.114) 





[X] S 1 K [M]
[H ]
 








[A] 1 K [M]
S [H ]
 
    
 
 (5A.116) 






















   
 
 (5A.118) 
Combining Equations (5A.115) to (5A.118), [X]eu,T and [A]eu,T at [H
+] = [H+]T can be 
expressed in terms of [X]eu,aq and [A]eu,aq at [H
















































E2, the eutectic between solid coformer, cocrystal, and solution, is described by 
solid solid aq aqHXHA HA HX HA   (5A.121) 
At E2, [X]eu,T and [A]eu,T are special solutions to Equation (5A.110) when the following 
condition is satisfied: 
T A,T[A] S  (5A.122) 
When drug and solubilization is mutually unaffected by coformer (and vice versa), then 
SA,T is equivalent to the pure coformer solubility in micellar solution (no drug), which is 
given by the total coformer concentration in the aqueous and micellar environments: 
A,T T aq aq mS [A] [HA] [A ] [HA]





S S 1 K [M]
[H ]
 





where SHA,aq is the coformer intrinsic solubility.  Solving for [X]eu,T and [A]eu,T according 
to Equation (5A.110) for E2 yields the same expressions as (5A.119) and (5A.120).   
 
 
Eutectic constant Keu of cocrystal HXHA 







  (5A.125) 







  (5A.126) 
Assuming there are no solution interactions aside from ionization and micellar 











1 1 K [M]
[H ] [H ]
K K
K K
1 K [M] 1




    
     
        
 (5A.127) 
where Keu,T is the total Keu in micellar solution at [H
+] = [H+]T, and Keu,aq is the Keu in 
pure water at [H+] = [H+]aq. 
 
CSC of cocrystal HXHA 
The CSC at [H+]T can be expressed as a function of Keu,aq at [H]aq.  The CSC is 




























   
    
   
   
       
   

   
    
   
 (5A.128) 


























   
    
   
   
       
    

   
    
   
 (5A.129) 
 
BHA (1:1 monoprotic weakly basic drug B, monoprotic weakly acidic coformer HA) 








































    (5A.136) 
Associated equilibrium constants are given by 
















































  (5A.143) 
 
Solubility of cocrystal BHA 
Mass balance on B is given by 
T aq aq m m[B] [B] [BH ] [B] [BH ]
      (5A.144) 




T s sB B
aq a a
K [H ] [H ]
[B] 1 K [M] K [M]
[HA] K K
  
     
 
 (5A.145) 
Mass balance on A is given by 
T aq aq m m[A] [HA] [A ] [HA] [A ]
      (5A.146) 
Substituting (2A.36), (4A.82), and (4A.84) into (5A.146) gives 
HA HA
a aHA A
T aq s s
K K
[A] [HA] 1 K [M] K [M]




     
 
 (5A.147) 
Combining (5A.145) and (5A.147) gives 
HA HA
sp a aB BH HA A
T s s s sB B
T a a
K [H ] [H ] K K
[B] 1 K [M] K [M] 1 K [M] K [M]





          
  
 (5A.148) 
Where [B]T and [A]T are the total concentrations of drug and coformer when cocrystal 




A-, then Equation 





K [H ] K
[B] 1 K [M] 1 K [M]








Eutectic solution concentrations of drug and coformer of cocrystal BHA 
At eutectic point E1, solid drug, cocrystal, and solution coexist in equilibrium. 
solid solid aq aqBHA B B HA   (5A.150) 
[B]eu,T and [A]eu,T, the total concentrations of drug and coformer at the eutectic, are 
special solutions to Equation (5A.149) when the following condition is satisfied: 
T B,T[B] S  (5A.151) 
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where SB,T is the solubility of B in the eutectic solution.  When drug and solubilization is 
mutually unaffected by coformer (and vice versa), then SB,T is equivalent to the pure drug 
solubility in micellar solution (no coformer), which is given by the total drug 
concentration in the aqueous and micellar environments: 
B,T T aq aq mS [B] [B] [BH ] [B]





S S 1 K [M]
K
 
   
 
 (5A.153) 





[B] S 1 K [M]
K
 








[A] 1 K [M]
S [H ]
 
    
 
 (5A.155) 



















   
 
 (5A.157) 
Combining Equations (5A.154) to (5A.157), [B]eu,T and [A]eu,T at [H
+] = [H+]T can be 
expressed in terms of [B]eu,aq and [A]eu,aq at [H


















































E2, the eutectic between solid coformer, cocrystal, and solution, is described by 
solid solid aq aqBHA HA B HA   (5A.160) 
[B]eu,T and [A]eu,T are special solutions to Equation (5A.159) when the following 
condition is satisfied: 
T A,T[A] S  (5A.161) 
When drug and solubilization is mutually unaffected by coformer (and vice versa), then 
SA,T is equivalent to the pure coformer solubility in micellar solution (no drug), which is 
given by the total coformer concentration in the aqueous and micellar environments: 
A,T T aq aq mS [A] [HA] [A ] [HA]





S S 1 K [M]
[H ]
 
   
 
 (5A.163) 
where SHA,aq is the coformer intrinsic solubility.  Solving for [B]eu,T and [A]eu,T according 
to Equation (5A.110) for E2 yields the same expressions as (5A.158) and (5A.159).   
 
Eutectic constant Keu of cocrystal BHA 







  (5A.164) 









  (5A.165) 
Assuming there are no solution interactions aside from ionization and micellar 






















    
  
  
        
 (5A.166) 
where Keu,T is the total Keu in micellar solution at [H
+] = [H+]T, and Keu,aq is the Keu in 
pure water at [H+] = [H+]aq. 
 
CSC of cocrystal BHA 
The CSC at [H+]T can be expressed as a function of Keu,aq at [H
+]aq.  The CSC at a given 


































   
   
  
       

   
        
 (5A.167) 




































   
   
  
        

   
        
 (5A.168) 
 
R2H2A (2:1 monoprotic weakly basic drug R, diprotic weakly acidic coformer H2A) 
Relevant equilibria are given by 
sp
2 2 solid aq 2 aq
K
R H A 2R H A  (5A.169) 
2H A
a
2 aq aq aq
K












R M R   (5A.172) 
2H A
s
2 aq 2 m
K














    (5A.175) 
Associated equilibrium constants are given by 
2
sp aq 2 aqK [R] [H A]  (5A.176) 
2 aq aqH A
a
2 aq























  (5A.179) 


























  (5A.182) 
 
Solubility of cocrystal R2H2A 
Mass balance on R is given by 
T aq m[R] [R] [R]   (5A.183) 
Substituting (2A.50) and (4A.118) into (4A.122) gives 
 2sp2 RT s
2 aq
K
[R] 1 K [M]
[H A]
   (5A.184) 
Mass balance on A is given by 
2 2
T 2 aq aq aq 2 m m m[A] [H A] [HA ] [A ] [H A] [HA ] [A ]
          (5A.185) 
Substituting (2A.51), (2A.52), and (4A.119)-(4A.121) into (4A.124) gives 
2 2 2 2
2
2
H A H A H A H AHA HA
a a a a a aH A HA A
T 2 aq s s s2 2
K K K K K K
[A] [H A] 1 K [M] K [M] K [M]
[H ] [H ] [H ] [H ]
 
 
   
 








2 2 2 2
2
2
H A H A H A H AHA HA
2sp a a a a a aH A2 R HA A
T s s s s2 2
T
K K K K K K K
[R] 1 K [M] 1 K [M] K [M] K [M]
[A] [H ] [H ] [H ] [H ]
 
 
   
 




Where [R]T and [A]T are the total concentrations of drug and coformer when cocrystal 
and solution are in equilibrium.  When 2H A HAs sK K






 , (4A.126) can 




H A H A HA
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Eutectic solution concentrations of drug and coformer of cocrystal R2H2A 
At eutectic point E1, solid drug, cocrystal, and solution coexist in equilibrium. 
2 2 solid solid aq aqR H A R R HA   (5A.189) 
[R]eu,T and [A]eu,T, the total concentrations of drug and coformer at the eutectic, are 
special solutions to Equation (4A.129) when the following condition is satisfied: 
T R,T[R] S  (5A.190) 
where SR,T is the solubility of R in the eutectic solution.  When drug and solubilization is 
mutually unaffected by coformer (and vice versa), then SR,T is equivalent to the pure drug 
solubility in micellar solution (no coformer), which is given by the total drug 
concentration in the aqueous and micellar environments: 
R,T T aq mS [R] [R] [R]    (5A.191) 
 RR,T R,aq sS S 1 K [M]   (5A.192) 
where SR,aq is the drug aqueous solubility.  Thus, 
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The eutectic concentrations in the absence of micellar solubilization are found when [M] 
= 0, 
eu,aq R,aq[R] S  (5A.195) 
2 2H A H A HA
sp a a a
eu,aq 2 2
R,aq
K K K K
[A] 1








Combining Equations (5A.193) to (5A.196), [R]eu,T and [A]eu,T at [H
+] = [H+]T can be 
expressed in terms of [R]eu,aq and [A]eu,aq at [H
+] = [H+]aq. 
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E2, the eutectic between solid coformer, cocrystal, and solution, is described by 
2 2 solid solid aq aqR H A HA R HA   (5A.199) 
At E2, [R]eu,T and [A]eu,T are special solutions to Equation (4A.129) when the following 
condition is satisfied: 
T A,T[A] S  (5A.200) 
When drug and solubilization is mutually unaffected by coformer (and vice versa), then 
SA,T is equivalent to the pure coformer solubility in micellar solution (no drug), which is 




A,T T 2 aq aq aq 2 mS [A] [H A] [HA ] [A ] [H A]
       (5A.201) 
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S  is the coformer intrinsic solubility.  Solving for [R]eu,T and [A]eu,T 
according to Equation (4A.129) for E2 yields the same expressions as (5A.197) and 
(5A.198).   
 
Eutectic constant Keu of cocrystal R2H2A 







  (5A.203) 







  (5A.204) 
Assuming there are no solution interactions aside from ionization and micellar 
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 (5A.205) 
where Keu,T is the total Keu in micellar solution at [H
+] = [H+]T, and Keu,aq is the Keu in 




CSC of cocrystal R2H2A 
The CSC at [H+]T can be expressed as a function of Keu,aq at [H
+]aq.  The CSC at a given 
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R2HAB (2:1 monoprotic weakly basic drug R, amphoteric coformer HAB) 
Relevant equilibria are given by 
sp
2 solid aq aq
K
R HAB 2R HAB  (5A.208) 
2H AB
a
2 aq aq aq
K
H AB HAB H
















2 aq 2 m
K
H AB M H AB













    (5A.214) 
Associated equilibrium constants are given by 
2
sp aq aqK [R] [HAB]  (5A.215) 
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  (5A.221) 
 
Solubility of cocrystal R2HAB 
Mass balance on B is given by 
T aq m[R] [R] [R]   (5A.222) 
Substituting (2A.66) and (4A.150) into (4A.154) gives 
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 2sp2 RT s
aq
K
[R] 1 K [M]
[HAB]
   (5A.223) 
Mass balance on AB is given by 
T aq 2 aq aq m 2 m m[AB] [HAB] [H AB ] [AB ] [HAB] [H AB ] [AB ]
          (5A.224) 
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 (5A.226) 
Where [R]T and [AB]T are the total concentrations of drug and coformer when cocrystal 
and solution are in equilibrium.  When 2H ABHABs sK K

  and HAB ABs sK K

 , (5A.226) can 
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Eutectic solution concentrations of drug and coformer of cocrystal R2HAB 
At eutectic point E1, solid drug, cocrystal, and solution coexist in equilibrium. 
2 solid solid aq aqR HAB R R HAB   (5A.228) 
[R]eu,T and [AB]eu,T, the total concentrations of drug and coformer at the eutectic, are 
special solutions to Equation (5A.227) when the following condition is satisfied: 
T R,T[R] S  (5A.229) 
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where SR,T is the solubility of R in the eutectic solution.  When drug and solubilization is 
mutually unaffected by coformer (and vice versa), then SR,T is equivalent to the pure drug 
solubility in micellar solution (no coformer), which is given by the total drug 
concentration in the aqueous and micellar environments: 
R,T T aq mS [R] [R] [R]    (5A.230) 
 RR,T R,aq sS S 1 K [M]   (5A.231) 
where SR,aq is the drug aqueous solubility.  Thus, 
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 (5A.233) 
The eutectic concentrations in the absence of micellar solubilization are found when [M] 
= 0, 
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 (5A.235) 
Combining Equations (5A.232) to (5A.235), [R]eu,T and [AB]eu,T at [H
+] = [H+]T can be 
expressed in terms of [R]eu,aq and [AB]eu,aq at [H
+] = [H+]aq 
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E2, the eutectic between solid coformer, cocrystal, and solution, is described by 
2 solid solid aq aqR HAB HAB R HAB   (5A.238) 
[R]eu,T and [AB]eu,T are special solutions to Equation (5A.227) when the following 
condition is satisfied: 
T AB,T[AB] S  (5A.239) 
When drug and solubilization is mutually unaffected by coformer (and vice versa), then 
SAB,T is equivalent to the pure coformer solubility in micellar solution (no drug), which is 
given by the total coformer concentration in the aqueous and micellar environments: 
AB,T T aq 2 aq aq mS [AB] [HAB] [H AB ] [AB ] [HAB]




AB,T HAB,aq sH AB
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     
 
 (5A.241) 
where SHAB,aq is the coformer intrinsic solubility.  Solving for [R]eu,T and [AB]eu,T 
according to Equation (5A.71) for E2 yields the same expressions as (5A.80) and (5A.81).   
 
Eutectic constant Keu of cocrystal R2HAB 







  (5A.242) 
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Assuming there are no solution interactions aside from ionization and micellar 
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         
 
 (5A.244) 
where Keu,T is the total Keu in micellar solution at [H
+] = [H+]T, and Keu,aq is the Keu in 
pure water at [H+] = [H+]aq. 
 
CSC of cocrystal R2HAB 
The CSC at [H+]T can be expressed as a function of Keu,aq at [H
+]aq.  The CSC at a given 





















































































































 Table 5A.1.  CBZD and coformer solubilities (±SE) measured as a function of SLS 
concentration, from which Ks values were calculated. 
Cocrystal 
component 
[SLS] (mM) Concentration (mM)
CBZ 8 1.00±0.01 
 10 1.86±0.05 
 15 3.58±0.12 
 17 3.97±0.05 
 20 5.10±0.03 
 35 9.30±0.29 
 51 13.43±0.41 
 67 17.35±0.19 
 100 24.81±1.13 
 140 33.53±0.85 
   
SLC, pH 3.0 35 34.01±0.46 
 52 43.44±0.97 
 69 50.32±0.63 
   
SAC, pH 2.2 35 26.15±0.10 
 52 28.89±0.07 
 69 30.46±0.46 





(1) Moroi, Y., Micelles: Theoretical and Applied Aspects. ed.; Plenum Press: 1992. 
(2) Christian, S. D.; Scamehorn, J. F., Solubilization in Surfactant Aggregates. ed.; 
Marcel Dekker, Inc.: 1995; Vol. 55. 
(3) Rangel-Yagui, C. O.; Junior, A. P.; Tavares, L. C., Micellar solubilization of 
drugs. Journal of Pharmaceutical Sciences 2005, 8, (2), 147-163. 
(4) Strickley, R. G., Solubilizing excipients in oral and injectable formulations. 
Pharmaceutical Research 2004, 21, (2), 201-230. 
(5) Bethune, S. J.; Huang, N.; Jayasankar, A.; Rodriguez-Hornedo, N., Understanding 
and Predicting the Effect of Cocrystal Components and pH on Cocrystal Solubility. 
Crystal Growth & Design 2009, 9, (9), 3976-3988. 
(6) Huang, N.; Rodriguez-Hornedo, N., Effect of Micellar Solubilization on Cocrystal 
Solubility and Stability. Crystal Growth & Design 2010, 10, (5), 2050-2053. 
(7) Huang, N.; Rodríguez-Hornedo, N., Engineering cocrystal solubility, stability and 
pHmax by micellar solubilization. Submitted to Journal of Pharmaceutical Sciences 
2011. 
(8) Rodríguez-Hornedo, N.; Nehm, S. J.; Jayasankar, A., Cocrystals: Design, 
Properties and Formation Mechanisms. Encyclopedia of Pharmaceutical Technology: 
Third Edition 2006, 615 - 635. 
(9) Good, D. J.; Rodríguez-Hornedo, N., Solubility Advantage of Pharmaceutical 
Cocrystals. Crystal Growth & Design 2009, 9, (5), 2252-2264. 
 
223 
(10) Jayasankar, A.; Reddy, L. S.; Bethune, S. J.; Rodriguez-Hornedo, N., Role of 
Cocrystal and Solution Chemistry on the Formation and Stability of Cocrystals with 
Different Stoichiometry. Crystal Growth & Design 2009, 9, (2), 889-897. 
(11) Good, D. J.; Rodríguez-Hornedo, N., Cocrystal Eutectic Constants and Prediction 
of Solubility Behavior. Crystal Growth & Design 2010, 10, (3), 1028-1032. 
(12) Wang, Y. L.; LoBrutto, R.; Wenslow, R. W.; Santos, I., Eutectic composition of a 
chiral mixture containing a racemic compound. Organic Process Research & 
Development 2005, 9, (5), 670-676. 
(13) Klussmann, M.; White, A. J. P.; Armstrong, A.; Blackmond, D. G., 
Rationalization and Prediction of Solution Enantiomeric Excess in Ternary Phase 
Systems. Angewandte Chemie International Edition 2006, 45, (47), 7985-7989. 
(14) Nordström, F. L.; Rasmuson, Å. C., Solubility and Melting Properties of Salicylic 
Acid. Journal of Chemical & Engineering Data 2006, 51, (5), 1668-1671. 
(15) Williamson, D. S.; Nagel, D. L.; Markin, R. S.; Cohen, S. M., Effect of pH and 
ions on the electronic structure of saccharin. Food and Chemical Toxicology 1987, 25, 
(3), 211-218. 
(16) Kojima, S.; Ichigabase, H.; Iguchi, S., Studies on Sweetening Agents. VII. 
Absorption and Excretion of Sodium Cyclamate (2). Chemical and Pharmaceutical 
Bulletin 1966, 14, (9), 965-971. 
(17) O'Neil, M.; Smith, A.; Heckelman, P.; Budavari, S., The Merck Index. 13 ed.; 
John Wiley and Sons: New York, 2001. 
(18) Robinson, R. A.; Biggs, A. I., The ionization constants of p-aminobenzoic acid in 
aqueous solution at 25 C. Australian journal of chemistry 1957, 10, (2), 128. 
 
224 
(19) Nehm, S. J.; Rodriguez-Spong, B.; Rodriguez-Hornedo, N., Phase solubility 
diagrams of cocrystals are explained by solubility product and solution complexation. 
Crystal Growth & Design 2006, 6, (2), 592-600. 
(20) Zughul, M. B.; Badwan, A. A., Rigorous analysis of S2L-type phase solubility 
diagrams to obtain individual formation and solubility product constants of both SL- and 
S2L-type complexes. International Journal of Pharmaceutics 1997, 151, (1), 109-119. 
(21) Li, P.; Tabibi, S. E.; Yalkowsky, S. H., Combined effect of complexation and pH 
on solubilization. Journal of Pharmaceutical Sciences 1998, 87, (12), 1535-1537. 
(22) He, Y.; Yalkowsky, S. H., Solubilization of monovalent weak electrolytes by 
micellization or complexation. International Journal of Pharmaceutics 2006, 314, (1), 
15-20. 
(23) Crison, J. R.; Shah, V. P.; Skelly, J. P.; Amidon, G. L., Drug dissolution into 
micellar solutions: Development of a convective diffusion model and comparison to the 
film equilibrium model with application to surfactant-facilitated dissolution of 
carbamazepine. Journal of Pharmaceutical Sciences 1996, 85, (9), 1005-1011. 
(24) Sheng, J. J.; Kasim, N. A.; Chandrasekharan, R.; Amidon, G. L., Solubilization 
and dissolution of insoluble weak acid, ketoprofen: Effects of pH combined with 
surfactant. European Journal of Pharmaceutical Sciences 2006, 29, (3-4), 306-314. 
(25) Rodríguez-Hornedo, N.; Nehm, S. J.; Seefeldt, K. F.; Pagan-Torres, Y.; 
Falkiewicz, C. J., Reaction Crystallization of Pharmaceutical Molecular Complexes. 
Molecular Pharmaceutics 2006, 3, 362-367. 
 
225 
(26) Rodríguez-Hornedo, N.; Murphy, D., Surfactant-facilitated crystallization of 
dihydrate carbamazepine during dissolution of anhydrous polymorph. Journal of 










Conclusions and future work 
 
 This dissertation has investigated how cocrystal solubility and stability can be 
engineered via ionization and micellar solubilization.  The objectives of this work were to 
(1) understand the effect of ionization on cocrystal solubility, (2) investigate the role of 
micellar solubilization on cocrystal solubility and stability, (3) develop mathematical 
models to describe cocrystal solubility and stability via ionization and micellar 
solubilization equilibria, and (4) understand how ionization and micellar solubilization 
affect cocrystal eutectic points and regions of thermodynamic stability.  In summary, this 
work sought to more completely understand cocrystal solution phase chemistry in the 
presence of multiple equilibria that affect the cocrystal components in solution. 
 The pH-dependence of cocrystal solubility was elucidated by deriving 
mathematical equations that considered the solution equilibria governing cocrystal 
dissociation and ionization of cocrystal components.  The model was validated for a 
series of cocrystals of the nonionizable, poorly water soluble drug carbamazepine (CBZ) 
with several coformers of different ionization properties (salicylic acid, saccharin, and 4-
aminobenzoic acid).   
Cocrystal solubilities were experimentally accessed via the cocrystal eutectic 
point where two solids (cocrystal and one of the cocrystal components) and a solution 
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coexist at equilibrium.  Cocrystal solubility-pH dependencies of CBZ cocrystals revealed 
that experiments were in excellent agreement with those predicted by the model 
equations.  Through cocrystallization, CBZ cocrystals achieved different pH-
dependencies according to the ionization properties of the coformer.  CBZ cocrystals 
with weakly acidic coformers had solubilities that increased exponentially when pH > 
pKa, while cocrystals with amphoteric coformers had U-shaped solubility-pH profiles 
according to the coformer’s two pKas.  The mathematical models provide a rational basis 
for selecting (1) coformers to customize cocrystal solubility-pH behavior, (2) solution 
conditions that promote (or avoid) cocrystal formation, and (3) experimental conditions 
that give meaningful assessments of cocrystal solubility. 
Micellar solubilization was discovered to influence cocrystal solubility and 
stability in a profoundly different way than its parent drug.  This study found that a 
cocrystal otherwise unstable in water can achieve stability in solutions containing a 
micellar surfactant.  1:1 CBZ-salicylic acid remained stable in a 1% w/w (35 mM) 
solution of sodium lauryl sulfate (SLS), despite having readily transformed to CBZ 
dihydrate in water.  A mathematical model was developed based on cocrystal 
dissociation, component ionization, and micellar solubilization equilibria that explained 
cocrystal solubility as a function of micellar surfactant concentration.  The model 
theorized a concentration of surfactant, called the critical stabilization concentration 
(CSC), where cocrystal solubility (under stoichiometric solution conditions) was equal to 
that of the drug.  Preliminary experiments, which measured cocrystal eutectic points in 
pure water and in 1% w/w SLS solutions, demonstrated the existence of the CSC.  The 
mechanism for the CSC is an enrichment of the aqueous phase in coformer and the 
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micellar phase in drug.  This is due to the differential solubilization of the hydrophobic 
drug over relatively hydrophilic coformer.  This study has important ramifications in the 
selection of additives to enhance cocrystal performance and to maintain cocrystal 
thermodynamic stability during pharmaceutical applications.  
A series of CBZ cocrystals that would otherwise be unstable in water were 
thermodynamically stabilized via the CSC in aqueous SLS solutions.  Mathematical 
models that described cocrystal solubility and CSC were derived in terms of 
experimentally accessible thermodynamic parameters for cocrystals of different 
stoichiometry and ionization properties.  The models showed that CSC was dependent on 
cocrystal aqueous solubility relative to drug, micellar solubilization constants for the 
cocrystal components (Ks), acid dissociation constants (Ka), and surfactant CMC.  The 
effectiveness of a surfactant in achieving CSC was shown to be the differential 
solubilization of the drug over coformer in the micellar solution.  The existence of a CSC 
imparted a pHmax to cocrystals that otherwise did not have one.  The CSC and pHmax 
described the solution conditions necessary for cocrystal to be thermodynamically stable.  
CSC was successfully evaluated by (1) monitoring conversion from cocrystal to drug as a 
function of surfactant concentration by solid phase analysis, (2) estimating from cocrystal 
and drug solubilities measured in pure water, combined with Ks and Ka for the cocrystal 
components, and (3) measuring cocrystal and drug solubilities in SLS solutions.  The 
CSCs measured by the three methods were in agreement, which showed that CSC and 
pHmax could be quantitatively predicted with the assistance of the mathematical models.  
The models identify the critical parameters that influence CSC and pHmax, and provide 
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guidelines for the selection of additives suitable for modulating cocrystal solubility 
relative to drug. 
It was demonstrated that the regions of cocrystal stability could be predictably 
altered by a surfactant.  The dependencies of cocrystal eutectic points and the eutectic 
constant Keu on ionization and micellar solubilization were derived according to 
mathematical models based on cocrystal solution phase equilibria.  Investigation of a 
series of CBZ cocrystals in aqueous SLS solutions showed that the solution 
concentrations of cocrystal components at the eutectic point and Keu were indeed 
influenced by micellar solubilization.  At eutectic point E1 (phases at equilibrium are 
cocrystal, drug, and solution), the solution compositions were initially coformer-rich due 
to the cocrystals having higher aqueous solubility than drug (CBZ dihydrate).  As 
surfactant concentration increased, the solution compositions at the eutectic became drug-
rich due to the differential solubilization of CBZ over the coformers.  Experimental 
eutectic concentrations and Keus were in excellent agreement with the predictions by the 
model equations.  Analysis of the cocrystal Keu values indicated that cocrystal to drug 
solubility ratios were strongly dependent on SLS concentration. This dependence was 
predicted according to the mathematical models from Keu measured in pure water, 
combined with Ks and Ka for the cocrystal components.  The surfactant was most 
effective in decreasing the cocrystal to drug solubility ratio in concentrations far below 
the CSC.  Therefore, a cocrystal’s solubility advantage can be adjusted with judicious use 
of additives such as surfactants. 
Future directions can focus on expanding the theoretical framework to consider 
additional solution phase equilibria not explicitly described in this dissertation.  In 
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principle the concept of differential solubilization applies to other solubilization 
mechanisms such as complexation (e.g. cyclodextrins), mixed micelle formation, etc.  
Complexing agents have the potential to be highly effective in achieving differential 
solubilization of one cocrystal component over another.  This creates the possibility of 
using a combination of solubilization strategies to adjust cocrystal solubilities relative to 
the drug. 
The mathematical models developed here are preliminary in nature and do not 
consider the range of solution nonidealities that may result from an additive or from 
changing pH conditions.  More rigorous considerations of the mathematical models can 
address the influence of ionic strength on cocrystal solubility and on additive properties 
such as the surfactant CMC.  Though the models were highly successful in describing the 
behavior of CBZ cocrystals, there is a need for more comprehensive understanding of the 
extent to which solution nonidealities affect cocrystal solubility and stability. 
There is increasing emphasis on measuring biorelevant solubilities, in media such 
as fasted state simulated intestinal fluid (FaSSIF), which contains biorelevant surfactants 
and other additives.  However, there is insufficient understanding as to how cocrystal 
solubility and dissolution may be affected by the choice of media.  This dissertation 
provides the theoretical foundation for describing the influence of FaSSIF on cocrystal 
solubility in terms of differential solubilization of cocrystal components.  Applying the 
concepts developed here to biorelevant situations can assist efforts to rationally design 






 This appendix addresses cocrystal dissolution in aqueous media containing 
surfactants and investigates the feasibility of coating cocrystal particles with surfactants 
to enhance their dissolution. 
 
Materials and methods 
Materials 
Anhydrous monoclinic carbamazepine (CBZ(III); lot no. 057K11612 USP grade) 
was purchased from Sigma Chemical Company (St. Louis, MO), stored at 5 °C over 
anhydrous calcium sulfate and used as received.  Salicylic acid (SLC; lot no. 09004LH), 
saccharin (SAC; lot no. 03111DD), succinic acid (SUC; lot no. 037K0021), 4-
aminobenzoic acid (4ABA; lot no. 068K0698), and sodium lauryl sulfate (SLS; lot no. 
104H0667) were purchased from Sigma Chemical Company (St. Louis, MO) and used as 
received.  Water used in this study was filtered through a double deionized purification 
system (Milli Q Plus Water System from Millipore Co., Bedford, MA). 
 
Cocrystal synthesis 
 Cocrystals were prepared by reaction crystallization.  CBZ-SLC was prepared in 
acetonitrile, CBZ-SAC and CBZ-SUC were prepared in ethanol, and CBZ-4ABA-HYD 
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was prepared in water.  CBZ dihydrate (CBZD) was prepared in water.  Solid phases 
were characterized by XRPD. 
 
Rotating disk dissolution 
 Cocrystal was compressed in a USP standard Wood’s die (8 mm diameter) using  
a Carver hydraulic press (Wabash, IN) by applying 1000-1500 psi for 15 minutes at 
ambient temperature.  Solid phases were analyzed by FTIR.  Rotation speed was set at 
200 rpm in 150 mL aqueous media at ambient temperature (24±1 °C).  Solution 
concentrations were measured by HPLC.  Sink conditions were maintained throughout 
the experiment.  Dissolution rates were determined from the initial linear portion of the 
concentration vs time profile.  35 mM SLS (1% w/w) was chosen due to its commonness 
as USP dissolution media. 
 
Coating cocrystal particles with surfactant 
 Excess CBZ-SLC (500 mg) was suspended in a small volume (2 mL) of water 
containing 50 mM SLS.  The concentration of SLS in solution was sufficiently high to 
achieve CSC for the cocrystal.  Water was removed by evaporation at ambient 
temperature (24 ± 1 °C).  The amount of SLS contained in the recovered solid was 
approximately 6-7 wt%. 
 
Fourier-transformed infrared spectroscopy (FTIR) 
 IR absorbance spectra of CBZ-SAC and CBZ-4ABA-HYD after disk dissolution  
studies were collected on a Bruker Vertex 70 FT-IR (Billerica, MA) unit equipped with a  
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DTGS detector and compared with reference cocrystal and single component crystal  
spectra. Samples were placed on a ZnSe Attenuated Total Reflectance (ATR) crystal  
accessory and 64 scans were collected for each sample at a resolution of 4 cm-1 over a  
wavenumber region of 4000-600 cm-1. 
 
Results 
 Figures A.1 – A.3 show that CBZ dissolution rate is enhanced in 35 mM SLS 
relative to water.  CBZ-SUC and CBZ-4ABA-HYD cocrystals transformed to CBZD, 
indicating that cocrystal was more soluble than CBZD in 35 mM SLS.  No phase 
transformations were detected for CBZ-SLC in 0 mM or 35 mM SLS after 30 minutes.  
The lack of transformation of CBZ-SLC in 0 mM SLS may be due to the cocrystal and 
CBZD having very similar solubilities in water (Table A.2); kinetics of transformation 
may be limited by the low supersaturation.  The lack of phase transformation of CBZ-
SLC in 35 mM SLS was expected, because its critical stabilization concentration (CSC) 
is calculated to be 10 mM SLS at pH 1.  The dissolution data alone are not able to discern 






Figure A.1.  [CBZ] vs time during rotating disk dissolution of CBZ-SLC cocrystal in 
water at pH 1 containing (■) 35 mM SLS and (●) 0 mM SLS. 
 
 
Figure A.2. [CBZ] vs time during rotating disk dissolution of CBZ-SUC cocrystal in 






Figure A.3. [CBZ] vs time during rotating disk dissolution of CBZ-4ABA-HYD 
cocrystal in water at pH 4 containing (■) 35 mM SLS and (●) 0 mM SLS. 
 
 Table A.1 summarizes the dissolution rates in Figures A.1 – A.3, and calculates 
the enhancement ratio in 35 mM SLS relative to 0 mM SLS.  These dissolution 
enhancement ratios were compared to the solubility enhancement ratios for the CBZ 
cocrystals in 35 mM SLS relative to 0 mM SLS, shown in Table A.2.  According to 
Tables A.1 and A.2, there appears to be a reasonably good correlation between cocrystal 
solubility enhancement and dissolution rate enhancement.  This finding suggests that the 
mathematical models developed in this dissertation can predict which cocrystals and what 
solution conditions yield improved dissolution characteristics.  Future work could expand 




Table A.1.  Dissolution rates of CBZ cocrystal in water (±SE) containing 0 mM SLS or 












(2) / (1) 
CBZ-SLC (1:1) 
pH 1 
0.015 ± 0.001 0.063 ± 0.001 4.2 
CBZ-SUC (2:1) 
pH 1 
0.028 ± 0.001 0.14 ± 0.01 5.0 
CBZ-4ABA-HYD (2:1) 
pH 4 
0.027 ± 0.001 0.13 ± 0.01 4.8 
 
 
Table A.2.  Solubilities of CBZ cocrystals and CBZD in water (±SE) containing 0 mM 












(2) / (1) 
CBZ-SLC (1:1) 
pH 1 
0.62 ± 0.03a 2.48 ± 0.02a 4.0 
CBZ-SUC (2:1) 
pH 1 
2.18 ± 0.02a 13.47 ± 0.04a 6.2 
CBZ-4ABA-HYD (2:1) 
pH 4 1.83 ± 0.02 11.49 ± 0.08 6.3 
a Solubility was measured at pH 3; solubility at pH 1 was calculated according to 
equations in Table 4.1. 
 
Table A.3.  Dissolution rates of CBZ-SAC and CBZD in water (±SE) containing 0 mM 
SLS or 22 mM SLS. 
Solid phase 
Dissolution rate 
0 mM SLS 
mg(CBZ)/min/cm2 
Dissolution rate 
22 mM SLS 
mg(CBZ)/min/cm2 
(1) CBZ-SAC (1:1) 
pH 1 
0.021 ± 0.001 0.059± 0.001 
(2) CBZD 0.012 ± 0.002 0.059 ± 0.001 
Ratio of dissolution rates 




 Surfactants have been shown to impact dissolution by reducing the drug’s 
effective diffusivity when solubilized by a micelle.  The distribution of drug in aqueous 
and micellar environments becomes an important factor in dissolution, especially for 
hydrophobic molecules.  According to Chapter 4 (Figure 4.2), at the CSC the distribution 
of drug between aqueous and micellar environments are equal for cocrystal and solid 
drug in micellar solutions.  Thus, the dissolution rates of drug and cocrystal should be 
equal at the CSC.  Dissolution of CBZ-SAC corystal at its CSC (22 mM at pH 1) 
confirms this type of behavior (Figure A.4).  Dissolution of CBZ-SAC cocrystal in 0 mM 
SLS (Figure A.5) reveals that cocrystal has a dissolution advantage over CBZD that was 
not apparent from the dissolution experiment at CSC.  The dissolution rates of CBZ-SAC 
and CBZD in 0 mM and 22 mM SLS are shown in Table A.3.  This experiment shows 
that cocrystal dissolution rates relative to drug can be strongly dependent on micellar 
solubilization. 






Figure A.4.  [CBZ] vs time (±SE) during rotating disk dissolution of (■) CBZ-SAC 




Figure A.5.  [CBZ] vs time (±SE) during rotating disk dissolution of (■) CBZ-SAC 




 Disk dissolution of coated and noncoated CBZ-SLC in water compared to 
noncoated CBZ-SLC in 35 mM SLS is shown in Figure A.6.  The coated cocrystal 
achieves a 3-fold increased dissolution rate in water relative to the noncoated cocrystal 
(Table A.3).  SLS dissolved into the media from the coated particles is vanishingly low, 
estimated at 0.03 mM (CMC of SLS is 8 mM).  For comparison, the dissolution rate 
achieved by CBZ-SLC cocrystal in media containing 35 mM SLS (in the bulk) is 4-fold 
relative to water.  This shows that the micelles are interacting with the cocrystal at the 
dissolving surface.  However, it is yet unclear whether or not the cocrystalline nature of 




Figure A.6.  [CBZ] vs time (±SE) during rotating disk dissolution of (▲) noncoated 
CBZ-SLC in 0.1 N HCl + 35 mM SLS, (■) coated CBZ-SLC in 0.1 N HCl, and (●) 







Table A.4.  Dissolution rates (±SE) of coated CBZ-SLC cocrystal in 0.1 N HCl. 
 
(1) 




CBZ initial rate 
coated 
mg/min/cm2 
Ratio of initial rates 
 
CBZ-SLC 
(6 wt% SLS) 
pH 1 
0.015 ± 0.001 0.045 ± 0.002 3.0 
 
